Studies on the human MDR1, MRP1, and MRP2 ABC transporters: functional relevance of the genetic polymorphisms in the MDR1 and MRP1 gene by Oselin, Kersti
DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS
85
STUDIES
ON THE HUMAN MDR1, MRP1, AND 
MRP2 ABC TRANSPORTERS: 
FUNCTIONAL RELEVANCE 
OF THE GENETIC POLYMORPHISMS 
IN THE MDR1 AND MRP1 GENE
KERSTI OSELIN
TARTU 2003
DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS
85
DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS
85
STUDIES 
ON THE HUMAN MDR1, MRP1, AND 
MRP2 ABC TRANSPORTERS: 
FUNCTIONAL RELEVANCE 
OF THE GENETIC POLYMORPHISMS 
IN THE MDR1 AND MRP1 GENE
KERSTI OSELIN
TARTU UNIVERSITY
P R E S S
Department of Pharmacology, Faculty of Medicine, University of Tartu, Estonia
Dissertation is accepted for the commencement of the degree of Doctor of 
Medical Sciences on June 19, 2003 by the Council of the Faculty of Medicine, 
University of Tartu, Estonia
Opponent: Professor M aija-Liisa Dahl, M.D., Ph.D.
Department of Medical Sciences 
Clinical Pharmacology 
University Hospital 
University of Uppsala 
Sweden
Commencement: September 24, 2003
The publication of this dissertation is granted by the University of Tartu
© Kersti Oselin, 2003
Tartu Ülikooli Kirjastus 
www.tyk.ut.ee 
Tellimus nr. 459
CONTENTS
LIST OF ORIGINAL PU BLICA TIO N S......................................................... 7
ABBREVIATIONS .............................................................................................  8
INTRODUCTION ...............................................................................................  9
REVIEW OF THE LITERATURE ..................................................................  10
1. Contribution of P-glycoprotein (Pgp) to physiology and drug 
disposition ......................................................................................................  10
1.1. Physiological role of P g p .....................................................................  10
1.2. Pgp role in drug disposition ................................................................. 11
1.3. Biochemical aspects of Pgp ................................................................. 14
1.4. Genetical aspects of P g p ......................................................................  16
2. General properties of MRP 1 and MRP2 ..................................................  17
2.1. Tissue distribution of the MRP1 and M R P 2 ....................................  17
2.2. Substrates, inhibitors, and inducers of MRP1 and MRP2 ............  19
2.3. Biochemical and genetical aspects of MRP1 and M R P 2 ............... 21
AIMS OF THE STUDY .....................................................................................  23
METHODS AND M A TERIA LS......................................................................  24
1. Study sub jects ................................................................................................. 24
2. M ateria ls..........................................................................................................  24
3. Rh 123 efflux study ........................................................................................ 25
4. Digoxin study ................................................................................................. 25
4.1. Study p ro toco l........................................................................................  25
4.2. Digoxin concentration measurements and pharmacokinetic
analysis ....................................................................................................  26
5. Principles of the LightCycler™ technology............................................  27
6. Quantitative determination of the MDR1, M RP1, and MRP2 mRNA 
expression in a L ightC ycler........................................................................  28
6.1. Cell sorting and isolation of total R N A ............................................  28
6.2. Real-time quantitative RT-PCR assays ............................................  30
6.3. Synthesis of external standards for quantitative real-time RT-PCR 30
7. Determination of the G2677T and C3435T SNPs in the MDR1, and 
the G816A,T825C, T1684C, and G4002A SNPs in the MRP1 using a 
LightCycler ................................................................................................... 32
8. Statistical analysis ......................................................................................... 36
RESULTS AND D ISC U SSIO N .......................................................................  37
1. Impact of the G2677T and C3435T SNPs in the MDR1 gene on Pgp
function and expression ...............................................................................  37
1.1. Rh 123 efflux study ...............................................................................  37
1.2. Digoxin s tu d y .......................................................................................... 38
1.3.MDR1 mRNA expression study ......................................................... 40
2 5
1.4. General discussion concerning the impact of the G2677T and
C3435T SNPs in the MDR1 on Pgp activity and expression ........ ......41
2. MRP1 and M RP2 mRNA expression in peripheral blood CD4+,
CD8+, CD19+, and CD56+ c e l l s .................................................................. ......43
3. Frequencies of the MRP1 genetic polymorphisms and their
functional significance in Caucasians ....................................................... ......45
3.1. Detection of a novel G816A SNP in the human M R P 1 ................. ......45
3.2. Frequencies of the G816A, T825C, T1684C, and G4002A SNPs
in the MRP1 ................................................................................................... 47
3.3.M RP1 mRNA expression in individuals with different MRP1 
genotypes ................................................................................................. ......49
3.4..General discussion concerning the SNPs in the MRP1 and their 
functional significance .......................................................................... ......50
CONCLUSIONS .................................................................................................. ......53
REFERENCES ...................................................................................................... ......54
A CK N O W LED G EM EN TS................................................................................ ......65
SUMMARY IN E ST O N IA N ....................................................................................66
PU B LIC A TIO N S.................................................................................................. ......69
6
LIST OF ORIGINAL PUBLICATIONS
I Oselin K, Gerloff T, Mrozikiewicz PM, Pähkla R, Roots I. MDR1 poly­
morphisms G2677T in exon 21 and C3435T in exon 26 fail to affect 
rhodamine 123 efflux in peripheral blood lymphocytes. Fundamental & 
Clinical Pharmacology 2003; 17:463^469.
II Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I. 
MDR1 genotype do not discriminate between absorptive pharmacokinetic 
parameters of a single oral dose of 1 mg digoxin in healthy white males. 
British Journal of Clinical Pharmacology 2002;54:610-616.
III Oselin K, Nowakowski-Gashaw I, M rozikiewicz PM, Wolbergs D, Pähkla 
R, Roots I. Quantitative determination of MDR1 mRNA expression in 
peripheral blood lymphocytes: a possible role of genetic polymorphisms in 
the MDR1 gene. European Journal of Clinical Investigation 2003;33:261- 
267.
IV Oselin K, M rozikiewicz PM, Pähkla R, Roots I. Quantitative determination 
of the human MRP1 and MRP2 mRNA expression in FACS-sorted periphe­
ral blood CD4+, CD8+, CD19+, and CD56+ cells. European Journal of 
Haematology 2003;71:119-123.
V Oselin K, M rozikiewicz PM, Gaikovitch E, Pähkla R, Roots I. Frequency 
of MRP 1 genetic polymorphisms and their functional significance in 
Caucasians: detection of a novel mutation G816A in the human MRP1 
gene. European Journal of Clinical Pharmacology 2003;59:347-350.
7
ABBREVIATIONS
ABC ATP-binding cassette
APC allophycocyanin
AUC area under the plasma concentration-time curve
bp base pairs
BSA bovine serum albumin
CD cluster of differentiation
CD4+ T helper cells
CD8+ T cytotoxic cells
CD19+ В lymphocytes
CD56+ natural killer cells
95% Cl 95% confidence interval
c'-'max maximum plasma drug concentration
DMEM Dulbecco’s Modified Eagle Medium
DMSO dimethyl sulfoxide
dNTPs deoxyribonucleotide triphosphates
DTT dithiothreitol
FACS fluorescence-activated cell sorting
FBS foetal bovine serum
FITC fluorescein isothiocyanate
LC Red640 LightCycler Red-640-N-hydroxy-succinimide ester
LC Red705 LightCycler Red-705-Phosphoramidite
MDR m ultidrug resistance
MDR1 multidrug resistance gene 1
M gCl2 magnesium chloride
M -MLV M oloney Murine Leukemia Virus
mRNA messenger ribonucleic acid
MRP1 and 2 multridrug resistance-associated protein 1 and 2
OR odds ratio
P probability
PBMC peripheral blood mononuclear cells
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PerCP-Cy5.5 peridinin chlorophyll protein cyanine 5 conjugate
PgP P-glycoprotein
R hl23 rhodamine 123
RFLP restriction fragment length polymorphism
RT-PCR reverse transcription —  polymerase chain reaction
SD standard deviation
SNP single nucleotide polymorphism
tmax time of occurrence of maximum plasma drug concentration
8
INTRODUCTION
The transport o f various molecules across lipid membranes is an essential 
function of cells in all living organisms and a large number of specific proteins 
have evolved to carry out this function. The largest transporter family is the 
superfamily of ATP-binding cassette (ABC) transporters (Dean et al. 2001). 
These proteins bind ATP and use the phosphate bond energy to drive the 
transport.
ABC transporters comprise of membrane proteins that extrude a wide 
variety of endogenous and exogenous compounds across the plasma membrane 
as well as intracellular membranes of the endoplasmic reticulum, peroxisome, 
and mitochondria. ABC genes typically encode 4 domains that include 2 ATP- 
binding domains and 2 domains with multiple transmembrane segments. The 
ATP-binding domains of the ABC genes contain motifs of characteristic con­
served residues: W alker A and W alker В motif, found in all ATP-binding 
proteins; and the С motif, specific to ABC transporters that distinguishes them 
from other ATP-binding proteins (Dean et al. 2001). The superfamily of ABC 
transporters is divided into seven subfamilies based on organization of domains 
and amino acid homology. In humans, 49 ABC transporters have been iden­
tified (http ://w w w .humanabc .org).
ABC transporters are expressed throughout many tissues of the body and 
they are essential in many processes in cells. Mutations in these genes cause or 
contribute to several human genetic disorders including cystic fibrosis and 
retinal degeneration; cholesterol, bile salts, and bilirubin transport defects; in­
sulin secretion and anaemia. Transporters of the subfamilies В (ABСВ/MDR/ 
TAP) and С (ABCC/MRP/CFTR), namely P-glycoprotein (ABCB1), MRP1 
(ABCC1), and M RP2 (ABCC2), appear to be most relevant for the absorption, 
distribution, metabolism, and excretion of drugs in humans. The present study 
deals with these ABC transporters.
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REVIEW OF THE LITERATURE
1. Contribution of P-gly coprotein (Pgp) 
to physiology and drug disposition
1.1. Physiological role of Pgp
Pgp (ABCB1/M DR1) was the first human ABC transporter identified and 
cloned through its ability to confer a multidrug resistance (MDR) phenotype in 
cancer cells (Juliano and Ling 1976). The phenomenon of MDR was charac­
terized by a transport of various anticancer agents out of the cells and decreased 
intracellular access to these agents resulted in a resistance to chemotherapeutics. 
It is now known that Pgp expression is not limited to cancer cells, but it is 
ubiquitously expressed throughout the body (Thiebaut et al. 1987; Cordon- 
Cardo et al. 1989), where it extrudes a wide variety of structurally and chemi­
cally unrelated compounds.
High level of Pgp has been found in the apical membrane of small and large 
intestinal epithelium (Thiebaut et al. 1987), which suggests Pgp function to 
prevent uptake of substrates across the gastrointestinal tract. Pgp is very 
abundant in the bile canalicular membrane of hepatocytes and on the brush 
border of renal proximal tubules (Thiebaut et al. 1987). The function of Pgp in 
these locations is extrusion of substrates from the hepatocytes into the bile, and 
in kidney from blood into the urine. This data strongly suggests Pgp role in 
absorption and excretion mechanisms.
In several tissues, Pgp functions as a barrier protecting cells from potential 
cytotoxic effects of xenobiotics. Pgp has been localized on the luminal surface 
of capillary endothelial cells in the brain and testis where it is considered to be a 
part of the blood-brain and blood-testis barrier (Cordon-Cardo et al. 1989). 
When substrates enter the endothelial cells from the blood, Pgp pumps these 
compounds back into the blood, reducing their distribution into the brain and 
into the testis. In m drla  knockout mice, the mouse has two members of Pgp 
encoded by m drla  and m drlb  which are expressed in tissue specific manner, 
the penetration of substrate agents from the blood into the brain tissue has been 
found to be dramatically increased up to 100 fold (Lin et al. 2003).
Pgp is functional in the placental syncytiotrophoblasts, facing the maternal 
blood compartment (Cordon-Cardo et al. 1990; MacFarland et al. 1994). The 
function of Pgp here appears to be analogous to that in the blood-brain barrier, 
protecting fetus from toxic xenobiotics and drugs, present in the maternal 
circulation, by active back-transport. As found by Lankas et al. (1998), m drla  
knockout mice, lacking placental Pgp, have an increased fetal susceptibility to 
avermectin induced teratogenicity.
Human adrenal gland is rich in Pgp, where it is expressed on the surface of 
cells in both the cortex and medulla (Thiebaut et al. 1987). It has been supposed
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that Pgp might be involved in secretion of steroids, or in protection of the 
steroid secreting cells from the toxic effects of high steroid concentrations. In 
vitro studies have revealed that cortisol and aldosterone were transported by 
epithelial monolayers expressing human Pgp (Ueda et al. 1992).
W ithin haematopoietic cells, Pgp has been found to be expressed and 
functionally active in all subsets of peripheral blood cells, except in granulo­
cytes (Drach et al. 1992). The expression and function of Pgp appeared to be 
the highest in CD56+ natural killer and CD8+ T cells. In several studies, Pgp 
pharmacological inhibitors and anti-Pgp monoclonal antibodies inhibited 
natural killer and T cell mediated cytotoxicity (Gupta et al. 1992; Klimecki et 
al. 1995). In human T lymphocytes, Pgp has been reported to participate in the 
transport o f cytokines, including IL-2, IL-4 and IFN-y (Drach et al. 1996; 
Raghu et al. 1996). These findings indicate that Pgp may play a role in specific 
immunological functions.
Preferential expression of Pgp in the apical membrane of epithelial cells 
suggests that the main function of Pgp is to protect cells from potential 
cytotoxic effects of xenobiotics. However, the physiologic function of Pgp is 
still not fully understood. Rodents have two m drl genes, termed m drla  and 
m drlb . Loss of either or both genes has no effect on viability, fertility, or life 
span of mice (Schinkel et al. 1997), indicating that Pgp has no essential 
physiologic function.
1.2. Pgp role in drug disposition
The anatomical localization of Pgp, consistent with its function as an efflux 
pump, suggests that Pgp may play an important role in the absorption, distri­
bution, metabolism, and excretion of drugs in humans. First, it was evidenced that 
Pgp conferred resistance to anticancer agents. It is now known that Pgp substrates 
comprise a number of drugs applied for a wide range of therapeutic applications 
(Table 1). Pgp transports compounds with diverse chemical structure, but not all 
members of a therapeutic class interact in the same manner with Pgp.
Evidence of the involvement of Pgp in drug absorption and secretion has been 
demonstrated in vitro in cell lines, in which Pgp is highly expressed. The human 
colon carcinoma Caco-2 cells are commonly used for studying intestinal drug 
transport. Pgp expression in the apical membrane of Caco-2 cells leads to a 
considerably higher transport of Pgp substrates in the basal-to-apical direction 
(corresponding to drug secretion into the gut lumen) in comparison with the 
apical-to-basal direction. For instance, the basal-to-apical transport of vinblastine 
and docetaxel in these cells was more than 10 fold greater than the apical-to-basal 
transport (Hunter et al. 1993; Wils et al. 1994). In the presence of Pgp inhibitors, 
the apical-to-basal transport of vinblastine and docetaxel was significantly 
enhanced. Wetterich et al. (1996) found that the transport rates of talinolol across 
Caco-2 monolayers were significantly higher in the secretory direction as
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compared to the absorptive direction. In the presence of Pgp inhibitor, verapamil, 
the secretory pathway was inhibited, leading to very similar transport rates of the 
compound in both directions, presumably mainly by a passive diffusion mecha­
nism. Similar results have been obtained using the kidney cell lines. Basal-to- 
apical transport of digoxin and vinblastine across human MDR1 gene transfected 
porcine and canine kidney epithelial cell monolayers, used as a model for renal 
secretion, was much greater than the apical-to-basal transport, and Pgp inhibitors 
cyclosporine A, verapamil, and quinidine inhibited the basal-to-apical transport 
(Tanigawara et al. 1992; Okamura et al. 1993; Horio et al. 1989).
Table 1. Some substrates, inhibitors, and inducers of human Pgp.
Substrates____________  Inhibitors Inducers
Anticancer agents 
actinomycin D 
daunorubicin 
doxorubicin 
etoposide 
paclitaxel 
vinblastine 
vincristine
Immunosupressants 
cyclosporine A 
tacrolimus
Steroids 
dexamethasone 
corticosterone 
cortisol
Cardiac drugs 
digitoxin 
digoxin 
diltiazem 
quinidine 
verapamil 
talinolol
H, antihistamines 
fexofenadine
HIV protease inhibitors 
amprenavir 
indinavir 
nelfinavir 
ritonavir 
saquinavir
Fluorescent dye
rhodamine 123 (Rhl23)
Modified from Schwab et al. 2003; Fromm 2002; Kim 2002; Schinkel and 
Jonker 2003.
dexamethasone 
rifampin 
St. John’s wort
valspodar (PSC833) 
verapamil
cyclosporine A 
ketoconazole 
quinidine 
ritonavir
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The development of transgenic m drl knockout mice has proven to be a 
useful tool for studying the role of Pgp in drug disposition. In mdrla(-/~) mice, 
the brain concentration of HIV protease inhibitors indinavir, saquinavir, and 
nelfinavir has been found to be higher compared with mdrla(+/+) mice by 7 to 
36 fold (Kim et al. 1998). After oral administration of indinavir, saquinavir, and 
nelfinavir plasma concentration was 2 to 5 fold higher in pgp knockout mice in 
comparison with the control animals. Markedly higher digoxin and cyclosporine 
A brain levels after intravenous administration have been observed in m drla (-/~) 
than in mdrla(+/+) mice (Schinkel et al. 1995). In vitro studies with human 
MDR1 transfected cells demonstrated that the tested HIV protease inhibitors, 
digoxin, and cyclosporine A were also good substrates for human Pgp. Con­
sistent with Pgp expression in hepatocytes and in renal tubular cells, Pgp contri­
butes to the excretion of unchanged drugs into the bile and urine. The biliary 
clearance of digoxin and doxorubicin was significantly greater in mdrla(+/+) 
than in mdrla(-/~) mice (Schinkel et al. 1997; van Asperen et al. 2000). The 
renal secretion of digoxin was markedly decreased in m drl a/1 b(-/~) mice in 
comparison with m drla/lb(+ /+ ) mice (Tsuruoka et al. 2001).
In humans, a good correlation between the intestinal Pgp expression and the 
pharmacokinetics of Pgp substrates tacrolimus, cyclosporine A, and talinolol 
has been observed (Masuda et al. 2000; Lown et al. 1997; Westphal et al.
2000). These data also indicate that interindividual variability in the expression 
of intestinal Pgp contributes to the interindividual variation in drug disposition.
It was recognized that certain compounds inhibited the transport of Pgp 
substrates (Tsuruo et al. 1981). These agents, so-called Pgp inhibitors or MDR 
reversal agents, were initially focused on reversing MDR in chemotherapy 
resistant cancer cells. Later insights indicated that the concomitant use of Pgp 
inhibitors and Pgp substrates might result in drug-drug interactions. In clinical 
practice, drug-drug interactions of digoxin with other cardiac drugs, such as 
verapamil and quinidine, have been well documented (Gordon and Goldenberg 
1986; Mordel et al. 1993; Verschraagen et al. 1999). In healthy volunteers, a 
daily dose of 240 mg verapamil caused a significant increase in digoxin steady 
state and peak plasma concentrations due to Pgp inhibition and increased 
absorption from intestine (Rodin et al. 1988). Coadministration of a single oral 
dose of Pgp inhibitor valspodar with steady state digoxin yielded an average 
76% increase in digoxin area under the plasma concentration-time curve (AUC) 
and a 62% decrease in digoxin renal clearance (Коvarik et al. 1999). After a 5 
day coadministration period, digoxin AUC increased by an average 211% and 
apparent total body clearance was decreased by 67% compared with steady state 
administration of digoxin alone. The inhibition of Pgp in tumors with MDR 
phenotype has been used to improve cytotoxic drug delivery to cancer cells. A 
significant increase in systemic exposure of paclitaxel, daunorubicin, doxoru­
bicin, etoposide, and mitoxantrone in cancer patients has been observed when 
used in combination with Pgp inhibitors valspodar, GF120918, or cyclosporine 
A (Fracasso et al. 2000; Tidefelt et al. 2000; Minami et al. 2001 Lacayo et al.
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2002; M alingre et al. 2001). However, the increase in AUC of anticancer drug 
led also to a substantial increase in haematological and central nervous system 
toxicity.
Experimental evidence obtained from human colon carcinoma cell lines 
indicated that Pgp expression was upregulated by rifampin (Schuetz et al. 
1996). Greiner et al. (1999) detected increased Pgp levels in enterocytes from 
healthy volunteers during rifampin administration (600 mg/day for 10 days). 
Concomitantly, the oral bioavailability of a single dose of 1 mg digoxin de­
creased 30%. During rifampin treatment (600 mg/day for 9 days), the AUC of 
intravenous and oral talinolol was decreased 21% and 35%, respectively, and 
total clearance of talinolol was increased by 30% after intravenous administra­
tion of the drug (W estphal et al. 2000). A significant increase in the expression 
of duodenal Pgp and MDR1 mRNA expression indicated that the observed 
talinolol-rifampin interaction could partially be explained by a decrease in drug 
absorption. Increased Pgp expression after administration of St. John’s wort has 
been evidenced in healthy volunteers (Hennessy et al. 2002). Coadministration 
of St. John’s wort (900 mg/day for 11 days) resulted in a 1.6 fold and 1.9 fold 
increase of the oral clearances of cyclosporine A and fexofenadine, respectively 
(Dresser et al. 2003).
Most drug-drug interactions have been attributed to inhibition or induction 
of drug m etabolising enzymes. It is now established that modification of Pgp 
function by concomitantly administered drugs is another important mechanism 
of drug-drug interactions (Table 1). The substrate binding sites and ATP- 
binding domains of Pgp interact cooperatively as a single functional unit. 
Inhibition of Pgp by inhibitors could result from either the competition in drug 
binding or by interrupting ATP hydrolysis, while the induction of Pgp occurs 
through increased protein synthesis and expression. Experimental data suggest 
that the induction of Pgp is likely to be regulated by pregnane X receptor 
activation (Geick et al. 2001).
1.3. Biochemical aspects of Pgp
The 1280 amino acids of Pgp are organized in two homologous halves of 610 
amino acids that are joined by a linker region of about 60 amino acids (Fig. 1) 
(Ambudkar et al. 1999). Each half contains six transmembrane domains and an 
ATP-binding domain. Deletion from the central core of the linker region 
resulted in a protein that was expressed at the cell surface in levels similar to the 
wild type protein, but both ATP hydrolysis and drug transport activities of the 
mutant were completely diminished (Hrycyna et al. 1998). These data suggest 
that the two halves of Pgp interact cooperatively. Data from site-directed 
mutagenesis suggest that the major substrate binding domains include residues 
from transmembrane domains 6 and 12 (Hrycyna 2001). It is also clear that the
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interaction between the ATP-binding sites and the substrate binding domains is 
essential to the transport.
Figure 1. Predicted secondary structure of Pgp, MRP1, and MRP2. Branches indicate 
putative N-glycosylation sites; N and С denote N-terminal and С-terminal ends of the 
protein, respectively; IN and OUT indicate cytoplasmic and extracellular side of the 
membrane; NBD — nucleotide binding domains. Adapted from Schinkel and Jonker 
2003.
The majority of experimental data support the fact that Pgp functions as a 
primary pump wherein the energy from the ATP hydrolysis is used for the 
transport of substrate, which is not linked to со- or countertransport of anions or 
cations. In the absence of any known substrate, Pgp exhibits a basal ATPase 
activity, which is unusual for an active transporter. It has been suggested that 
this Pgp basal activity reflects the presence of an unknown endogenous 
substrate. Recently, Garrigues et al. (2002) showed that the basal ATPase 
activity is tightly dependent on the presence of cholesterol in the membrane. 
Various compounds, known to be transported by Pgp, stimulate Pgp ATPase 
activity.
Full-length Pgp contains N-linked glycosylation sites (Ambudkar et al. 
1999). All three sites are located within the first extracellular loop at amino acid 
residues 91, 94, and 99 (Fig. 1). The phosphorylation sites of Pgp locate within 
the linker region. Both, the glycosylation and phosphorylation of Pgp, are 
posttranslational modifications. Studies with the mutant, glycosylation deficient 
Pgp, demonstrated that N-linked glycosylation was not required for the function 
of Pgp, although it appeared to affect protein level at the cell surface (Schinkel
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et al. 1993; Gribar et al. 2000). Similarly, Germann et al. (1996) showed that 
the phosphorylation of Pgp was not essential for its drug efflux activity.
1.4. Genetical aspects of Pgp
In humans, Pgp is encoded by the MDR1 gene, which is located in chromosome 
7q21 and consists of 28 exons (Chen et al. 1990). Recently, several single 
nucleotide polymorphisms (SNPs) in the MDR1 gene were identified (Table 2) 
(Mickley et al. 1998; Hoffmeyer et al. 2000; Kim et al. 2001; Saito et al. 
2002a). The phenotypic consequences of the identified SNPs were evaluated in 
the study from Hoffmeyer et al. (2000). It was evidenced that the C3435T poly­
morphism in exon 26 determined Pgp expression in duodenal enterocytes from 
healthy volunteers. Comparison of Cmx values for 0.25 mg digoxin during 
steady state conditions revealed that subjects homozygous for TT had signi­
ficantly higher Ста* values than those with CC genotype.
Table 2. SNPs identified in the coding region of the human MDR1.
Position SNP* NCBI SNP rs Effect Location
Mutant allele 
frequency in 
Caucasians
(%)
Reference
exon 2 A61G Asn21Asp N-terminus 11.2 Cascorbi et al. 2001
exon 7 A548G Asnl83Ser 1 intracellular 
loop
1.4 Kim et al. 2001
exon 11 G1199A 2229109 Ser400Asn linker region 5.5 Cascorbi et al. 2001
exon 12 C1236T 1128503 Gly412Gly linker region 41.0 Cascorbi et al. 2001
exon 13 C1474T Arg492Cys linker region 1.4 Kim et al. 2001
exon 21 C2650T Leu884Leu 4 intracellular 
loop
2.7 Kim etal. 2001
G2677T
G2677A
2032582 Ala893Ser
Ala893Thr
4 intracellular 
loop
41.6
1.9
Cascorbi et al. 2001
exon 26 C3435T 1045642 Ilel 145Ile C-terminus 53.9 Cascorbi et al. 2001
* The positions of the SNPs correspond to GenBank accession number M14758 with 
the first base of the ATG start codon set to 1.
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Subsequently, several studies were performed to determine the allele and 
genotype distribution of the C3435T in different ethnic groups (Schwab et al. 
2003). The lowest frequency for the T3435 allele has been observed in Afri­
cans, ranging from 10% (Ghanaian) to 27% (Sudanese). Higher frequency for 
the T3435 allele was found in Caucasians, ranging from 46% (Northern Italian) 
to 57% (Portuguese). In Southwest Asians, the frequency of the T3435 allele 
was 66%. Also a marked variation in the allele frequency for other SNPs in the 
MDR1 has been found between different ethnic groups.
The present study aimed to investigate the functional significance of the 
C3435T SNP in the MDR1 on Pgp expression and activity, based on the data 
from Hoffmeyer et al. (2000). A second SNP, G2677T, was included in the 
study, since it was found to be in a strong linkage disequlibrium with the 
C3435T SNP (Tanabe et al. 2001) and unlike the C3435T results in amino acid 
change. Also, both of these SNPs occur with the highest frequency in Cau­
casians (Cascorbi et al. 2001).
2. General properties of MRP1 and MRP2
The human multidrug resistance-associated protein 1 (MRP1/ABCC1) and 2 
(MRP2/ABCC2) were first identified in 1992 by Cole et al. in doxorubicin 
selected human small cell lung cancer cells, and in 1996 by Taniguchi et al. in 
cisplatin resistant human head and neck cancer cell line, respectively. Sub­
sequent analysis showed that these transporters conferred MDR against a wide 
range of anticancer drugs. The resistance profiles of MRP1, MRP2, and Pgp 
transfected cells are similar, and typically include crossresistance to the anthra- 
cyclines, vinca alkaloids, taxanes, and epipodophyllotoxins.
2.1. Tissue distribution of the MRP1 and MRP2
Unlike Pgp, MRP1 is localized to the basolateral membrane of epithelial cells 
and therefore pumps its substrates into the interstitial space rather than into bile, 
urine, or gut (Leslie et al. 2001). Studies on m rp l(-/~) knockout mice have 
revealed that MRP1 may have an important protective role in some tissues.
In normal liver, m rpl expression in the basolateral membrane of hepatocytes 
is very low, but it is induced during liver regeneration, endotoxemia, and 
obstructive cholestasis (Roelofsen et al. 1997; Vos et al. 1998; Pei et al. 2002). 
In the small intestine, the highest levels of m rpl were found in the Paneth cells, 
located in the crypts (Peng et al. 1999). M rpl expression in villi enterocytes 
was not detectable. In colon, all of the cells lining the crypt-villous axis of the 
colon wall contained m rpl. In m rpl(-/-) mice, an increased accumulation of
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etoposide in colon and concomitantly an increased crypt degeneration and 
frequency of colitis has been observed during etoposide treatment (Wijnholds et 
al. 2000). No differences in AUC of etoposide after intravenous administration 
were observed in knockout and control mice, indicating that m rpl does not 
contribute to renal, liver, or intestinal clearance, but protects the proliferative 
cell compartment in the crypt. In mice, m rpl is present in the basal epithelial 
layer of the tongue and mucosal layer of the cheek (Wijnholds et al. 1998). The 
lack of m rpl protein in knockout mice resulted in increased oropharyngeal 
toxicity during etoposide administration (Wijnholds et al. 1998). These cells 
have the basolateral membrane facing the blood circulation and m rpl protects 
the basal epithelium in the oropharyngeal cavity of wild type mice.
In human brain, MRP1 expression in capillary endothelial cells has not been 
detected (Seetharaman et al. 1998), indicating that MRP1 probably does not 
form blood-brain barrier. In rats and mice, m rpl has been found in epithelium 
of choroid plexus (W ijnholds et al. 2000; Rao et al. 1999). The latter is 
responsible for the production of cerebrospinal fluid. In rats, after intracerebro- 
ventricular administration, estradiol 17-ß-D-glucuronide, a substrate for m rpl, 
was eliminated rapidly from the cerebrospinal fluid to blood (Nishino et al. 
1999). Simultaneous administration of probenecid, an inhibitor for m rpl, redu­
ced the elimination o f estradiol 17-ß-D-glucuronide. The m rpl(-/-) mice accu­
mulated 10 fold more etoposide in the cerebrospinal fluid than did control 
animals whereas levels in brain and plasma concentrations did not differ. These 
findings indicate that m rpl is a part of the blood-cerebrospinal fluid barrier.
In kidney, MRP1 was expressed in the basolateral membrane of the 
epithelial cells of the loop of Henle and the urinary collecting ducts in the 
marrow and cortex, as well as in glomeruli and proximal tubules (Flens et al. 
1996; Peng et al. 1999; Schaub et al. 1999). M rpl {-I-) knockout mice acquired 
hypotonic polyuria when treated with etoposide (Wijnholds et al. 1998). It was 
supposed that etoposide treatment caused damage in the basolateral membrane 
of the collecting ducts, leading to reduced tubular responsiveness to vaso­
pressin.
Relatively high levels of MRP1 have been found in the sex hormone 
producing Leydig cells in the interstitial tissue and in the basal membrane of 
Sertoli cells in the seminiferous tubules of the testis (Flens et al. 1996; Wijn­
holds et al. 1998). No MRP1 expression in the endothelial layer of the blood 
vessels in the testis, a location for Pgp, was observed. Estrogen is synthesized in 
the testis and is required for normal testicular function. Recently, using MRP1 
expressing cell lines, Qian et al. (2001) showed that MRP1 transports estrogen 
conjugates. MRP1 expression in Leydig cells may serve to protect the testis 
from the potential feminizing effects of endogenously produced estrogen 
conjugates. Treatment with etoposide resulted in increased impairment of 
spermatogenesis in m rpl knockout mice (Wijnholds et al. 1998), indicating that 
m rpl plays an important role in the protection of the Sertoli cells.
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Regardless o f the increased sensitivity toward vincristine and etoposide, in 
terms of lethality (Wijnholds et al. 1998; Johnson et al. 2001) and increased 
bone marrow toxicity (Lorico et al. 1997; Johnson et al. 2001) in mrpl(-/~) 
mice, there is no direct evidence that MRP1 contributes to the systemic drug 
absorption or excretion, consistent with its low expression in gut and liver. 
However, the basolateral location of MRP1 seems to protect basal cell layers 
from destruction. At the cellular level, MRP1 contributes to the resistance of 
cells to a range of anticancer drugs, as demonstrated in vitro in knockout and 
transfected cell lines (Allen et al. 2000; Lorico et al. 1996).
Unlike MRP1, but similar to Pgp, MRP2 localizes to the apical membrane of 
epithelial cells and is predominantly expressed in the liver and intestine 
(Schinkel and Jonker 2003). ln  vivo MRP2 has been found in the bile canali­
cular membrane of hepatocytes, in the luminal membrane of the small intestinal 
epithelium, in the luminal membrane of the proximal tubules of the kidney, and 
in the syncytiotrophoblasts of term placenta. In human jejunum, MRP2 rnRNA 
levels, as measured by RT-PCR, were amongst the highest of all tested ABC 
transporters (Taipalensuu et al. 2001). In brain, mrp2 is expressed in capillary 
endothelial cells (Miller et al. 2000), possibly forming a functional component 
of the blood-brain barrier. Similar location with Pgp, in a range of tissues im­
portant for the pharmacokinetics of drugs, indicates that MRP2 may contribute 
to the systemic drug absorption and disposition. As shown by Dietrich et al. 
(2001 a,b), the mrp2 deficiency in rats increased bioavailability and impaired 
intestinal and hepatobiliary excretion of the food-derived carcinogen 2-amino- 
l-methyl-6-phenylimidazo[4,5-b]pyridine.
Within haematopoetic cells, Pgp has been found to be expressed in all sub­
sets of peripheral blood cells, except in granulocytes (Drach et al. 1992), and 
Pgp contribution to immunological functions has been supposed. Limited 
number of studies with variable results has investigated MRP1 and MRP2 in 
human blood cells. Therefore, the present study aimed to assess the expression 
of MRP1 and M RP2 in different subsets of peripheral blood mononuclear cells 
(PBMC).
2.2. Substrates, inhibitors, and inducers of MRP1 and MRP2
There are many similarities between the spectrum of substrates transported by 
MRP1 and M RP2, with both extruding various exogenous and endogenous 
compounds conjugated with sulfate, glucuronide, or glutathione (Table 3). 
Many good substrates of these transporters are highly charged or hydrophilic 
conjugates which enter intact cells very poorly. Therefore, for the characte­
rization of substrate specificity, vesicular uptake in inside-out vesicles derived 
from MRP1 or M RP2 transfected cells is determined. In vivo studies, the 
toxicological relevance of MRP1 and MRP2 has been investigated using m rpl 
(-/-) knockout mice and mrp2 deficient rats.
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Table 3. Some substrates, inhibitors, and inducers of MRP1 and MRP2.
Substrates MRP1 MRP2 Inhibitors MRP1 MRP2
Anticancer agents probenecid + +
daunorubicin + + sulfinpyrazone + +
doxorubicin + + MK571 + +
etoposide + + indomethacin +
vinblastine + + buthionine
vincristine + + sulfoximine + +
methotrexate + + valspodar + +
cisplatin + cyclosporine A + +
Miscellaneous Inducers
leukotriene C4 + +
glutathione + + cisplatin +
glutathione disulfide + + vinblastine + +
estradiol- dexamethasone +
17 ß-D-glucuronide + + phenobarbital +
estrone 3-sulfate + rifampicin +
monoglucuronosyl sulindac +
bilirubin + +
bisglucuronosyl
bilirubin + +
saquinavir + +
Modified from Faber et al. 2003; Sun et al. 2003; Schinkel and Jonker 2003; Gerk and 
Vore 2002; Leslie et al. 2001; Borst et al. 1999.
The first substrate, shown to be actively transported by MRP1 using inside- 
out vesicles, was the glutathione conjugated leukotriene C4 (Leier et al. 1994). 
M rp I(-/~) knockout mice are viable, fertile, and have no physical or histological 
abnormalities. However, mrp](-/~) mice have an impaired response to inflam­
matory stimulus and decreased secretion of leukotriene C4 from leukotriene 
synthesizing cells (Wijnholds et al. 1997; Verbon et al. 2002; Schultz et al. 
2001). There is no mrp2 knockout mouse, but there are natural mutant GY/TR 
and EHBR rats, lacking mrp2. Studies of mrp2 deficient rats indicated that this 
protein was required for the excretion of a wide range of conjugated organic 
anions, including bilirubin glucuronides into the bile (Borst et al. 1999; Leslie 
et al. 2001).
The involvement of glutathione is an important feature of MRP-mediated 
drug resistance. Transport of vincristine and daunorubicin in membrane vesicles 
from MRP1 expressing cell lines has been found to be dependent on the con­
centration of ATP and glutathione (Renes et al. 1999). Zaman et al. (1995)
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demonstrated that the depletion of intracellular glutathione resulted in a 
complete reversal of resistance to vinca alkaloids and anthracyclines in lung 
carcinoma cells transfected with MRP1. They also showed that the cells 
transfected with MRP1 secreted more glutathione into the medium than parental 
cells. Since stable glutathione conjugates of vincristine and daunorubicin could 
not be detected in media, it was supposed that MRP1 mediates co-transport of 
glutathione and hydrophobic drugs. Also in MRP2 transfected cells, increased 
apical glutathione secretion has been demonstrated (Paulusma et al. 1999), 
vinblastine transport occurred stoichiometrically with glutathione transport 
(Evers et al. 2000), and depletion of cellular glutathione resulted in decreased 
drug resistance (Cui et al. 1999).
In primary cultures of rat hepatocytes, an induction of mrp2 mRNA and 
protein expression after treatment with cisplatin and vinblastine has been found 
(Schrenk et al. 2001), with possible impact on the acquisition of MDR during 
chemotherapy of tumors. In rats, mrp2 was also inducible by dexamethasone 
and phenobarbital. M RP2 has been implicated in drug and estrogen induced 
cholestasis. Pregnancy and treatment of rats with ethinylestradiol markedly 
decreased mrp2 protein expression (Gerk and Vore 2002). In clinical studies, 
expression of M RP2 mRNA and protein was decreased in patients with obstruc­
tive cholestasis (Shoda et al. 2001). In another clinical study, MRP2 mRNA and 
protein expression in the apical membrane of duodenal enterocytes in healthy 
volunteers was significantly induced by rifampin treatment (600mg/day 9 days) 
(Fromm et al. 2000). No increase in MRP1 expression was observed in the 
same study. Upregulation of MRP1 by vinblastine, but not by cisplatin, 
doxorubicin, phenobarbital, rifampicin, and tamoxifen, has been found in 
mammary carcinoma cells (Schrenk et al. 2001).
To reverse M RP-mediated resistance, to improve the efficacy of anticancer 
therapy, the number of small molecular inhibitors that can be used in intact cells 
is quite limited. Several non-steroidal anti-inflammatory drugs, as indomethacin 
and mefenamic acid, have been demonstrated to significantly enhance the cyto­
toxicity of anticancer drugs in vitro when coadministered in MRP1 over­
expressing cell lines (Duffy et al. 1998).
2.3. Biochemical and genetical aspects of MRP1 and MRP2
MRP1 and M RP2 have the same basic structure as Pgp, but in addition they 
have an N-terminal extension consisting of 5 putative transmembrane segments 
(Fig. 1) (Borst et al. 1999). The N-terminus of MRP1 and MRP2 is located 
extracellularly. These proteins are N-glycosylated at the N-terminus and at the 
sixth extracellular loop, and share 49% amino acid identity.
The MRP1 protein comprises 1531 amino acids and is encoded by the MRP1 
gene, which is located in chromosome 16p 13.1 (Grant et al. 1997). Recently,
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identification of several SNPs in the human MRP1 has been reported (Perdu et 
al. 2001; Ito et al. 2001; Conrad et al. 2001; Saito et al. 2002b).
The MRP2 protein comprises 1545 amino acids and MRP2 gene is located to 
chromosome 10q24 (Toh et al. 1999). Mutations in the MRP2 gene were 
reported to cause Dubin-Johnson syndrome (Kartenbeck et al. 1996; Paulusma 
et al. 1997; Toh et al. 1999), an autosomal recessive disease characterized by 
conjugated hyperbilirubinemia. As shown in several studies, hepatobiliary 
excretion of conjugated bilirubin is mediated by M RP2 (Gerk and Vore 2002).
The present study aimed to determine the frequencies of genetic poly­
morphisms in the human MRP1 in healthy Caucasians. Three of the SNPs 
T825C, T1684C, and G4002A, located in exons 8, 13, and 28, respectively, 
were selected for the study. Other SNPs identified previously in exonic regions 
of MRP1 occurred with a low frequency, and were observed by a single 
investigator, but not confirmed by the others. A novel silent mutation G816A in 
exon 8 was identified in this study and the frequency of the G816A in Cau­
casians was also determined.
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AIMS OF THE STUDY
The specific aims of this study were:
1. to assess the impact of the genetic polymorphisms G2677T and C3435T in 
the MDR1 gene, we determined
1.1. Rh 123 efflux in peripheral blood CD56+ and CD4+ cells from healthy 
individuals with different MDR1 genotypes;
1.2. the absorption of a single oral dose of digoxin in healthy subjects with 
different MDR1 genotypes;
1.3.MDR1 mRNA expression in peripheral blood CD4+, CD8+, CD19+, and 
CD56+ cells from healthy individuals with different MDR1 genotypes;
2. to determine the MRP1 and MRP2 mRNA expression in human peripheral 
blood CD4+, CD8+, CD19+, and CD56+ cells;
3. to investigate the prevalence of the genetic polymorphisms G816A, T825C, 
T1684C, and G4002A in the MRP1 gene in healthy Caucasians, and to assess 
the functional importance of these polymorphisms by determining MRP1 
mRNA levels in peripheral blood CD4+ cells from healthy individuals with 
different MRP1 genotypes.
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METHODS AND MATERIALS
1. Study subjects
The study protocols were approved by the Ethics Committee of the Humboldt 
University. All subjects gave their written informed consent before entry into 
the study. The subjects took no medication and were ascertained to be healthy 
by a clinical examination and routine laboratory tests.
46 male healthy volunteers (age range 19 to 45 years, median 25 years) were 
recruited for the R hl23  efflux study.
A total of 50 healthy male Caucasians (nonsmokers, age range 19 to 45 
years, median 26 years) were enrolled in the digoxin study. Their weight ranged 
from 45.1 kg to 74.6 kg. Electrocardiogram, urine analysis, and tests for 
hepatitis В and C, and HIV were performed before the study. All volunteers 
refrained from alcohol, coffee, tea, and cola beverages consumption.
45 healthy Caucasians (39 males and 6 females, age range 21 to 33 years, 
median 25 years) were enrolled in the MDR1 mRNA expression study.
20 healthy volunteers (17 males and 3 females, age range 21 to 33 years, 
median 25 years) were enrolled in the MRP1/MRP2 mRNA expression study.
The prevalence of the MRP1 genetic polymorphisms was studied in DNA 
samples from 230 healthy unrelated Caucasians of German origin (194 males 
and 36 females, age range 20 to 59 years, median 28 years).
To assess the functional importance of the MRP1 polymorphisms, MRP1 
mRNA levels in CD4+ cells were determined in 61 healthy volunteers (47 males 
and 14 females, age range 21 to 32 years, median 26 years).
2. Materials
Biocoll lymphocyte separating solution (density 1.077 g/ml) was from Biochrom 
KG (Berlin, Germany). M I C- and PE-conjugated antibodies were obtained from 
Immunotech Beckman Coulter (Munich, Germany); APC- and PerCP-Cy5.5- 
conjugated antibodies were from Becton Dickinson (San Jose, CA, USA). Rhl23, 
verapamil hydrochloride, BSA fraction V powder, and DMSO were purchased 
from Sigma Chemicals (Munich, Germany). DMEM, FBS, and PBS were 
obtained from Gibco-BRL (Karlsruhe, Germany). All oligonucleotide primers 
and hybridisation probes for PCR and RT-PCR were from Tib Molbiol (Berlin, 
Germany). 10 x PCR buffer, MgCl2, and dNTPs were obtained from Rapidozym 
(Berlin, Germany). Recombinant RNasin® ribonuclease inhibitor, T7 RNA 
polymerase and RQ1-DNase were purchased from Promega (Madison, WI, 
USA); 5 x First Strand Buffer, 10 mM DTT, M-MLV reverse transcriptase and 
Taq DNA Polymerase from Invitrogen (Karlsruhe, Germany). BioTherm™ DNA 
polymerase was from GeneCraft (Munster, Germany).
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3. Rhl23 efflux study
PBMC were isolated from 20 ml whole blood by gradient centrifugation over 
Biocoll lymphocyte separating solution. To allow Rhl23 accumulation, cell 
suspension (lx lO 6 cells/ml in DMEM/10%FBS) was incubated for 30 min at 
37°C in 5% C 0 2 with R hl23 in a final concentration o f 150 ng/ml (0.39 цМ). 
After accumulation, the control sample was put on ice for a measurement of the 
baseline dye uptake. The efflux samples were performed for 30 min and 90 min 
efflux at 37°C in 5% C 0 2 in a R hl23 free medium for the measurement of 
R hl23 efflux in CD56+ and CD4+ cells, respectively. In parallel, one sample 
was incubated with verapamil hydrochloride in a concentration of 1 |lg/ml 
(2 |iM). After efflux, samples were washed with cold PBS and stained with PE- 
anti-CD56 or PE-anti-CD4 antibody. PE-mouse IgGj antibody was used as an 
isotype control.
After staining, cells were analysed using a FACScan™ flow cytometer 
(Becton Dickinson, San Jose, CA, USA) equipped with a 488 nm argon laser. 
The viability of isolated cells was determined using a trypan-blue exclusion and 
was always greater than 97%. The samples were gated on forward scatter versus 
side scatter to include lymphocytes. A second gate was set around the PE- 
CD56+ or PE-CD4+ cells. A minimum of 2000 of CD56+ and CD4+ events were 
collected per sample. Data was expressed as median R hl23 fluorescence in 
CD56+ and CD4+ cells. Median R hl23 fluorescence in control sample, after 
baseline dye uptake, was set as 100% (Fig. 2). R hl23 fluorescence in efflux 
sample was used to calculate % of R hl23 retained in the cells in comparison to 
control. Final data was presented as the mean±SD of Rhl23 efflux for each 
genotype group. The coefficient of variation for interassay variability of the 
R hl23 efflux was less than 2%.
4. Digoxin study
4.1. Study protocol
After an overnight fast, each subject received a single oral dose of 1 mg digoxin 
(Dilanacin™, Arzneimittelwerk Dresden GmbH, Radebeul, Germany) along 
with 200 ml water. Venous blood samples (5 ml) for drug analysis were 
collected before and 10, 20, 30, 35, 40, 45, 50, 60, 75, 90, 120, 180, and 240 
min after digoxin intake. The plasma was separated by centrifugation and stored 
at -22°C  until analysis.
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4.2. Digoxin concentration measurements and pharmacokinetic analysis
Digoxin plasma concentrations were determined by an immunoassay (IMx® 
Digoxin Assay, Abbott Laboratories, USA). The lower limit of quantification 
was 0.3 p.g/1. The plasma samples o f each volunteer were analysed in duplicate 
together with calibration and quality control samples. Further calculations were 
done with the respective mean values. The interassay coefficient of variation at 
plasma concentrations o f 0.9 p.g/1, 1.9 pg/1, and 3.2 pg/1 were 8.37%, 5.75%, 
and 4.68%, respectively.
Стах and tmax of digoxin were derived directly from the measured values. The 
tmax for digoxin ranged from 0.5 to 3 h in our samples. Thus, an AUC from 0 to 
4 h (AUC0_4h) was considered a suitable measure of digoxin absorption. AUCo_4h 
was calculated by use of the trapezoidal rule, using WinNonlin™ (version 1.5, 
Pharsight Corporation, Mountain View, CA, USA).
A. B.
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Figure 2. Two-dimensional flow cytometric dot piots of a two-colour flow cytometric 
assay of CD56+ natural killer cells. PE-CD56 versus Rhl23 fluorescence is shown. 
Rhl23 fluorescence was determined in cells gated for lymphocytes and PE-CD56 
profile. Median Rhl23 fluorescence in control sample (A) was set as 100%. Rhl23 
fluorescence in efflux samples incubated for 30 min in a Rhl23 free medium without 
verapamil (B) and with 2 pM verapamil (C) was used to calculate % of Rhl23 retained 
in the cells in comparison to control.
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5. Principles of the LightCycler™ technology
The LightCycler technology comprises fluorescence based method for the 
detection of PCR amplification in real-time (Meuer et al. 2001). PCR reaction 
mixture contains, in addition to the reaction components used for conventional 
PCR, two sequence-specific oligonucleotides (hybridisation probes) labelled 
with fluorescent dyes. The hybridisation probes hybridize during the annealing 
step of each PCR cycle adjacently to target DNA within a primer set (Fig. 3). 
One of the probes (donor) has a fluorescein label at its 3 "end and another probe 
(acceptor) has LC Red640 or LC Red705 label at its 5 'end. The donor’s 
fluorescein dye is excited by the LightCycler Light Emitting Diode and 
thereupon emits fluorescent light at 530 nm. The emitted energy excites the 
acceptor LC Red640 or LC Red705 dye that subsequently emits fluorescent 
light at 640 nm or 705 nm, respectively. This energy transfer, referred to as 
fluorescence resonance energy transfer, occurs only when both of the 
hybridisation probes are bound to their target and locate in close proximity (1-5 
nucleotides apart). The intensity of the light emitted by the LC Red640 or LC 
Red705 is measured by the LightCycler optics.
LightCycler technology allows cDNA quantification and detection of genetic 
polymorphisms.
During quantification, the fluorescence is monitored at each cycle and the 
second derivative maximum method automatically calculates the cycle num­
bers, referred to as crossing point, where the second derivative is at its maxi­
mum. A calibration curve is generated by plotting the crossing point versus the 
logarithm of copies in respective standard sample (Fig. 4). The calibration 
curve, in turn, is used to estimate the number of copies in unknown samples.
For the detection of genetic polymorphisms, melting curve analysis of the 
PCR products is performed subsequently to an amplification run. The cycle 
program for melting curve analysis comprises a slow heating (temperature 
elevation of 0.1-0.2°C/sec) to monitor the melting of the hybridisation probes 
from double stranded DNA. When hybridisation probes melt, the fluorescence 
decreases. Melting temperature has been defined as a temperature at which 50% 
of the probe has separated from the template. One of the hybridisation probes, 
referred to as sensor, covers the predicted site of the mutation and is comple­
mentary to the wild type allele (or to the mutated sequence). If the amplified 
gene carries a point mutation within this specific region, a single mismatch 
significantly reduces the melting temperature of the sensor. Therefore, the wild 
type sample (if sensor is complementary to the wild type sequence) has a higher 
melting temperature than the mutant sample. For visualisation of melting tem­
peratures, melting peaks are displayed by plotting the negative derivative of 
fluorescence versus temperature (Fig. 5).
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Figure 3. Schematic illustration of the principles of the LightCycler technology. Donor 
excitation by a Light Emitting Diode (LED) leads to the fluorescence resonance energy 
transfer and excitation of acceptor dye. The light emitted by the acceptor dye is 
measured by the LightCycler optics. FI -  fluorescein label, F2 -  LC Red640 or LC 
Red705 label.
6. Quantitative determination of the MDR1, MRP1, 
and MRP2 mRNA expression in a LightCycler
6.1. Cell sorting and isolation of total RNA
PBMC were isolated from 20 ml whole blood by gradient centrifugation over 
Biocoll lymphocyte separating solution. Cells were stained with FITC-anti- 
CD4, PE-anti-CD56, APC-anti-CD8, and PerCP-Cy5.5-anti-CD19 antibody, 
and sorted using FACSDiva™  Turbosorter (Becton Dickinson). Purity of sorted 
cells was analysed with FACSCalibur™  and was > 98% (n=10). Total RNA 
from FACS-sorted cells was isolated with the RNeasy Mini Kit (QLAGEN, 
Hilden, Germany). RNA concentration was measured spectrophotometrically 
and samples were maintained at -80°C  until analysis.
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Table 4. Oligonucleotide primers and hybridisation probes used for real-time quantitative RT-PCR.
Gene Sequence* Position (bp)
MDR1
Forward primer 
Reverse primer 
LightCycler probes
5 ’ -CC АТС ATTGC A ATAGC AGG-3 ’
5 ’ -G AGC ATAC ATATGTTC A A ACTTC-3 ’
5 ’ -TGGG AAG ATCGCT ACTG A AGC A AT-3 ’ -fluorescein 
5 ’ -LC Red640-AACTTCCGAACCGTTGTTTCTTTGA-3 ’ -phosphate
(3018-3036)
(3163-3185)
(3100-3123)
(3128-3152)
MRP1
Forward primer 
Reverse primer 
LightCycler probes
5 ’ -TTCCGG A ACT ACTGCCTGCGCT A- 3 ’
5 ’ -GGGTCCTGGGGG ATG ATGGTG A-3 ’
5 ’ -CTCGTTG ATCCG A A ATA AGCCC AGGGTC A-3 ’ -fluorescein 
5 ’ -LC Red640-ACGACTTCCCAGCTCCCGTCCGCC-3 ’ -phosphate
(4079-4101)
(4143-4164)
(4231-4203)
(4199-4176)
MRP2
Forward primer 
Reverse primer 
LightCycler probes
5 ’ -GGCTG AG ATTGG AG AG A AGGGT AT A- 3 ’
5 ’ - ACTGC AG AC AGGGGGTC AT-3 ’
5 ’ -TTTGGTAGGT AGCTCTGGCC AGGCT-3 ’ -fluorescein 
5’-LC Red640-ATCCGCTGCTTCTGACCCCCAC-3’-phosphate
(2292-2314)
(2409-2391)
(2369-2345)
(2343-2322)
T7 primer** 
RT primer***
5 ’ - AGAGCGT AAT ACG ACTC ACT AT AGGGTATCTGC AG A- 
5 ’ -ТТТТТТТГП ’П Т 1T-
* Area amplified refers to sequences with accession numbers as follows: NM_000927 (MDR1), NM_004996 (MRP1), 
NM_000392 (MRP2).
** T7 promoter sequence was incorporated at the 5’-end of the forward primers to obtain templates for in vitro external 
standard RNA synthesis.
*** dT(15) sequence was incorporated at the 5’end of the reverse primers to obtain templates for in vitro external standard 
RNA synthesis.
6.2. R eal-tim e quantitative R T-PCR assays
cDNA was synthesized from total RNA in а 25ц1 final reaction volume 
containing 50 ng of sample RNA or dilutions of standard RNA (run in the same 
plate but separate tubes), 1 x First Strand Buffer, 10 mM DTT, 0.4 mM of each 
dNTP, 8 U ribonuclease inhibitor, 120 U M-MLV reverse transcriptase and 0.8 
|iM  oligo dT(15) primer. The mixture was pre-incubated for 10 min at 26°C, 
then incubated at 42°C for 60 min followed by heating at 95°C for 2 min, and 
cooled.
Quantitative PCR was performed with gene-specific primers and hybridi­
sation probes shown in Table 4 in a LightCycler. PCR amplification was carried 
out in a 16 ц1 reaction volume containing 5 jil of cDNA (of 25 |il of total 
cDNA), 1.25 U Taq DNA Polymerase, 1.6 |il of 10 x PCR buffer, and MgCl2, 
dNTPs, reverse and forward primer, hybridisation probes, BSA and DMSO 
optimised for each reaction. The PCR reactions were initiated with a denatura- 
tion at 94°C for 60 sec, followed by the amplification with 45 cycles at 95°C 
0 sec, annealing (depending on the primer pair) for 10 sec, and 72°C for 10 sec. 
Calibration curves were generated from serial dilutions of the external standard 
cDNAs and used to estimate the number of mRNA copies in samples (Fig. 4). 
Final data was expressed as the mean±SD of the MDR1 (or MRP1 or MRP2) 
mRNA copies/ng of total RNA. The coefficient of variation for MDR1, MRP1, 
and M RP2 mRNA levels were 8.9%, 26.1%, 21.5%, respectively. PCR products 
migrated as a single fragment with an expected size on an agarose gel. The 
specificity of PCR products was verified by sequencing (ABI Prism™ 310, 
Applied Biosystems, Foster City, CA, USA).
6.3. Synthesis of external standards for quantitative real-time RT-PCR
In order to establish the calibration standard curve, external standard RNA was 
prepared. RT-PCR was carried out in a two-step reaction for each gene as 
described above, using primers listed in Table 4. The subsequent PCR with T7 
prim er (T7 promoter sequence was incorporated at the 5’-end of the forward 
primer) and RT primer (dT(15) sequence was incorporated at the 5’-end of the 
respective reverse primer) was carried out to obtain a template for in vitro 
transcription. After purification with Ultrafree MC 30.000 filters, the template 
was used for in vitro transcription at 37°C for 90 min using the DNA-dependent 
T7 RNA polymerase. After digestion with RNase-free RQ1-DNase, RNA 
transcripts were purified using RNeasy Mini Kit and RNA Cleanup Protocol 
from QIAGEN. All of the RNA standards were quantified spectrophoto- 
metrically and maintained at -80°C . The number of standard RNA molecules 
was determined as follows:
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Figure 4. Representative amplification plot for MDR1 mRNA expression. (A) Ampli­
fication curves of serial dilutions of standard RNA, ranging from lx l08 to lxlO3 starting 
copies, were displayed by plotting the fluorescence data versus cycle number. No­
template controls for RT and PCR were also performed. (B) Calibration curve was 
generated by plotting the crossing point versus the logarithm of the number of copies of 
standard RNA. Crossing point values for unknown samples were interpolated on the 
calibration curve and used to calculate the number of copies.
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RNA concentration (R N A ^ )  = А2бо x 40 |ig/ml
where A 26o is an absorbance at 260 nm, and when A 26o=l> then spectrophoto- 
metric conversion for single stranded RNA is 40 ng/ml
number o f standard RNA molecules/ц! =
___________ RNAconc x 6.02 x 1023x IQ'9__________
number of bp of standard RNA x 330 p.g/|j.mol
where 6.02 x 1023 is Avogadro number, and 330 (ig/^mol is an average mole­
cular weight of a nucleotide in RNA.
The specificity of obtained transcripts was verified by sequencing with ABI 
Prism™ 310 gene analyser. A series of dilutions of external standard RNA were 
performed.
7. Determination of the G2677T and C3435T SNPs in the 
MDR1, and the G816A, T825C, T1684C, and G4002A SNPs 
in the MRP1 using a LightCycler
DNA was isolated from 200 Ц.1 of whole blood by M agNA Pure® LC (Roche, 
Mannheim, Germany). Genotyping was performed with gene-specific primers 
and hybridisation probes shown in Table 5 in a LightCycler. Genomic DNA 
was added to PCR mixtures (20 jj.1) consisting o f 1 x PCR buffer, 0.1 mM each 
dNTP, 30 mg/L BSA, and M gCl2, DMSO, forward and reverse primer, 
hybridisation probes, and BioTherm™  DNA polymerase optimised for each 
reaction. After an initial denaturation at 95°C for 30 sec, the amplification was 
performed by means o f 45 cycles of denaturation at 95°C for 0 sec, annealing 
(depending on the primer pair) for 15 sec, and extension at 72°C for 15 sec. 
M elting curve acquisition was from 35°C to 95°C at 0.1-0.2°C/sec, optimised 
for each reaction. Confirmation of the LightCycler analysis was performed by 
sequencing on an ABI Prism™ 310 automatic sequencer and by PCR-RFLP. 
Typical results for melting curve analysis, as determined in a LightCycler, are 
shown in Fig. 5. At position 2677 in the MDR1 three nucleotide variants (G, T, 
or A) have been identified. The frequency of the A2677 allele has been 
observed to be very low in Caucasians (Cascorbi et al. 2001). In our study, 
individuals carrying the A allele (genotype GA with melting temperature 58°C 
and ТА with melting temperature 52/59°C) were excluded from the analysis.
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Table 5. Oligonucleotide primers and hybridisation probes used for PCR.
Gene Sequence* Position (bp)
MDR1
G2677T
Forward primer 5 ’ -GC AGGAGTTGTTGA AATG A AA ATG-3 ’ (156-179)
Reverse primer 5 ’ -CGCCTGCTTT AGTTTGACTC A-3 ’ (232-252)
Sensor 5’-ACCTTCCCAGTACCTTCT-3’-fluorescein (215-232)
Anchor 5’-LС Red640-CTTTCTTATCTTTCAGTGCTTGTCC-3’-phosphate (186-210)
C3435T
Forward primer 5 ’-TGTTTTC AGCTGCTTGATGG-3 ’ (15-34)
Reverse primer 5 ’ - A AGGC ATGT ATGTTGGCCTC-3 ’ (192-211)
Sensor 5 ’ -LC Red640-GGAAGAGATCGTGAGGGC AG-3 ’ -phosphate (167-186)
Anchor 5’-GACAACAGCCGGGTGGTGTCA-3’-fluorescein (144-164)
MRP1
G816A
Forward primer 5 ’ -TGTGGTAGGGGGCTGC A-3 ’ (13-29)
Reverse primer 5 ’-TTCGC ATCC ACCTTGG AACT-3 ’ (125-144)
Sensor 5 ’ -LC-Red705-GTTCC AGGC AGCCAGTGA A-3 ’ -phosphate (66-84)
Anchor 5 ’ -CCC AC AACGGCTTC ACCTCCTT-3 -fluorescein (42-63)
T825C
Forward primer 5’-TGTGGTAGGGGGCTGCA-3’ (13-29)
Reverse primer 5’-TTCGCATCCACCTTGGAACT-3’ (125-144)
Sensor 5 ’ -GTG AAGGTCGTGTACTCC-3 ’ -fluorescein (80-97)
Anchor 5 ’ -LC-Red640-CC AAGG ATCCTGCCC AGCCGA A-3 ’ -phosphate (99-120)
T1684C
Forward primer 5 ’ - ACTCGGGGC AC AGC AGT-3 ’ (33-49)
Reverse primer 5 ’ -TTG A AC AAGGCC AAAGACA-3’ (149-167)
Sensor 5 ’ - ACGGC A AATGTGC AC A AGGCC-3 ’ -fluorescein (78-98)
Anchor 5 ’ -LC-Red640-CCTGC A AGC AAG AACGCCC AGTG-3 ’ -phosphate (54-76)
G4002A
Forward primer 5 ’ -GCC AGC ATTCCC ACC AC ACCT-3 ’ (28-48)
Reverse primer 5 ’ -GCTTGCC AGCTCTGGCTCACC-3 ’ ** (251-271)
Sensor 5 ’ -GGTC AGGG ACGAC11CCC-3 ’ -fluorescein (95-112)
Anchor 5 ’ -LC-Red640-CTCCCGTCCGCCCC ACG-3 ’ -phosphate (76-92)
* Area amplified refers to sequences with accession numbers as follows: M29440 
(G2677T), M29445 (C3435T), AF022830 (G816A, T825C), AF022835 (T1684C), 
AF022850 (G4002A).
** PCR primer as reported by Ito et al. (2001).
The position of the variable base in sensor is underlined.
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Figure 5. Melting curve analysis of the G2677T (A) and C3435T (B) SNPs in the 
MDR], and the G816A (С), T825C (D), T1684C (E) and G4002A (G) SNPs in the 
MRP 1 using a LightCycler.
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8. Statistical analysis
Differences in R hl23 efflux between three genotype groups were compared 
using the Student’s unpaired r-test. Pharmacokinetic parameters of digoxin were 
compared between the wild type groups and those carrying a SNP using the 
nonparametric Kruskal-Wallis test. Differences in MDR1, MRP1, and MRP2 
mRNA expression between cell populations were analysed by Wilcoxon signed 
ranks test. MDR1 and MRP1 mRNA expression between three genotype groups 
was analysed by Kruskal-Wallis test. All calculations were performed with 
SPSS™ for Windows (version 10.0, SPSS Inc., Chicago, IL, USA).
OR, 95%CI, and P for the allele and genotype frequencies of the MRP 1 were 
calculated using Fisher’s exact test (STATA, version 7.0, Stata Corporation, 
College Station, TX, USA). Estimation of haplotype frequencies for MRP1 was 
performed using the program FASTEH+ based on the expectation-maximiza- 
tion algorithm (Zhao and Sham 2002). Linkage disequilibrium between the 
pairs of SNPs was determined using the disequlibrium coefficient D \
P values of 0.05 were considered to be of statistical significance.
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RESULTS AND DISCUSSION
1. Impact of the G2677T and C3435T SNPs in the MDR1 gene 
on Pgp function and expression
1.1. Rhl23 efflux study
A clear difference concerning the R hl23 efflux pattern was observed between 
the CD56+ and CD4+ cells (Table 6), which is in accordance with studies pub­
lished previously (Drach et al. 1992). Statistical analysis revealed no significant 
differences in R hl23  efflux in CD56+ and CD4+ cells between individuals with 
different MDR1 genotypes. The verapamil effect on Pgp activity was analysed 
after 30 min of R hl23  efflux in CD56+ cells and after 90 min efflux in CD4+ 
cells. Verapamil was a strong inhibitor of R hl23 efflux, but this effect was not 
associated with the genetic polymorphisms at G2677T and C3435T. When 
Rhl23 efflux rate was calculated by comparing fluorescence measurement in 
CD56+ and CD4+ cells, incubated in a R hl23 free medium with or without 
verapamil, no significant differences between individuals with different MDR1 
genotypes were observed.
Pgp has been found to be expressed and functionally active in all peripheral 
blood cells, except in granulocytes (Drach et al. 1992). A good correlation 
between R hl23 efflux, Pgp expression, and MDR1 mRNA levels has been 
found (Drach et al. 1992; Robey et al. 1999). For studies designed to overcome 
Pgp mediated resistance, measurement of the extent of in vivo inhibition of Pgp 
mediated drug efflux is deemed essential. It has been shown that PSC833 effect, 
a selective inhibitor for Pgp, decreased with an increase in Pgp expression and 
the high Pgp expression could explain an incomplete reversal of Pgp-mediated 
Rhl23 efflux by PSC833 in some patients (Robey et al. 1999). No Pgp inhibitor 
was used for pretreatment of control cells in our study. However, one sample, 
incubated with verapamil, was used as a positive control for the method.
An impaired R hl23  efflux in haematopoietic progenitor cells from m drla/  
lb(-/~) knockout mice compared to wild type mice has been demonstrated by 
Schinkel et al. (1997). In humans, Hitzl et al. (2001) demonstrated a slower 
Rhl23 efflux in CD56+ natural killer cells in individuals with TT genotype at 
3435 compared to CC genotype. However, Calado et al. (2002) found no 
significant differences in R hl23  efflux in CD34+ cells between individuals with 
different G2677T and C3435T genotypes.
In contrast to m drl knockout mice, the carriers of the G2677T and C3435T 
SNPs in the MDR1 do not lack Pgp expression. Hoffmeyer et al. (2000) found 
that Pgp expression in duodenal enterocytes from TT3435 subjects was signi­
ficantly lower than from CC3435 subjects. There is a considerable overlap 
between the substrate specificity of Pgp and other ABC transporters. Daoud et 
al. (2000) reported that R hl23  also binds to multiple sites on the MRP1. There­
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fore, it is not possible to exclude a confounding effect of other transporters on 
R hl23 efflux.
Table 6. Rhl23 efflux in CD56+ and CD4+ cells from individuals with different 
G2677T and C3435T genotypes of the MDR1 gene.
G2677T C3435T
GG(n=22) GT(n=14) TT(n=9) CC(n=17) CT(n=14) TT(n=15)
CD56+
30 min 
verpamil*
27.5±4.7
88.7±6.0
26.9±5.0
86.0±7.2
24.6±3.7
89.5±5.3
28.0±5.3
89.7±6.3
26.7±4.4
84.6±6.7
25.5±3.9
88.8±5.0
CD4+
90 min 62.6±7.8 60.5±7.5 60.5±8.7 64.4±7.0 60.1 ±7.8 59.3±8.1
verpamil* 91.8±3.9 93.8±4.1 90.3±5.7 92.8±3.3 91.6±5.0 91.7±5.5
Data are presented mean±SD in %. After Rhl23 accumulation, cells were incubated for 
30 min and 90 min in a Rhl23 free medium for the measurement of Rhl23 efflux in 
CD56+ and CD4+ cells, respectively, with (*) or without 2 цМ verapamil. Numbers in 
parenthesis indicate the number of individuals. One individual was determined to carry 
the A allele at 2677 and was excluded from the G2677T analysis. P values according to 
unpaired t-test exceeded values 0.05.
1.2. Digoxin study
Pharmacokinetic parameters of a single oral dose of 1 mg digoxin, characterized 
by AUC0.4h, Стах, and tmax, were not significantly different between individuals 
with different MDR1 genotypes (Table 7, Fig. 6). No significant differences 
were observed after normalization to ideal body weight (data not shown). 
Digoxin is considered a good probe for Pgp, since it’s metabolized in a minor 
extent in humans. The experimental design was chosen to assess the impact of 
the MDR1 SNPs on the absorption of digoxin, since Pgp acts primarily as an 
efflux pump across apical membranes of enterocytes.
Several studies have determined the potential effects of the G2677T and 
C3435T SNPs in the MDR1 on disposition of drugs (Table 8). Comparison of the 
Стах values for 0.25 mg digoxin after oral administration on steady state 
conditions revealed that subjects homozygous for TT had significantly higher 
Стах values than those with CC genotype (Hoffmeyer et al. 2000). Comparison of 
the AUCo-qo values for a single oral dose of 180 mg fexofenadine revealed no 
significant differences between healthy individuals with different G2677T and 
C3435T genotypes (Drescher et al. 2002). No association between the C3435T 
mutation and the doses needed to maintain similar cyclosporine A trough con­
centrations was observed in renal transplant recipients (von Ahsen et al. 2001).
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The conflicting results obtained by different authors could partially be 
explained by differences in study design. Various transporters, other than ABC 
transporters, have been reported to contribute to the disposition of drugs. For 
instance, in humans, digoxin has been shown to be a substrate for the organic 
anion transporting polypeptides, also expressed in intestine (Hagenbuch and 
M eier 2003). A large variation in the distribution of the kinetic data within the 
genotype groups in our study indicates that further transporters and hitherto 
unknown SNPs may influence the absorption of digoxin.
Table 7. Pharmacokinetic parameters of a single 
oral dose of 1 mg digoxin in individuals with 
different G2677T and C3435T genotypes in the 
MDR1 gene.
Genotype Стах (Hg/l) Tmax (h)
2677GG (n=12) 4.22±1.5 1.00±0.4
2677GT (n=21) 3.91±1.0 1.00±0.6
2677TT (n=7) 3.69±0.8 1.10±0.5
3435CC (n=12) 4.12±1.2 0.92±0.2
3435CT (n=25) 3.87±1.3 1.05±0.6
3435TT (n=13) 4.14±1.1 0.95±0.4
Data are presented as mean±SD. P values ac­
cording to Kruskal-Wallis test exceeded values 
0.05. Individuals carrying the A allele at 2677 
were excluded from the analysis of the G2677T 
SNP. n = number of individuals.
A. B.
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Figure 6. AUCo_4h data for a single oral dose of 1 mg digoxin in healthy individuals in 
relation to the G2677T (A) and C3435T (B) MDR1 polymorphisms. The boxes repre­
sent the distribution of the 25th to 75th percentiles, the bars represent the 5th to 95th 
percentiles. Median values for each genotype group are given within the boxes. P values 
according to Kruskal-Wallis test exceeded values 0.05. n = number of subjects.
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Table 8. Some of the studies, where the impact of the G2677T and C3435T SNPs in the 
MDR1 on the disposition of drugs that are substrates for Pgp has been investigated.
Drug SNP Result Reference
Digoxin C3435T Cmax: TT>CC Hoffmeyer et al. 2000
C3435T AUC(Mh: CC>CT=TT Sakaeda et al. 2001
Fexofenadine C3435T
G2677T
AUCW CC=TT
g g =g t =t t
Drescher et al. 2002
C3435T
G2677T
AUC(Mh: CT>CC>TT 
GT=GG>TT
Kim et al. 2001
Talinolol C3435T
G2677T
AUCo-co: CC=CT=TT 
GG=GT=TT
Siegmund et al. 2002
Nelfinavir C3435T Plasma concentration: 
CC>CT>TT
Fellay et al. 2002
Cyclosporine A C3435T Dose adjusted through 
concentration: CC=CT=TT
von Ahsen et al. 2001
C3435T AUCo-24h- CC=CT=TT Min et al. 2002
Docetaxel C3435T Clearance: CC=CT=TT Goh et al. 2002
Tacrolimus C3435T Concentration:dose ratio 
CC=CT=TT
Goto et al. 2002
Modified from Fromm 2003.
1.3. MDR1 mRNA expression study
The MDR1 mRNA exhibited the highest abundance in CD56+ cells (1430±485 
molecules/ng of total RNA) and a 14 fold variation between individuals (Fig. 
7). The lowest expression of the MDR1 mRNA was found in CD19+ cells 
(223±98.8) with an 8 fold variation between individuals. The differences in 
MDR1 mRNA expression between cell populations were statistically significant 
(P<0.0001), except CD4+ versus CD19+cells (P>0.05). No significant differen­
ce (P>0.05) in the MDR1 expression, in regard to different genotypes at 
G2677T and C3435T in the MDR1, was observed (Fig. 7). Although the diffe­
rence was not significant, both polymorphisms were associated with the lowest 
level of mRNA in homozygous mutant individuals in CD8+ and CD56+ cells, 
and heterozygous individuals displayed an intermediate phenotype.
The association between the MDR1 genetic polymorphisms and MDR1 
mRNA and/or Pgp expression has been investigated in several studies. Higher
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mRNA levels, in duodenal enterocytes in healthy subjects homozygous for TT 
at 3435 than in CT or CC individuals, were observed by Nakamura et al. 
(2002). In contrast, quantification of MDR1 transcripts and Pgp expression in 
PBMC from HIV-infected individuals showed significantly lower mRNA and 
protein levels in 3435 TT than in CC subjects (Fellay et al. 2002). A good 
correlation between Pgp expression and SNP in the promoter region T-129C of 
the MDR1 was found in placental samples from Japanese women (Tanabe et al.
2001). However, the G2677T and C3435T SNPs did not show statistically 
significant effect. Markedly lower renal Pgp expression and an increased risk 
for development of renal epithelial tumors was observed in individuals homo­
zygous for TT than those homozygous for CC at 3435 (Siegsmund et al. 2002). 
In contrast, in previously untreated acute myeloid leukaemia patients the 
CC3435 genotype demonstrated lower bone marrow MDR1 mRNA expression 
and significantly decreased overall survival in comparison with TT3435 geno­
type when treated according to protocol (Illmer et al. 2002).
The conflicting results obtained by different authors indicate the complex 
regulation of the MDR1 gene expression. These results also raise the possibility 
of differential gene regulation in various body tissues.
A. B.
CD4+ CD8f CD19+ CD56+ CD4+ CD8+ CD19+ CD56+
Figure 7. MDR1 mRNA levels in PBMC from individuals with different G2677T (A) 
and C3435T (B) genotypes in the MDR1. Each bar represents the mean±SD. P values 
according to Kruskal-Wallis test exceeded 0.05. One individual was determined to carry 
ТА at 2677 and was excluded from the analysis of the G2677T SNP. n = number of 
subjects.
1.4. General discussion concerning the impact of the G2677T and 
C3435T SNPs in the MDR1 on Pgp activity and expression
It’s known that the expression of the MDR1 in gastrointestinal tract and kidney 
significantly alters the extent of drug absorption and excretion. Numerous
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SNPs, identified within the MDR1 gene, support that wide interindividual 
variation in disposition of drugs, which are substrates of Pgp, may have a 
genetic basis. In several studies, the potential role of the SNPs in the MDR1 in 
Pgp expression and activity has been investigated, but the results published so 
far are conflicting.
In the first published studies solely the impact of the C3435T polymorphism 
in the MDR1 was investigated, on a basis of the study from Hoffmeyer et al. 
(2000). Later, a strong association between the SNPs G2677T and C3435T was 
observed (Tanabe et al. 2001). The G to T transversion at position 2677 results 
in amino acid Ala 893 change by Ser. The C3435T SNP is a silent poly­
morphism that does not result in its encoded lie amino acid change. Therefore, 
it was supposed that the linked polymorphism G2677T rather than C3435T is 
causative for individual differences in Pgp expression and function. When the 
studies were extended to investigate the impact of the G2677T on Pgp, the 
results remained conflicting. More recently, strong linkage disequilibrium 
between the SNPs T1236C in exon 12, G2677T in exon 21, and C3435T in 
exon 26 was observed in a population of European Americans and African 
Americans (Kim et al. 2001), and in Asian subjects (Tang et al. 2002). The 
linkage disequilibrium, spanning the 40 kb between exon 12 and exon 26, 
varied among different Asian ethnic groups. Phenotype-genotype correlations 
using MDR1 haplotypes were therefore supposed to provide a greater power to 
detect associations with functional differences. Two studies have investigated 
the role of the MDR1 genetic polymorphisms in pharmacokinetics of digoxin by 
haplotype analysis. A significantly lower oral bioavailability of a single dose of 
digoxin in GG2677/CC3435 subjects compared with those of noncarriers was 
observed by Kurata et al. (2002). No significant differences in steady state 
pharmacokinetics of digoxin between GG2677/CC3435 and TT2677/TT3435 
individuals were observed by Johne et al. (2002). In our studies, no significant 
differences between the GG2677/CC3435 and TT2677/TT3435 groups were 
observed in R hl23 efflux, in digoxin absorption and in MDR1 mRNA expres­
sion (data not shown).
Synonymous coding SNPs do not lead to amino acid changes, but the variant 
mRNA transcripts may exhibit altered stability and/or splicing, these changes 
may alter protein expression. Nonsynonymous coding SNPs result in amino 
acid differences that may affect overall protein structure, cellular localization, 
and affinity with individual substrates. Introduction of different amino acid 
substitutions into various positions along the Pgp affected drug resistance in 
varying degrees. For instance, cells carrying the Val to Ala change at position 
338 exhibited increased resistance to colchicine and doxorubicin, and reduced 
resistance to vinblastine (Loo and Clarke 1994). While cells carrying the Gly to 
Val change at position 341 have decreased resistance to colchicine and doxo­
rubicin, but resistance to vinblastine and actinomycin D was unchanged. Using 
a vaccinia virus-based expression system, no modification of Pgp cell surface 
localization and expression was observed by the G2677T MDR1 SNP (Kimchi-
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Sarfaty et al. 2002). Transport studies indicated that the substrate specificity of 
the pump to several compounds was not substantially affected by the tested 
polymorphism. There is a possibility that the G2677T SNP could affect disposi­
tion of some drugs, other than investigated so far. However, this does not 
explain the conflicting results as obtained from different authors using the same 
probe drug.
In summary, no significant difference in MDR1 mRNA expression between 
individuals with different G2677T and C3435T genotypes, and accordingly the 
lack of association between the MDR1 SNPs and R hl23 efflux in PBMC and 
digoxin pharmacokinetics was observed in the present studies. These findings, 
together with evidence from studies published previously, indicate that MDR1 
genetic polymorphisms G2677T and C3435T have probably no clinically im­
portant effect on Pgp function. It has been hypothesized that the linkage 
between the silent SNP C3435T and different unobserved causal SNPs may ex­
plain contradictory results associating the T3435 allele with different functional 
changes of MDR1 (Tang et al. 2002). Further studies are required to elucidate 
the significance of this explanation.
2. MRP1 and MRP2 mRNA expression in peripheral blood 
CD4+, CD8+, CD19+, and CD56+ cells
The MRP1 mRNA exhibited the highest abundance in CD4+ cells (7400±3200 
molecules/ng of total RNA) with a 6.7 fold difference between individuals, 
followed by CD8+ (5700±2500), CD19+ (400011800), and CD56+ (360011300) 
cells (Fig. 8A). The differences between cell populations were statistically sig­
nificant (P<0.01), except CD19+ versus CD56+ cells. The MRP2 mRNA expres­
sion was highest in CD4+ cells (6701280) with a 5.2 fold difference between 
individuals, followed by CD8+ (5701190), CD56+ (4901220), and CD19+ 
(4201160) cells (Fig. 8B). The differences observed were statistically signifi­
cant (P<0.05). No correlation between the MRP1 and MRP2 mRNA expression 
was observed.
Within haematopoietic cells it has been found that CD3+ cells exhibited the 
highest and CD19+ cells the lowest MRP1 mRNA levels (Legrand et al. 1996). 
Protein analysis determined that CD4+ cells exhibited higher MRP1 expression 
than other cells. In another study, Abbaszadegan et al. (1994) showed that 
regardless of the cell lineage, normal peripheral blood and bone marrow 
haematopoietic cells express similar basal levels of the MRP1 mRNA. Re­
cently, Laupeze et al. (2001) investigated MRP activity in normal mature 
leucocytes using the carboxy-2’,7’-dichlorofluorescein efflux assay. Similar 
cellular export was evidenced in CD3+, CD4+, CD8+, CD14+, CD15+, CD20+, 
and CD56+ cells, whereas CD34+ cells showed higher efflux rate. Investigation
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of the mRNA expression revealed that leucocytes were found to mostly express 
MRP1, whereas MRP2 transcripts were not present or only at very low levels.
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Figure 8. Quantitative determination of the MRP1 (A) and MRP2 (B) mRNA levels in 
PBMC. Each bar represents the mean±SD, as determined in 20 individuals. The 
differences in MRP1 expression between cell populations were statistically significant 
(PcO.Ol), except CD19+ versus CD56+ cells. All differences in MRP2 expression were 
statistically significant (P<0.05).
MRP1 and M RP2 have similar substrate specificity. There are no drugs yet 
that specifically inhibit a single M RP species without effect on other transpor­
ters. Therefore, a sensitive technique RT-PCR, instead of efflux assays, was 
used in the present study. Similar to the results reported previously (Legrand et 
al. 1996), the MRP1 mRNA expression was found to be highest in CD4+ cells. 
However, larger interindividual variation (20 fold) than in the present study was 
observed by Legrand et al. (1996). In contrast to Laupeze et al. (2001), the 
MRP2 mRNA was evidenced in all cell populations investigated.
The impact of the MRP1 and M RP2 transcription in PBMC remains to 
ascertain. Pgp has been found to be highly expressed in CD8+ and CD56+ 
cytotoxic cells (Drach et al. 1992). In the present study, CD4+ cells exhibited 
the highest abundance of the MRP1 and M RP2 mRNA, with more than 7 fold 
higher MRP1 expression. This indicates that the expression of different ABC 
transporter genes in haematopoietic cells may be variously regulated during 
differentiation and miscellaneous ABC transporters may have different func­
tion. For instance, Pgp has been reported to be involved in the natural killer and 
T  cell mediated cytotoxicity (Klimecki et al. 1995; Gupta et al. 1992), and in 
the transport of cytokines (Drach et al. 1996). MRP1, unlike Pgp, facilitates the 
secretion of leukotrienes (Leier et al. 1994), the major mediators of inflamma­
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tion. Further studies are required to specify the physiological function of the 
MRP1 and M RP2 transporters in PBMC cells.
Several HIV protease inhibitors and reverse transcriptase inhibitors are 
substrates o f MRP1 and MRP2 (Williams et al. 2002; Huisman et al. 2002). 
The highest level of the MRP1 and MRP2 mRNA was found in CD4+ cells, at 
major site of virus replication. Hence, MRPs may have an important role in 
limiting drug exposure within these cells and therefore the efficacy of HIV 
therapy. Recently, Jones et al. (2001) demonstrated that the accumulation of 
ritonavir, indinavir, saquinavir, and nelfinavir in MRP1 expressing cells was 
significantly reduced in comparison with control cells. MRP1 inhibitor MK571 
partially reversed these effects. An inverse relationship between the MRP1 
expression and intracellular accumulation of ritonavir and saquinavir in PBMC 
from HIV-infected individuals has been shown by Meaden et al. (2002). Both 
MRP1 and M RP2 expression in PBMC indicates that not only MRP1, but also 
MRP2 and probably other MRPs account for the resistance to anti-HIV-drugs. 
Recently, several SNPs in the human MRP1 and MRP2 gene were identified 
(Saito et al. 2002b). Conrad et al. (2002) found that G1299T polymorphism in 
the MRP1 increased resistance to doxorubicin. Genetic polymorphisms in the 
MRP2 have been found to result in a conjugated hyperbilirubinemia named 
Dubin-Johnson syndrome (Toh et al. 1999). Further studies should confirm if 
these mutations also affect MRP1 and MRP2 expression in PBMC and therefore 
contribute to therapeutic outcome of HIV therapy.
3. Frequencies of the MRP1 genetic polymorphisms and 
their functional significance in Caucasians
3.1. Detection of a novel G816A SNP in the human MRP1
Using a LightCycler technique, we established real-time PCR assays for the 
SNPs located in exon 8 (T825C), in exon 13 (T1684C), and in exon 28 
(G4002A) in the MRP1. Unexpectedly, a novel silent mutation in exon 8, a G to 
A transversion at position 816 (Pro to Pro at codon 272) was identified (Fig. 9). 
The derivative melting curves on the LightCycler are highly reproducible under 
constant conditions (M euer et al. 2001). Shifts greater than 1°C from the 
characteristic melting curve suggests the presence of two mismatches, as oc­
curred also in our study. First, the long sensor probe (position at 813-834 bp) 
used for T825C genotyping, determined 4 individuals with atypical melting 
curves. Subsequent sequencing showed that all these individuals, but not sub­
jects with typical melting curves for T825C, were heterozygous GA at position 
816. Hence, the G816A substitution destabilized the binding of the long T825C 
sensor. A new, shorter sensor probe (position at 817-834 bp, see methods) for
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T825C detection, and another pair of hybridisation probes (position at 779-800 
bp anchor, and 803-821 bp sensor) for G816A detection were designed. When 
designing hybridisation probes to recognize the G816A and T825C poly­
morphisms, oligonucleotides that cover the both mutation sites should be 
avoided. As reported previously, aberrant derivative melting curves have effec­
tively identified unexpected variants in factor V, hereditary haemochromatosis, 
and cystic fibrosis (Meuer et al. 2001).
C A C A A C  C T  T C A C  С О G C  T
С А С A A C C T  T C A C  T G G C  T
C A C  G A C C T T C A C T G O C T
С
Figure 9. Identification of G816A and T825C polymorphisms in the human MRP1 gene 
by sequence analysis (reverse primer).
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3.2. Frequencies of the G816A, T825C, T1684C, 
and G4002A SNPs in the MRP1
The results of MRP1 genotyping are given in Table 9.
Table 9. Observed frequencies of MRP1 genetic variants in 230 healthy Caucasians. 
Expected genotype frequencies were calculated according to the Hardy-Weinberg 
equilibrium from the allele frequencies.
Allele Geno­
type
Number Genotype frequency
Position Allele frequency
%
of
subjects
% , 95% Cl Observed
%
Expected
816 G 95.9 GG 211 91.7 87.40-94.95 91.9
A 4.1 GA 19 8.3 5.05-12.60 7.9
AA 0 0.0 0.0-0.02 0.0
825 T 70.0 TT 115 50.0 43.36-56.64 49.0
С 30.0 TC 92 40.0 33.62-46.64 42.0
CC 23 10.0 6.45 -  14.63 9.0
1684 T 20.0 TT 15 6.5 3.70- 10.53 4.0
С 80.0 TC 62 27.0 21.34-33.18 32.0
CC 153 66.5 60.02 -  72.59 64.0
4002 G 71.7 GG 118 51.3 44.65-57.93 51.4
A 28.3 GA 94 40.9 34.45 -47.52 40.6
AA 18 7.8 4.70- 12.09 8.0
The novel mutation G816A was found heterozygously in 19 of 230 
individuals with an allele frequency of 4.1%. The allele frequency of the T 
allele at position 825 was found to be 70.0% in Caucasians, as determined in the 
present study, and 62.5% in Japanese (n=48), as reported by Ito et al. (2001) 
(OR 1.4, 95% Cl 0.86-2.26, P=0.18). The frequency of the G allele at position 
4002 was 71.7% in Caucasians and 84.4% in Japanese (OR 0.47, 95% Cl 0.24-
0.86, P=0.01). When genotyping results of the T1684C polymorphism were 
compared between Caucasians and Japanese, it was found that the frequency of 
T allele was 20.0% in Caucasians, and 80.2% in Japanese (OR 0.06, 95% Cl
0.03-0.11, P<0.0001). In the first published MRP1 sequence (AF022835), 
derived from a lung cancer cell line, a T nucleotide at position 1684 was 
reported and defined as a wild type allele. We found that a С allele at position 
1684 was the most common variant for Caucasians.
A marked difference in the frequencies of the T1684C and G4002A SNPs 
in the MRP1 was observed between Caucasians and Japanese. Three additional 
mutations T1062C, C2007T, and G2168A have been identified in Japanese by 
Ito et al. (2001) and Saito et al. (2002b). None of these mutations was found by 
Conrad et al. (2001) by screening 36 healthy Caucasians. Three of the SNPs 
C1299T, C1704T, and G2021T, identified by Conrad et al. (2001), and the
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G816A mutation, identified in the present study, were not found in Japanese. 
These findings suggest an ethnic variation of the polymorphisms in the MRP1.
Estimation of the haplotypes based on the expectation-maximization algo­
rithm showed that of 16 possible haplotypes only 11 were observed, and four 
haplotypes GTCG, GTCA, GCCG, and GTTG together accounted for 80% of 
the haplotypes (Table 10). Linkage disequilibrium between the different pairs of 
SNPs was determined using the statistic D ’. A D ’ value of 1 indicates complete 
linkage disequlibrium, while a value of 0 corresponds to complete linkage equi­
librium. In our population, a strong linkage disequilibrium between the G816A 
and T825C SNPs (D ’=1.000, /><0.001), and between the G186A and T1684C 
SNPs (D’=0.996, PcO.OOl) was observed (Table 11).
Table 10. Distribution of haplo- 
type frequencies (%) for the four 
SNP loci of the MRP1 gene in 
Caucasians.
Haplotype Estimated
GTCG 38.96
GTCA 18.12
GCCG 14.28
GTTG 9.49
GCTG 6.30
GCCA 4.55
GTTA 3.44
ACCG 2.68
ACCA 1.42
GCTA 0.74
ACTG 0.03
Table 11. Linkage analysis of the MRP1 SNPs in Caucasians.
G816A T825C T1684C G4002A
G816A D’=l .000 
/><0.001
D’=0.996 
P <0.001
D’=0.075
/>=0.706
T825C D’=0.074
/>=0.393
D’=0.194
/>=0.226
T1684C D’=0.237
/>=0.258
G4002A
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3.3. MRP1 mRNA expression in individuals with 
different M RP1 genotypes
Functional significance of the SNPs in the MRP1 was investigated in peripheral 
blood CD4+cells. MRP1 mRNA expression was 10300±3800 molecules/ng of 
total RNA with an 8 fold variation between individuals. Statistical analysis 
revealed no significant (P>0.05) difference in MRP1 expression with regard to 
different genotypes in the MRP1 (Fig. 10). Also the novel mutation G816A was 
not found to determine MRP1 mRNA expression, since homozygous wild type 
GG individuals displayed 10400±3400 and heterozygous GA individuals 
9830±5500 MRP1 mRNA molecules/ng of total RNA.
25.0,
20.0 .
15.0.
10.0 .
5.0
G816A
♦
t
GG
n=52
GA
n=9 n=27 n=20 n=14
25.0,
20.0
15.0
10.0
5.0
T1684C
t
TT
n=4
TC
n=18
CC
n=39 n=31 n=21 n=9
Figure 10. Quantitative determination of the MRP1 mRNA expression in peripheral 
blood CD4+ cells from individuals with different MRP1 genotypes. Data are presented 
as MRP1 mRNA copies/ng of total RNA. Bars represent the mean values for each 
group. No difference in MRP1 mRNA expression was observed between subjects with 
the different MRP1 genotypes (P > 0.05).
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All mutations investigated in this study were silent mutations, which do not 
alter the amino acid sequence. However, synonymous SNPs may affect RNA 
folding and stability (Shen et al. 1999). As shown by Conrad et al. (2001), 
sense mutations T825C and C1704T seemed to correlate with a lower MRP1 
mRNA expression in peripheral blood lymphocytes, but the numbers of samples 
for each genotype were too low for statistical analysis. In the present study, no 
correlation between the MRP1 mRNA levels in CD4+ cells and G816A, T825C, 
T1684C, and G4002A SNPs in the MRP1 was found.
Two of the mutations identified by Conrad et al. (2001), G1299T and 
G2012T, cause the exchange of amino acids. In subsequent transfection studies, 
the mutant G2012T (Gly671Val) showed a phenotype similar to wild-type 
MRP1 (Conrad et al. 2001). Transfected HeLa cells expressing G1299T 
(Arg433Ser) mutant MRP1 were 2 fold more resistant to doxorubicin than cells 
expressing wild type MRP1 (Conrad et al. 2002). Transport experiments also 
revealed a 2 fold reduction in the transport of the MRP1 substrates leukotriene 
C4 and estrone sulfate. However, the amino acid substitution of Arg 433 to Ser 
was found in a single individual heterozygously among 91 Caucasians.
3.4. General discussion concerning the SNPs in the MRP1 and 
their functional significance
It’s well known that the frequencies of genetic polymorphisms in several genes, 
involved in absorption, metabolism, and/or excretion of drugs, vary markedly in 
different ethnic groups. Human MRP1 is polymorphic and more than 80 SNP’s 
have been identified in the gene (Table 12) (Perdu et al. 2001; Ito et al. 2001; 
Conrad et al. 2001; Saito et al. 2002b). A marked difference in the frequencies 
of the T1684C and G4002A SNPs of the MRP1 was observed in Caucasians in 
comparison with Japanese (Ito et al. 2001). Moreover, a novel polymorphism 
was identified in exon 8, a G to A transversion at position 816. So far, syste­
matic population screening has been performed by Conrad et al. (2001) in 36 
healthy Caucasians, and in healthy Japanese by Ito et al. (2001) and Saito et al. 
(2002b), both involved 48 subjects. The differences observed, together with 
findings from the present study, indicate that further analyses in larger various 
ethnic groups are required to identify potential unobserved SNPs and their 
frequencies.
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Table 12. Summary of genetic polymorphisms identified in exonic sequences of the 
human MRP1 (GenBank accession numbers AF022824-AF022853).
Location SNP* NCBI SNP rs
Amino acid 
substitution
Mutant 
allele fre­
quency (%)
Reference
Exon 2 G128C Cys43Ser 1.0 Ito et al. 2001
C218T Thr73Ile 1.0 Ito et al. 2001
Exon 3 T350C Thrl 17 Ala 100.0 Perdu et al. 2000
Exon 8 G816A Pro272Pro 4.1 Oselin et al. 2003 (V)
T825C 246221 Val275Val 37.5
2.8
30.0
Ito et al. 2001 
Conrad et al. 2001 
Saito et al. 2002b 
Oselin et al. 2003 (V)
Exon 9 T1062C 35587 Asn354Asn 35.4 Ito et al. 2001 
Saito et al. 2002b
Exon 10 G1299T Arg433Ser 1.4 Conrad et al. 2001
Exon 13 T1684C 35605 Leu562Leu 19.8
8.3
80.0
Ito et al. 2001 
Conrad et al. 2001 
Saito et al. 2002b 
Oselin et al. 2003 (V)
C1704T Tyr568Tyr 2.8 Conrad et al. 2001
Exon 16 C2007T 2301666 Pro669Pro 8.3 Ito et al. 2001 
Saito et al. 2002b
G2012T Gly671Val 2.8 Conrad et al. 2001
Exon 17 G2168A 4148356 Arg723Gln 7.3 Ito et al. 2001 
Saito et al. 2002b
Exon 20 C2665T Pro889Pro 1.0 Ito et al. 2001
T2694C Asn898Asn 1.0 Ito et al. 2001
Exon 23 G3173A Argl058Gln 1.0 Ito et al. 2001
Exon 24 G3450A 4148377 Prol150Pro Saito et al. 2002b
Exon 28 G4002A 2239330 Serl334Ser 15.6
2.8
28.3
Ito et al. 2001 
Conrad et al. 2001 
Saito et al. 2002b 
Oselin et al. 2003 (V)
Exon 31 C4524T Tyrl508Tyr 1.0 Ito et al. 2001
Allele frequencies for genetic variants observed by Saito et al. (2002b) were not given 
in the publication.
* The positions of the SNPs correspond to GenBank accession number L05628 with the
first base of the ATG start codon set to 1.
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Individuals carrying polymorphisms in the MRP1 might be subject to a 
variety of effects. Altered MRP1 expression and/or activity could influence the 
pharmacokinetic properties of drugs that are substrates for MRP1. Transport of 
glutathione disulfide and leukotriene C4 (Leier et al. 1996; Leier et al. 1994), 
suggests MRP1 involvement in oxidative stress and anti-inflammatory respon­
ses. In the present study, we observed that MRP1 mRNA expression in PBMC 
was the highest among the ABC transporters studied. In CD56+ cells, which 
have been considered to express high levels of Pgp and MDR, MRP1 mRNA 
expression was more than 2 fold higher than that of the MDR1 expression. Also 
in CD4+ cells, target for HIV therapy, the MRP1 mRNA expression was found 
to be the highest. Accordingly, interindividual variation in the expression of 
MRP1 has the highest potential to modify therapeutic outcome of HIV therapy 
and other therapies related to PBMC.
Limited number of studies has investigated the effects of genetic variants in 
the MRP1. No significant differences in MRP1 mRNA expression in peripheral 
blood CD4+ cells between individuals with different MRP1 genotypes were 
observed in the present study. However, further studies are required to deter­
mine the potential contribution of MRP1 SNPs to pharmacokinetic properties of 
drugs and therapeutic response as well as to anti-inflammatory and antioxida­
tive defence system.
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CONCLUSIONS
In the past decade, several ABC transporters have been identified. The contri­
bution of various SNPs in the ABC transporter genes to the pharmacokinetics of 
drugs as well as to the aetiology of several genetic disorders has been reported.
Main purpose of the present work was to assess the functional importance of 
the SNPs in the human ABC transporters, MDR1 and MRP1, genes. The studies 
gave the following conclusions:
1. Using a R hl23  efflux assay, we could not find significant differences in 
Pgp activity in peripheral blood CD56+ and CD4+ cells from healthy indi­
viduals with different MDR1 genotypes at G2677T and C3435T.
2. The G2677T and C3435T SNPs in the MDR1 did not contribute to the 
absorptive pharmacokinetics of a single oral dose of 1 mg digoxin in 
healthy volunteers.
3. The genetic polymorphisms G2677T and C3435T in the MDR1 gene did 
not have any significant effect on the MDR1 mRNA expression in PBMC 
from healthy subjects.
4. On a mRNA level MRP1 and MRP2 were found to be expressed in human 
peripheral blood CD4+, CD8+, CD19+, and CD56+ cells, with more than 7 
fold higher MRP1 expression in all cell populations.
5. A novel polymorphism G816A (Pro to Pro at codon 272) was identified in 
the human MRP1 gene and marked ethnic variations in the frequencies of 
the MRP1 G816A, T825C, T1684C, and G4002A SNPs were observed.
6. In healthy individuals, MRP1 mRNA expression in CD4+ cells was not 
found to correlate with genetic polymorphisms G816A, T825C, T1684C, 
and G4002A in the MRP1.
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SUMMARY IN ESTONIAN
M DRl, MRP1 JA MRP2 ABC TRANSPORTERID: 
GENEETILISE POLÜMORFISMI TÄHTSUS MDRl JA MRP1 GEENIDES
Rakkudel on võime transportida teatud aineid rakust läbi rakumembraani raku- 
välisesse keskkonda. Valke, mis seda funktsiooni teostavad, nimetatakse trans- 
porteriteks. Käesolev uurimistöö käsitleb ATP-ga seonduvaid (inglise k. ATP- 
binding cassette — ABC) transportereid.
Ravimite imendumisel, jaotumisel ja  eritumisel osalevad järgmised ABC 
transporterid: MDRl ehk P-glükoproteiin, MRP1 ja MRP2. P-gliikoproteiin oli 
esimene ABC transporter, mis isoleeriti esmalt kemoterapeutikumide suhtes 
resistentsetest kasvajarakkudest. Praeguseks on teada, et lisaks kasvajarakku- 
dele ekspresseerub P-glükoproteiin ka normaalsetel rakkudel, eeskätt soole 
enterotsüiitide apikaalsel membraanil, maksarakkude kanalikulaarsel pinnal ja 
proksimaalsete neerutorukeste epiteelirakkudes. P-glükoproteiin viies neist 
rakkudest välja paljusid ravimeid, vähendab nii nende imendumist gastrointesti- 
naaltraktist ja  kiirendab eliminatsiooni maksa ning neerude kaudu. Samaselt P- 
glükoproteiiniga transpordivad ka MRP1 ja MRP2 mitmeid ravimeid rakust 
rakuvälisesse keskkonda, kuid võrreldes P-glükoproteiiniga on nende substraa­
tide spekter erinev.
Mitmes hiljuti avaldatud uuringus on leitud, et P-glükoproteiini ja  MRP1 
kodeerivad geenid on polümorfsed. Käesoleva uurimistöö peamine eesmärk oli 
hinnata, kas geneetilised mutatsioonid nimetatud geenides omavad funktsio­
naalset tähtsust ning kas individuaalsed erinevused ravimite imendumises ja 
eritumises on seletatavad geneetilise polümorfsusega nimetatud geenides.
Töö eesmärgid ja uurimismeetodid
1. Selgitada, kas MDRl geeni polümorfsed variandid G2677T ja C3435T mõju­
tavad P-glükoproteiini ekspressiooni ja funktsiooni tervetel isikutel. Selle 
eesmärgi täitmiseks viisime läbi järgmised uuringud:
1.1. voolutsütomeetriat kasutades mõõtsime erineva genotüübiga isikute peri­
feerse vere CD56+ ja CD4+ rakkudes P-glükoproteiini substraadi, 
rodamiin 123, väljavoolu määra;
1.2. erineva genotüübiga isikutel määrasime P-glükoproteiini substraadi, 
digoksiini, farmakokineetilised parameetrid 1 mg ühekordse suukaudse 
annuse manustamise järgselt, digoksiini kontsentratsiooni määramiseks 
seerumis kasutasime immunoloogilist meetodit;
1.3. kvantitatiivset RT-PCR kasutades määrasime erineva genotüübiga isikute 
perifeerse vere CD4+, CD8+, CD19+ ja CD56+ rakkudes MDRl geeni 
mRNA ekspressiooni. Erinevate rakutüüpide eraldamiseks perifeerse vere 
mononukleaarsetest rakkudest kasutasime voolutsütomeerit.
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2. Selgitada, kas ABC transporterid MRP1 ja MRP2 on ekspresseeritud tervete 
isikute perifeerse vere CD4+, CD8+, CD19+ja CD56+ rakkudes, selleks määra­
sime voolutsütomeetriga sorteeritud rakupopulatsioonides MRP1 ja MRP2 
geeni mRNA ekspressiooni, kasutades kvantitatiivset RT-PCR.
3. Uurida MRP1 geeni erinevate alleelide T825C, T1684C ja G4002A esinemis­
sagedust eurooplastel ja  hinnata, kas nimetatud mutatsioonid omavad funktsio­
naalset tähtsust. Selleks määrasime kvantitatiivset RT-PCR kasutades erineva 
genotüübiga isikute perifeerse vere CD4+ rakkudes MRP1 geeni mRNA 
ekspressiooni.
Töö tulemused ja järeldused
1. Rodamiin 123 väljavoolu määr, digoksiini farmakokineetilised parameetrid 
ja MDR1 geeni mRNA ekspressioon ei erinenud oluliselt erineva G2677T ja 
C3435T genotüübiga isikutel. Seega ei määra uuritud alleelide kandlus 
MDR1 geenis individuaalseid erinevusi P-glükoproteiini ekspressioonis ja 
aktiivsuses. Samuti pole isikutevaheline varieeruvus P-glükoproteiini sub­
straatide farmakokineetikas seletatav uuritud polümorfismide kandlusega 
MDR1 geenis.
2. MRP1 ja MRP2 geenid olid ekspresseeritud kõigis uuritud rakutüüpides, 
kusjuures MRP1 geeni ekspressioon oli umbes 7 korda kõrgem. MRP1 ja 
MRP2 transportides rakust rakuvälisesse keskkonda mitmeid ravimeid, 
vähendavad nende rakusisest kontsentratsiooni. Seega võivad individuaalsed 
erinevused MRP1 ja  MRP2 ekspressioonis perifeerse vere rakkudel mõju­
tada nendele rakkudele suunatud ravi, näiteks HIV ravi, efektiivsust.
3. Leidsime uue geneetilise mutatsiooni inimese MRP1 geeni lookuses G816A 
ja märkimisväärseid erinevusi teiste uuritud mutatsioonide esinemissage­
dustes eurooplastel võrreldes jaapanlastega. Erinevate MPR1 genotüüpidega 
(G816A, T825C, T1684C ja  G4002A) isikutel ei esinenud perifeerse vere 
CD4+ rakkudes olulist erinevust MRP1 geeni mRNA ekspressioonis. Kas 
nimetatud geneetiliste mutatsioonide kandlus mõjutab ravimite farmako- 
kineetikat, vajab edasisi täiendavaid uuringuid.
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A B S T R A C T
P-glycoprotein (Pgp) is a m em ber of the  A BC-transporter family, and  in hum ans, is 
encoded by th e  MDR1 gene. Recently, several single-nucleotide polym orphism s in the  
MDR1 gene w ere identified. The aim  of the  present study w as to evaluate  the  effect of 
the  MDR1 genetic polym orphism s G 2677T  and C 3435T  on Pgp activity in CD56+ 
and  CD4+ peripheral blood cells. Using flow cytom etry, rhodam ine  123 (R h l2 3 )  
efflux w as de term ined  in  4 6  m ale h ea lth y  volunteers. M edian R h l2 3  fluorescence in 
contro l sam ple, after baseline dye uptake, w as set as 100% . R h l2 3  fluorescence in 
efflux sam ples, exposed to  different efflux periods, w as used to  calculate the  
percentage of R h l2 3  re ta ined  in th e  cells in com parison w ith  control. There was no 
significant difference in R h l2 3  efflux in CD56+ cells after 5, 10, 15, and  30 m in 
efflux betw een individuals w ith  different MDR1 genotypes. Also, in CD4+ cells after 
15, 30, 60, and  90  m in, R h l2 3  efflux did no t reveal statistically  different results for 
the  th ree  genotypes a t 2 6 7 7  and  3 4 3 5 . R h l2 3  efflux w as no t enhanced  by a 10-day 
rifam pin adm in istra tion , as determ ined in 15 individuals before and  after rifam pin 
trea tm en t. In  conclusion, w e found no  im pact of the  MDR1 G 2677T  and  C 3435T 
polym orphism s on Pgp activity  in CD56+ and  CD4+ peripheral blood lym phocytes.
I N T R O D U C T I O N
The hum an MDR1 gene encodes a 170-kDa plasma 
membrane protein, P-glycoprotein (Pgp), a member of 
the ATP-binding cassette transporters [1]. In several cell 
lines, overexpression of Pgp has been found to correlate 
with decreased in tracellular accum ulation of drugs tha t 
are substrates for Pgp. In contrast, mice w ith a targeted 
disruption of the M DRla gene display a two-fold to 
50-fold higher concentration of Pgp substrates in m any 
tissues [2-4].
P-glycoprotein substrates comprise a wide spectrum  of 
therapeutic agents, such as anticancer drugs paclitaxel, 
etoposide; hum an immunodeficiency virus-protease inhi­
bitors saquinavir, indinavir; im m unosuppressive drugs
dexamethsone, cyclosporin A, etc. [2-7]. Digoxin has 
been identified in vitro and in animal experiments as a 
substrate of renal and intestinal Pgp [2.8]. Pgp expres­
sion in enterocytes from healthy volunteers has been 
found to correlate significantly with plasma area under 
the concentration-tim e curve values for digoxin after 
its oral administration [9]. Recently, several single­
nucleotide polymorphisms in the MDR1 gene were 
identified [10,11]. The C3435T polymorphism in exon 
26  was found to determine intestinal Pgp expression and 
digoxin absorption [11]. Nevertheless, comparison of 
the area under the concentration-tim e curve values for 
fexofenadine, another substrate for Pgp. revealed no 
significant differences between individuals w ith different 
C3435T and G2677T genotypes [12].
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The aim of the present study was to assess the  effect of 
the genetic polymorphisms G 2677T and C 3435T in the 
MDR1 gene on Pgp activity in peripheral blood lympho­
cytes. We measured rhodam ine 123 (R h l2 3 ) efflux in 
peripheral blood CD56+ natu ral killer (NK) and CD4+ 
T-helper cells from healthy individuals w ith different 
MDR1 genotypes. To evaluate w hether the rifampin 
treatm ent modulates Pgp expression in peripheral blood 
lymphocytes, R h l2 3  efflux was determined before and 
after a 10-day rifampin adm inistration.
M E T H O D S
Clinical study
The study protocol was approved by the Ethics Commit­
tee of the Humboldt University. Based on the genotype in 
exon 26 of the MDR1, 46 male healthy volunteers (age 
range 19—45 years) were recruited for R h l2 3  efflux 
study after an informed consent. The subjects took no 
medication and were ascertained to be healthy by a 
clinical exam ination and routine laboratory tests. In 15 
individuals R h l2 3  efflux was determined before and 
after a 10-day rifampin treatm ent (600  mg/day, given in 
the morning; Grünenthal GmbH, Aachen, Germany).
Materials
Oligonucleotide primers and hybridization probes for 
polymerase chain reaction (PCR) were purchased from 
Tib Molbiol (Berlin, Germany): R h l2 3 , verapamil 
hydrochloride, and BSA fraction V powder from Sigma 
Chemicals (Munich, Germany). Dulbecco’s Modified Eagle 
Medium (DMEM), Fetal Bovine Serum (FBS), and 
Phosphate Buffered Saline (PBS) were obtained from 
Gibco-BRL (Karlsruhe. Germany); Biocoll lymphocyte 
separating solution (density 1 .077) was from Biochrom 
KG (Berlin, Germany). Phycoerythrin (PE)-conjugated 
antibodies (CD56, CD4, and IgG ^ were obtained 
from Im m unotech Beckman Coulter GmbH (Munich, 
Germany). R h l2 3  and verapam il stock solutions were 
prepared in ethanol in a concentration of 0.1 and 1 mg/mL, 
respectively, and m aintained at 4  °C.
D N A  iso lation and gen o typ in g  o f the M DR1 exon  
26 C3435T and exon 21 G2677T polym orph ism s
The DNA was isolated from 2 0 0  |iL of whole blood by 
MagNA Pure LC (Roche, M annheim , Germany). Geno­
typing was performed on real-tim e PCR assays in a 
LightCycler™ (Roche). G 2677T m utation in exon 21 
(GenBank Accession No. M 29440). was detected with 
primers 5'-GCA GGA GTT GTT GAA ATG AAA ATG
(forward) and 5'-CGC CTG CTT TAG IT T  GAC TCA 
(reverse), and hybridization probes 5'-ACC TTC CCA 
GTA CCT TCT (sensor) and 5'-LC Red640-CTT TCT TAT 
CTT TCA GTG CTT GTC С (anchor). To detect C3435T 
m utation in exon 26 (GenBank Accession No. M 29445) 
primers 5'-TGT TTT CAG CTG CTT GAT GG (forward) 
and 5'-AAG GCA TGT ATG TTG GCC TC (reverse) were 
used. Fluorescent detection was performed with hybrid­
ization probes 5'-GAC A AC AGC CGG GTG GTG TCA 
(anchor) and 5'-LC Red640-GGA AGA GAT CGT GAG 
GGC AG (sensor).
Rhodam ine 123 efflux assay
Peripheral blood m ononuclear cells were isolated from 
20 mL whole blood by centrifugation over Biocoll 
lymphocyte separating solution (density 1.077). Cells 
were washed twice w ith PBS and diluted to 
1 x 106 ceUs/mL in DMEM/10% FBS. To allow R hl23 
accumulation, cell suspension was incubated for 30 min 
at 37 °C in 5% C 02 w ith R h l2 3  in a final concentration 
of 1 50 ng/mL. After accum ulation, cells were aliquoted 
into 1.5 mL Eppendorf tubes, centrifuged for 5 min at 
400 g and washed twice w ith PBS to remove extracel­
lular R h l2 3 . After washing, the  control sample was put 
on ice for m easurem ent of the baseline dye uptake. All 
other samples were resuspended in 1 mL DMEM/10% 
FBS and performed for 5. 10. 15, and 30 min efflux in 
CD56+: and for 15, 30. 60. and 90 min efflux in CD4+ 
cells at 37 °C in 5% C 02. In preliminary experiments, the 
R h l2 3  efflux time was varied from 5 to 120 min. Four 
different timepoints were chosen to evaluate the early 
and late phase of the  efflux. One sample was incubated 
with verapam il in a concentration of 1 |ig/mL for 
30 min in CD56+ and for 90 min in CD4+ cells. After 
efflux, samples were washed once with cold PBS. stained 
with PE-labeled anti-CD56 antibody, PE-labeled anti-CD4 
antibody or PE-labeled mouse IgG, as a negative control, 
for 30 min on ice in the dark. After staining, cells were 
washed twice w ith cold PBS/1% BSA and analyzed using 
a FACScan flow cytometer (Becton Dickinson, San Jose. 
CA, USA) with a 488 nm  argon laser.
The viability of isolated cells was determined using 
trypan-blue exclusion and was always >97%. R hl23  
fluorescence was collected after 530-nm bandpass filter 
and PE fluorescence was collected after 585-nm band­
pass filter. The appropriate threshold value was set to 
exclude clumps and debris. Fluorescence compensation 
was determined using samples stained with either 
R h l2 3  or PE alone. The samples were gated on forward 
scatter vs. side scatter to include lymphocytes. A second
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gate was set around the PE-CD56+ or PE-CD4+ cells. 
A minimum of 2 0 0 0  of CD56+ and CD4+ events were 
collected per sample. Data was expressed as median 
R h l2 3  fluorescence in CD56+ and CD4+ cells. Median 
R h l2 3  fluorescence in control sample, after baseline dye 
uptake, was set as 100%. R h l2 3  fluorescence in efflux 
samples, exposed to different efflux periods, was used to 
calculate the percentage of R h l2 3  retained in the cells in 
comparison with control.
Statistical analysis
Data were presented as m ean ± SD. The Student's 
unpaired t-test was used to com pare the m ean R h l2 3  
efflux between individuals w ith different genotypes. The 
paired t-test was used to com pare the m ean R h l2 3  
fluorescence before and after rifampin treatm ent. All 
calculations were performed with SPSS™ for Windows 
(version 10.0; SPSS Inc., Chicago, IL, USA). P-values < 
0.05 were considered to be of statistical significance.
R E S U L T S
MDR1 genetic polym orph ism s analyzed  
with real-time PCR assays in a L igh tC yc le r™
For the G2677T polymorphism, the melting tem perature 
of the fluorescent hybridization probes was 56 °C to 
the homozygous wild-type GG, 52 °C to the m utan t TT 
sample and 54 °C to heterozygous GT (Figure I). DNA 
samples with known genotypes was let run  in parallel. 
At position 2677 in exon 21, three nucleotide variants 
(G. T. or A) have been identified. The frequency of the
T em perature ('C)
Figure 1 Genotyping of the G2677T polymorphism in the MDR1 
gene with hybridization probes on the LightCycler™. Typical results 
for a homozygous 2677T allele (—x—). heterozygous GT (— ), and 
a sample homozygous for 2677G allele (----).
Figure 2 Genotyping of the C343 5T exon 26 polymorphism of 
the MDR1 gene on the LightCycler™. The homozygous TT sample
(------ ). heterozygous CT (---- ). and the homozygous wild-type
CC sample (-•-•-).
Table I Distribution of G2677(T,A) and C3435T polymorphisms 
of the MDR1 gene in 46 individuals.
G2677T
С3435Т
c c CT TT
GG 15 7 0
GT 2 6 6
TT 0 0 9
ТА 0 1 0
2677A  allele has been observed to be very low in 
Caucasians. In our study, one individual was determined 
to carry the A allele (genotype GA with melting 
tem perature 58 °C) and was excluded from the analysis. 
For the С3455Т polymorphism, the melting point was 
64 °C when hybridized to the wild-type allele and 55 °C 
w hen hybridized to the m utan t allele (Figure 2). The 
heterozygous sample generated both peaks. A strong 
association between the G 2677T and C3435T polymor­
phisms was observed (Table I).
Influence of the G2677T and C3435T genetic 
polym orph ism s in the M DR1 on Rh123 efflux 
in CD56* NK and CD4+ T-helper cells
Based on R h l2 3  fluorescence m easurement, two 
clearly separated populations of lymphocytes were 
determined after 90 min efflux, indicating cells with 
higher and lower Pgp activity {Figure 3). Therefore, two 
subpopulations of peripheral blood m ononuclear cells, 
CD56+ cells with the highest and CD4+ cells with 
intermediate expression of Pgp [13], were selected for 
the  analysis.
In CD56+ cells we could detect very quick R h l2 3  
efflux. After 5 min incubation in R hl23-free  medium
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Figure 3 Rh 123 fluorescence in lymphocytes after 90 min efflux. 
Peripheral blood mononuclear cells were incubated with Rhl2 3 in 
a final concentration of 150 ng/mL and were exposed to 90 min 
efflux in Rhl23-free medium. The histogram presents Rhl23 
fluoresence in gated lymphocytes indicating two large subpopula­
tions of cells with higher and lower Pgp activity.
more than  10% of R h l2 3  had been eflluxed. However, 
there was no statistical significance in R h l2 3  efflux in 
CD56+ cells between individuals w ith different MDRl
genotypes (Table If). A clear difference concerning the 
R h l2 3  efflux pattern was observed between the CD56+ 
and CD4+ cells. The data shows more than 20% 
difference in efflux rate in CD56+ and CD4+ cells already 
after 15 min efflux. Similar to the results above, there 
was no statistical significance in R h l2 3  efflux in CD4+ 
cells between individuals with different genotypes in the 
MDRl gene (Table ИГ). Slower efflux in peripheral blood 
and haem atopoietic cells may render them more vul­
nerable to cytotoxic compounds, but it seems to be 
independent of the genetic polymorphisms in MDRl 
gene.
Verapam il effect in vitro and rifampin effect 
in vivo on Pgp-m ediated Rh123 efflux
The verapamil effect on Pgp activity was analyzed after 
30 min of R h l2 3  efflux in CD56+ cells (Figure 4) and 
after 90 min efflux in CD4+ cells. Verapamil was a strong 
inhibitor of R h l2 3  efflux, but this effect was not 
associated with the genetic polymorphisms at G2677T 
and C3435T [Tables II and III). In addition, when R hl23 
efflux rate was calculated by comparing fluorescence 
m easurem ent in CD56+ and CD4+, incubated for 30 and 
90 min in R hl23-free medium, respectively, with or 
w ithout verapamil, no significant difference between
Efflux
G2677T C3435T
GG (n =  22) GT (n =  14) TT (n =  9) CC (n =  17) CT (n =  14) TT (n =  15)
5 min 80.2 ± 4.7 80.7 ±  6.0 77.8 ± 3.4 80.9 ± 5.0 79.9 ±  6.3 78.8 ± 3.6
10 min 67.2 ±  6.1 67.8 ± 5.1 63.6 i  5.7 68.9 ± 5.7 65.6 ± 5.6 65.2 ± 5.6
15 min 55.6 ±  6.7 57.0 ± 7.4 52.5 ± 4.6 56.8 ± 7.6 54.4 ± 6.5 54.7 ± 5.6
30 min 27.5 ± 4.7 26.9 ±  5.0 24.6 ± 3.7 28.0 ±  5.3 26.7 ± 4.4 25.5 ± 3.9
Verapamil* 88.7 ± 6.0 86.0 ± 7.2 89.5 ± 5.3 89.7 ±  6.3 84.6 ± 6.7 88.8 ± 5.0
Data are presented in percentage as mean ± SD. P-values according to unpaired f-test exceeded values 0.05. 
Numbers in parenthesis indicate the number of individuals.
•Cells were incubated 30 min in Rh123-free medium with verapamil (1 цд/mL).
Table II Rhl23 fluorescence in CD56* 
natural killer cells from individuals with 
different genotypes of the MDRl gene 
in exon 21 (G2677T) and exon 26 
(C3435T) after 5, 10, 15. and 30 min 
efflux in comparison with control 
(100%).
Efflux
G2677T C3435T
GG (n =  22) GT (n =  14) TT (n =  9) CC (л =  17) CT (n =  14) TT(n =  15)
15 min 83.6 ± 5.9 84.8 ±  5.0 82.1 *  5.2 84.2 ± 5.3 84.2 ±  6.5 82.6 ± 5.0
30 min 76.1 ± 7.3 75.9 ± 5.5 76.1 ± S.7 77.2 ± 5.5 75.0 ± 7.6 75.7 ± 6.3
60 min 67.0 ± 7.8 67.5 ± 6.2 66.4 ±  7.7 68.6 ± 7.5 66.7 ± 6.6 65.6 ± 7.4
90 min 62.6 ± 7.8 60.5 ± 7.5 60.5 ± 8.7 64.4 ± 7.0 60.1 ± 7.8 59.3 ± 8.1
Verapamil* 91.8 ± 3.9 93.8 ± 4.1 90.3 ±  5.7 92.8 ± 3.3 91.6 ± 5.0 91.7 ± 5.5
Data are presented in percentage as mean ±  SD. P-values according to unpaired (-test exceeded values 0.05. 
Numbers in parenthesis indicate the number of individuals.
'Cells were incubated 90 min in Rhl23-free medium with verapamil (1 цд/mL).
Table III Rhl23 fluorescence in CD4+ 
T-helper cells from individuals with 
different genotypes of the MDRl gene 
in exon 21 (G2677T) and exon 26 
(C3435T) after 15, 30. 60. and 90 min 
efflux in comparison with control 
(100%).
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Figure 4 Two-dimensional flow-cytometric dot plots of a two-color 
llow cytometric assay of natural killer cells. PE-CD56 vs. Rhl23 
lluorescence is shown. Peripheral blood mononuclear cells were 
incubated with Rh 123 in a final concentration of 150 ng/mL. After 
accumulation, control sample was put on icc for measurement of the 
baseline dye uptake. All other samples were exposed to efflux in 
Rhl23-free medium. After staining with PE-conjugated anti-CD56 
antibody, median Rhl23 fluorescence was determined in cells gated 
for lymphocytes and PE-CD56 profile. Median Rhl2 3 lluorescence in 
control sample (a) was set as 100%. Rhl23 fluorescence in efflux 
samples incubated for 30 min in a Rhl23-free medium without 
verapamil (b) and with verapamil (c) was used to calculate the 
percentage of Rhl23 retained in the cells in comparison with control.
individuals with different MDR1 genotypes was observed 
(data not shown).
We could not find a significant induction of Pgp 
activity after a 10-day rifampin administration in CD56+ 
and CD4+ cells in healthy individuals (Table IV). Also, 
there was no difference in R h l2 3  efflux in CD56+ and 
CD4+ cells incubated with verapamil before and after 
rifampin treatm ent.
D I S C U S S I O N
In the present study, we determined R h l2 3  efflux in 
peripheral blood CD56+ NK and CD4+ T-helper cells from 
healthy individuals w ith different MDR1 genotypes at 
G2677T and C3435T. Statistical analysis revealed no 
significant difference in Pgp activity between individuals 
with different MDR1 genotypes.
P-gp has been found to be expressed and functionally 
active in all peripheral blood cells, except in granulocytes 
[14]. The expression and function of Pgp appeared to be 
the highest in CD56+ NK and CD8+ T cells. A good 
correlation between R h l2 3  efflux, Pgp expression and 
MDR1 mRNA level has been found, indicating that 
R h l2 3  efflux provides a surrogate m arker for Pgp 
expression [14,15]. For studies designed to overcome 
Pgp-mediated resistance, m easurem ent of the extent of 
in vivo inhibition of Pgp-mediated drug efflux is deemed 
essential. Also, it has been shown that the effect of 
PSC833, a selective inhibitor for Pgp, decreases with an 
increase in Pgp expression and the high Pgp expression 
could explain an incomplete reversal of Pgp-mediated 
R h l2 3  efflux by PSC833 in some patients [15]. There­
fore, no Pgp inhibitor was used for pretreatm ent of 
control cells in our study. However, one sample, incu­
bated with verapamil in a concentration of 1 ug/mL, was 
used as a positive control for the method.
A strong association between the two polymorphisms 
G 2677T in exon 21 and C3435T in exon 26 has been 
found [16]. The G —» T transversion at position 2677 
results in amino acid Ala893 change by Ser. MDR1 
m utation C3435T in exon 26 does not change amino 
acid sequence and is not located at a promoter region. 
Therefore, it was supposed tha t the linked mutation 
G2677T ra ther than  C3435T is causative for individual 
differences in Pgp expression. No association between the 
R h l2 3  efflux and the G2677T m utation was found in 
the present study. Hitzl et al. demonstrated a slower 
R h l2 3  efflux in CD56+ NK cells in individuals with 
TT genotype at 3435 compared with CC genotype [17]. 
However, Calado et al. found no significant differences in
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Efflux
CD56" cells
Efflux
CD4* cells
Before (л =  15) After (n =  15) Before (n — 15) After (n — 15)
5 min 79.0 ± 3.2 80.2 ± 3.3 15 min 84.9 ± 5.8 86.1 ± 5.7
10 min 63.9 ± 6.1 67.1 ±  6.5 30 min 76.9 ± 6.4 77.7 ± 6.0
15 min 53.6 ± 5.5 55.7 ± 6.4 60 min 67.7 ± 7.1 68.1 ± 7.2
30 min 25.5 ± 3.7 27.3 ± 6.4 90 min 62.8 ±  7.3 63.9 ± 9.8
Verapamil* 88.2 ± 6.2 88.4 ± 5.4 Verapamil** 90.5 ± 4.3 92.7 ± 5.5
Data are presented in percentage as mean ±  SD in comparison with control, set as 100%  after baseline dye 
uptake. P-values according to paired t-test exceeded values 0.05 indicating no significant difference in Rhl23 
efflux before and after rifampin administration. Numbers in parenthesis indicate the number of individuals. 
•Cells were incubated 30 min in Rh123-free medium with verapamil (1 (ig/mL).
••Cells were incubated 90 min in Rh123-free medium with verapamil (1 |ig/mL).
Table IV Rhl23 efflux in CD56  ^natural 
killer and CD4+ T-helper cells from 
healthy individuals before and after 
10-day rifampin administration.
R h l2 3  efflux in CD34+ cells between different G2677T 
and C3435T genotypes [18]. There is a considerable 
overlap between the substrate specificity of Pgp and 
other ABC family transporters. Recently, Daoud et al. 
reported th a t R h l2 3  also binds to multiple sites on the 
m ultidrug-resistant protein 1 [19]. The contribution of 
ABC transporters other than  Pgp to the transport of 
known Pgp substrates m ight explain the lack of associ­
ation with MDRl genetic polymorphisms as found in 
several studies. We also consider th a t the differences 
between our study and Hitzl et al. may result from 
different experimental design.
Experimental evidence obtained from hum an colon 
carcinoma cell lines indicated tha t Pgp expression was 
upregulated by rifampin [20]. Pgp induction by rifampin 
treatm ent in enterocytes from healthy volunteers has 
been found by Hoffmeyer et al. [11], with the highest 
induction in individuals with CC genotype at 3435 of the 
MDRl. In our study, R h l2 3  efflux in CD56+ NK and 
CD4+ T-helper cells was no t enhanced after a 10-day 
rifampin treatm ent. Greiner et al. detected increased Pgp 
levels in enterocytes from healthy volunteers during 
rifampin adm inistration [9]. Concomitantly, the oral 
bioavailability of digoxin decreased 30.1%. Renal clea­
rance was no t altered and only a limited effect was found 
after intravenous digoxin adm inistration. These findings 
indicate the possibility of tissue-specific regulation of Pgp 
expression.
In conclusion, using a R h l2 3  efflux assay we could 
not find significant differences in Pgp activity in peri­
pheral blood lymphocytes from healthy individuals with 
different MDRl genotypes at G2677T and C3435T. 
However, o ther m utations in the MDRl gene could 
determine the  genetically determined effect on Pgp 
activity.
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A im s  A  noncod ing  single nucleotide polym orphism  (SNP) in exon 26 3435C  > T  
o f  the  highly polym orphic M D R 1  gene has been  dem onstrated to alter digoxin 
absorption after induction  o f  the M D R 1 gene product P-glycoprotein by rifam picin 
o r after m ultiple oral dosing. T h e  aim  o f  the study was to investigate the effects o f  
the m ajor know n M D R 1 SNPs on the absorption o f  digoxin after a single oral dose 
in s  large sample w ithou t d rug  pretreatm ent.
M ethods Fifty healthy w hite  male subjects betw een the age o f  18 and 40 years were 
enrolled. Following an overnight fast, all subjects received a single oral dose o f  1 mg 
digoxin. Venous b lood samples were taken at intervals up to 4 h post dose to obtain 
a pharm acokinetic profde.
Results A U C (0,4  h), Спих and t,mx, used as indices o f  digoxin absorption, were not 
significantly different in any o f  the genotype groups tested. In particular, there was 
no  significant difference betw een hom ozygous carriers o f  the С  and T  allele in exon 
26 3435 (A UC(0,4 h) 9.24 and 9.38 ng Г 1 h, Cln„  4.73 and 3.81 ng Г 1, rlmx 0,83 
and 01.14 h).
Conclusions This lack o f  effect o f  the m ajor M D R 1 SNPs on digoxin absorption 
m ight be explained by saturation o f  the m axim um  transport capacity o f  intestinal 
Pgp at the dose used.
Keywords: d rug  absorption, P-glycoprotein, pharm acogenetic effects
In tro d u c tio n
The intestinal ep ithelium  is n o t only involved in the 
absorption o f  nutrients, water, xenobiotics and drugs, but 
also has barrier and excretory  functions. T h e  latter are 
mainly provided by P-glycopro tein  (Pgp), the  product o f  
the M D R 1 gene, w hich  is a m ajor de term inan t o f  drug 
export from enterocytes in to  the  gut lum en. Pgp is a 
m ember o f  the A T P -b ind ing  cassette (ABC) superfamily 
o f mem brane transporters [1] and was originally discov­
ered through its ability to  confer resistance to  antineo­
plastic agents in tu m o u r cells [2]. A broad range o f  
diverse, structurally unrelated  com pounds, including  the 
cardiac glycoside digoxin [3], anthracycline antibiotics, 
vinca alkaloids, epipodophyllotoxins [4, 5], daunom ycin, 
and the im m unosuppressant cyclosporin A  [6] are trans-
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p o rted  from  cells by Pgp in an A T P -dependent m anner. 
Pgp is located as a 170 kDa integral m em brane protein 
in the apical pole o f  lum inal epithelial cells o f  the stom ­
ach, the small intestine, the colon [7], the biliary canal- 
iculi o f  the liver, and the brush border o f  the renal 
proxim al tubules [8]. T he  expression o f  Pgp in these 
tissues is related to its role in the excretion o f  substances 
in to  the gut, the bile, and the urine. Furtherm ore Pgp 
can be found in the endo thelium  o f  capillary blood 
vessels in brain, testis, and o ther blood—tissue barrier sites 
[9—11]. T he  extensive tissue distribution and the wide 
variety o f  therapeutically relevant com pounds that are 
transported by Pgp, clearly indicate its im portant role in 
d rug  absorption, distribution, and elim ination. Therefore, 
alterations o f  the transport function or the degree o f 
expression o f  Pgp are likely to  affect the pharm acokinet­
ics o f  many drugs.
R ecen tly  a num ber o f  single nucleotide polym or­
phisms (SNPs) o f  the M D R 1 gene have been identified 
[12—14]. M ost o f  the SNPs are intronic or silent and 
therefore do no t change the am ino acid com position o f 
Pgp. However, the silent polym orphism  in exon
6 10 ©  2002 Blackwell Science Ltd br J Clin Pharmocol, 54, 610-616
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26 3435C  > T  was found to  correlate significantly w ith  
the am ount o f  intestinal Pgp p rote in  and the  ex ten t o f  
absorption o f  digoxin in a small num ber o f  subjects 
(n = 8) pretreated w ith  rifam picin o r given m ultiple doses 
(0.25 m g d ay '1) o f  digoxin [12]. However, it is unclear 
w hether this pharm acogenetic effect requires Pgp induc­
tion or steady state conditions. Therefore, in the present 
study we investigated the  effects o f  the m ajor M D R l 
SNPs, including that in exon 26 3435C  > T  on the 
absorption o f  a single 1 m g oral dose digoxin in a large 
sample o f  50 subjects w ithou t pretreatm ent w ith  
rifam picin.
M eth o d s
Subjects
A total o f  50 healthy unrelated Caucasian male volunteers 
(nonsmokers) w ith a m edian age o f  26 years were 
enrolled from the Berlin area. T hey were considered to 
be healthy as determ ined  by the ir medical histories, phys­
ical exam ination, electrocardiogram , urine analysis, and 
routine tests o f  biochemistry, haematology, hepatitis В 
and C, arid HIV. T h e ir weight ranged from  45.1 kg to 
74.6 kg. All volunteers refrained from  alcohol, coffee, tea 
or cola beverages consum ption and did n o t take m edi­
cations during  the study. All subjects gave their w ritten  
inform ed consent before entry  in to  the study. T he inves­
tigation was approved by the local ethics com m ittee o f  
the C harite  M edical C enter, H um bold t U niversity o f  
Berlin. M D R l genotype was de term ined  using poly­
merase chain reaction (P C R )—based restriction fragm ent 
length polym orphism  (RFLP) assays [13].
Study protocol
After an overnight fast, each subject received a single oral 
dose o f  1 m g digoxin (Dilanacin™ , A rzneim ittelw erk 
Dresden G m bH , R adebeul) along w ith  200 m l water. 
Venous blood samples (5 ml) for d rug  analysis were col­
lected in to  syringes contain ing  ethylene d iam inetetraace- 
tic acid (EDTA) before and 10, 20, 30, 35, 40, 45, 50, 
60, 75, 90, 120, 180, and 240 m in  after digoxin intake. 
T he  plasma was separated by centrifugation  and im m e­
diately stored in polypropylene tubes at —22 °C.
Digoxin concentration measurements
Digoxin plasma concentrations were de te rm ined  by a 
m icroparticle enzym e im m unoassay (IMx®1 D igoxin 
Assay, A bbott Laboratories; USA). T h e  low er lim it o f 
quantification was 0.3 |tg  Г '.Т Ь е  plasma samples o f  each 
volunteer were analyzed in duplicate together w ith  cali­
bration and quality contro l samples. F u rth er calculations
were done w ith  the  respective m ean values. T he  m ter- 
assay coefficients o f  variation at plasma concentrations o f  
0.9 ng Г ', 1.9 H gT 1 and 3.2 ng Г ' were 8.37%, 5.75% 
and 4.68%, respectively.
Pharmacokinetic analysis
Previous investigations dem onstrated that pharm aco­
kinetic differences betw een the genotypic groups occur 
prim arily during  the initial hours o f  absorption and are 
best reflected by area under the plasma concentration 
tim e curves (AUCs) covering the early hours after oral 
drug intake [15—17].T h e  t„ax for digoxin is know n to be 
a variable param eter [18] ranging from  0.5 to  3 h in  our 
sample. Thus, an A U C  from 0 to 4 h A U C(0,4 h) was 
considered a suitable measure o f  digoxin absorption. 
A U C (0,4 h) was calculated by use o f  the trapezoidal rule, 
using W inN onlin™  (professional edition; version 1.5, 
Pharsight C orporation , M ountain  View, CA, USA). Clmx 
and tm3X o f  digoxin were derived directly from  the m ea­
sured values.
Statistical analysis
T he prim ary aim  o f  this exploratory study was to eval­
uate the functional relevance o f  m ajor know n M D R l 
SNPs on digoxin absorption represented by AUC(0,4 h). 
For a tw o groups com parison the M an n -W h itn ey -U  two 
sample test was used. W h en  m ore than two groups were 
being com pared the Kruskal—Wallis test was used. A 
P  value o f  <0.05 was considered significant. Calculations 
were done using SPSS™ software (version 9.0, SPSS Inc., 
Chicago, USA).
R esu lts
To study the influence o f  M D R l variant genes on 
digoxin pharm acokinetics we included SNPs occur­
ring  at a frequency o f  at least 10% in  the Caucasian 
population (exon 6 + 1 3 9 C > T ,  exon 1 7 -7 6 T > A , 
3435C  > T ), SNPs changing the am ino acid composition 
(61 A > G, 1 199G > A, 2677G  > T  > A), and a SNP that 
directly precedes the translation start codon o f  the 
M D R l gene (exon 2 - lG > A ) .  T he allelic frequency 
distribution o f  the  investigated genetic variants in our 
sample (Table 1) is in good agreem ent w ith previous 
studies [12, 13] and did n o t show significant deviation 
from  Hardy—W einberg equilibrium .
After adm inistration o f  a single oral dose o f  1 mg 
digoxin the pharm acokinetics o f  the absorptive phase 
characterized by A U C(0,4 h), Cna.x and f„MX was not 
significantly different betw een the genotypic groups. 
C om parison o f  the linked M D R l polym orphism s in 
exon 21 2677 and exon 26 3435 also did n o t discrimi-
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Table 1 Location, position, effects of protein expression, allelic frequencies and genotype prevalence of the MDR1 variants studied.
LiklltlOH Position Allele Effect
Allelic
frequency
(%)
Allelic 
frequency 
(14) (%) Genotype
GenotyjH' 
prei'tilence 
(observed) (%)
Ccnoty]>e prei'tilence 
(95% confidence internal)
Inrron 1 Exon 2-1 G initiation of translation? 93.0 91.0 G/G 86.0 73.3, 94.2
A 7.0 9.0 G/A 14.0 5.8, 26.7
A/A 0.0 0 .0 , 0.1
Exon 2 cDNA 61 A 21 Asn 87.0 88.8 A/A 74.0 59.7, 85.4
G 21 Asp 13.0 11.2 A/G 26.0 14.6, 40.3
G/G 0.0 0 .0 , 0.1
Inrron 6 Exon 6 + 139 С j 61.0 62.8 C/C. 36.0 22.9, 50.8
T 39.0 37.2 C/T 50.0 35.5, 64.7
T/T 14.0 5.8, 26.7
Exon 11 cDNA 1199 С, 400Ser 98.0 94.5 G/G 96.0 86.3, 99.5
A 4<X)Asn 2.0 5.5 G/A 4.0 0.5, 13.7
A/A 0.0 0.0 , 0.1
Intron 16 Exon 17-76 T ? 53.0 53.8 T/T 28.0 16.2, 42.5
A 47.0 46.2 T/A 50.0 35.5,64.5
A/A 22.0 11.5,35.7
Exon 21 cDNA 2677 G 893Ala 52.0 56.5 G /G 24.0 13.1,38.2
T 893Ser 38.0 41.6 G/T 42.0 28.2, 57.0
A 893Thr 10.0 1.9 T/T 14.0 5.8,26.7
G/A 14.0 5.8. 26.7
T/A 6.0 1.3, 16.6
A/A 0.0 0 .0 , 0.1
Exon 26 cDNA 3435 С Wobble 49.0 46.1 C/C 24.0 13.1, 38.2
T 51.0 53.9 C/T 50.0 35.5.64.5
T/T 26.0 14.6, 40.3
The positons of rhe MDR1 polymorphisms correspond to the MDR1 cDNA (GenBank accession no. AC002457/AC005068). The first base of 
the ATG st.irt codon is set to no. 1. Intro nie SNPs are described as (exon + n), with n bases upstream (-) or downstream (+) of the exons. Eight 
polymorphisms were analysed.
nate betw een subjects carry ing  the genotype exon 21 
2677G G /exon 26 3435C C  and exon 21 2 6 7 7 T T /ex o n  
26 3435TT. A dditional hom ozygous allelic com binations 
were no t investigated due to  low  frequencies. Pharm a­
cokinetic data and statistical analysis are sum m arized in 
Table 2. T here were also no  significant differences after 
normalization to ideal body  w eight to  elim inate in te rin ­
dividual differences in w eight and height o f  the  subjects. 
There was considerable variation  in  the  kinetic param e­
ters w ithin each genotypic g roup  (Figure 1).
D iscussion
Very recently a num ber o f  M D R 1  SNPs were detected 
and tested prelim inarily  for th e ir ability to  alter the phar­
macokinetics o f  orally adm inistered digoxin [12]. T he 
main findings were that a po lym orphism  in exon 26 
(3 4 3 5 C > T ), although noncod ing , resulted in a m ore 
than 2-fold decrease in  duodenal epithelial Pgp protein 
content in hom ozygous T / T  subjects com pared w ith  
carriers o f  the C /C  variant. This was accom panied by a 
significantly h igher d igoxin bioavailability in the T / T
612
genotype. T he  finding was supported by a lowered efflux 
o f  rhodam ine-123 from  C D 56+ natural killer cells, m edi­
ated by Pgp, in 3435T T  com pared w ith C C  carriers [19]. 
T hese studies were lim ited because o f  the small num ber 
o f  subjects investigated. Accordingly the aim o f  the 
present study was to extend the  sample num ber to  seek 
for additional pharm acokinetic effects o f  the m ajor 
M D R 1  SNPs and to evaluate the im pact o f  the know n 
functional active exon 26 3435C >T  polym orphism .
In contrast to the previously reported results [12] no  
significant differences in A U C(0,4 h), Cirax and fn m  were 
observed betw een M D R 1 genotype com binations in this 
study.
A  m ajor finding o f  one o f  the previous studies was 
tha t the observed difference in the bioavailability o f  
digoxin betw een genotypes w ith respect to  exon 
26 3435C  > T  SN P was observed only after pretreatm ent 
w ith  rifam picin [12]. This antibiotic is reported to be a 
strong inducer o f  intestinal Pgp expression [16], increas­
ing p ro te in  con ten t 3.5 fold above control levels. T he 
ability o f  rifam picin to  increase epithelial Pgp content 
was significantly higher in individuals carrying the C /C
©  2002 Blackwell Science Ltd Br J Clin Pharmacol, 54. 610-616
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Table 2 Pharmacokinetic parameters and statistical analysis.
Locution Position Genotype
p
I’tiluc
AUCfO.4 h) 
Menu
(M Г' l,J 
Difference between 
mean of S.\'P and 
wiltl type groups 
(95% Cl)
P
ralue
C«,,
Mean
. (n r * )
Difference between 
mean of S l\rP anil 
wilt1 type groups 
(95% Cl)
P
ralue
t«,
Mean
»■ (10
Difference between 
mean t»f SN P anil 
will! type groups 
(95% Cl)
Intron 1 Exon 2-1 G/G 0.426 9.17 0.780 4.00 0.232 1.02
G/A 9.73 0.563 (-0.81, 1.94) 3.98 0.00 (-1.01, 0.97) 0.80 - 0.22 (-0.59, 0.15)
Exon 2 cDNA 61 A/A 0.091 9.51 0.382 4.11 0.815 0.96
A/G 8.51 -1.00 (-2.05, 0.06) 3.68 -0.43 (-1.20, 0.34) 1.09 0.13 (-0.17, 0.42)
Intron 6 Exon 6 + 139 C/C 0.785 9.22 1.000 4.10 0.907 0.96
C/T 9.17 0.05 (-1.05, 1.15) 3.90 0.19 (-0.58, 0.97) 1.00 -0.04 (-0.33, 0.25)
T/T 9.60 -0.38 (-1.84, 1.08) 4.08 0.01 (-1.21, 1.24) 1.06 - 0.10 (-0.46, 0.25)
Exon 11 cDNA 1199 G/G - 9.21 - 4.03 - 0.98
G/A 10.21 - 3.26 - 1.18 -
Intron 16 Exon 17-76 T/T 0.718 9.01 0.294 3.88 0.228 1.07
T/A 9.46 -0.45 (-1.58, 0.68) 4.21 -0.33 (-1.14, 0.47) 0.92 0,15 (-0.17, 0.47)
A/A 9.07 -0.05 (-1.39, 1.28) 3.67 0.21 (-0.76, 1.17) 1.05 0.03 (-0.33, 0.38)
Exon 21 cDNA 2677 G/G 0.875 9.06 0.648 4.22 0.736 1.00
G/T 9.10 -0.03 (-1.28, 1.21) 3.91 0.30 (-0.57, 1.17) 1.00 -0.06 (-0.36, 0.35)
T/T 8.95 0.11 (-1.51, 1.74) 3.69 0.53 (-0.77, 1.83) 1.10 - 0.10 (-0.50, 0.30)
G/A 9.91 -0.84 (-2.65, 0.96) 4.00 0.21 (-1.30, 1.73) 0.85 0.15 (-0.20, 0.50)
T/A 10.50 - 4.39 - 0.96 -
Exon 26 cDNA 3435 C/C 0.295 9.72 0.799 4.12 0.871 0.92
C/T 8.89 0.83 (-0.39, 2.05) 3.87 0.26 (-0.64, 1.15) 1.05 - 0.12 (-0.46, 0.22)
T/T 9.51 0.20 (-1.10, 1.51) 4.14 -0.02 (-0.98, 0.94) 0.95 -0.03 (-0.30, 0.24)
Exon 21/ cDNA 2677 3435
Exon 26 2677/ G/G C/C 0.393 9.06 0.712 3.84 0.478 0.90
3435 T/T T/T 9.06 0.00 (-1.78, 1.78) 3.69 0.15 (-1.07, 1.36) 1.11 - 0.21 (-0 .68 , 0.26)
Pharmacokinetic parameters were compared between the wildtype groups and those carrying a SNP using the nonparametric Mann-Whitney-U two sample test or Kruskal-Wallis tost. A P value 
of < 0.05 was considered significant. P values and 95% Cl were not given for subject groups with a lower number than 4.
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Figure 1 AUC(0,4 h) data for digoxin after a 1 mg oral dose in relation to the M DRl polymorphisms, n = number of subjects in each 
group.
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genotype in M D R l exon 26 3435C  > T  than in subjects 
hom ozygous for the T  allele. Since digoxin is transported 
back into the intestinal lum en m ainly by Pgp, induction 
o f  this efflux system may be an im portant prerequisite 
for the M D R l SN P 3435C  > T  dependent m odulation 
o f  digoxin bioavailability. This could  also explain w hy 
there was a lack o f  association betw een the 3435C  > T  
polym orphism  and Pgp expression in 100 placentas 
obtained from  Japanese w om en n o t treated w ith  inducing 
agents [14].
T he transport capacity o f  Pgp is a function o f  the 
am ount o f  carrier p ro te in  expressed in epithelial cells. 
Digoxin is preferentially absorbed in the duodenum . If 
the local digoxin concentration  exceeds the maximal Pgp 
secretory capacity, further digoxin absorption is merely 
dependent on  passive diffusion o r uptake carriers. M em ­
bers o f the organic anion-transporting  polypeptide family 
in humans (OATP) and rats (Oatp) have been identified 
as candidate uptake transporters for am phipathic drugs, 
including digoxin [20, 21]. Localization o f  O A TPs/O atps 
to the basolateral pole o f  hepatocytes facing portal 
venous blood and to the apical m em brane o f  enterocytes 
[22], suggests an involvem ent o f  this uptake system in 
digoxin absorption. Thus, the counteracting  effects pas­
sive diffusion and OATPs could dramatically diminish the 
m odulatory actions o f  M D R l SNPs on digoxin pharm a­
cokinetics after exceeding a ceiling dose. T he  latter could 
be increased by protein  induction  o f  the Pgp carrier 
system and w ould be dependent on  the drug, as the 
maximal transport capacity Vaш o f  a carrier is substrate 
specific. T he  oral dose o f  1 m g digoxin used in ou r study 
m ight be h igher than that needed to saturate the trans­
po rt capacity o f  Pgp. A  recent study investigating the 
effects o f  the noncoding SN P in exon 26 3435C  > T  on 
digoxin pharm acokinetics after a single low dose o f
0.25 m g resulted in decreased digoxin plasma concentra­
tion in hom ozygous subjects o f  the T  allele com pared 
with carriers o f  the C C  genotype [23].
In the present study A U C (0,4  h), C lmx and tnm were 
determ ined after a single oral dose o f  digoxin. This 
experim ental design was chosen to  assess prim arily the 
impact o f  M D R l SNPs on the absorption o f  digoxin. 
Since drugs absorbed in to  the enterocytes are pum ped  
back into the intestinal lum en by Pgp, one w ould expect 
the m ajor effect o f  the latter to  occur during  the first 
hours after oral adm inistration. H owever, in one o f  the 
previous studies, digoxin pharm acokinetics were m oni­
tored under steady state conditions [12]. In  this case the 
observed differences betw een the 3435C  > T  genotypes 
may be due partly to genetic effects on  digoxin distribu­
tion and elim ination.
In our study there was a large variation in  digoxin 
pharm acokinetics w ith in  each genotypic group.T his high 
variability indicates that additional factors may influence
the absorption o f  digoxin. These may include o ther as 
yet undetected  SNPs o r dietary and o ther environm ental 
factors, that induce o r inhib it the Pgp activity [5, 24, 25].
In summary, we conclude that the M D R l SNPs stud­
ied, including that in exon 26 previously show n to  have 
functional relevance, apparently do n o t con tribu te  to the 
absorptive pharm acokinetics o f  a single oral dose o f  1 m g 
digoxin. O u r  study suggests that o ther genetic and envi­
ronm ental factors m ay play an im portan t role in M D R l 
SN P m ediated m odulation  o f  digoxm pharm acokinetics.
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Quantitative determination of M D R I m R N A  expression in 
peripheral blood lymphocytes: a possible role of genetic 
polym orphism s in the M D R I gene
K. Oselin +, I. Nowakowski-Gashaw*, P. M. Mrozikiewicz*, D. Wolbergs*, R. Pähkla* 
and I. Roots
‘Humboldt University, Berlin, Germany, +Tartu University, Tartu, Estonia
Abstract Background P-glycoprotein is a transmembrane efflux pump that extrudes a wide variety
o f drugs, thereby reducing their intracellular access. In  humans, P-glycoprotein is encoded 
by the M D R I gene. Recently, several single nucleotide polymorphisms in the M DRI 
gene were identified. Moreover, it was postulated that, in addition to the full-length P- 
glycoprotein, a ‘mini’ P-glycoprotein was also present in lymphocytes.
Materials and methods We investigated the effect of the genetic polymorphisms G2677T 
and C 3435T in the M DRI gene on M DRI mRNA expression in FACS-sorted peripheral 
blood C D 4+, CD 8+, CD 19+, and CD 56+ cells. M DRI mRNA expression was determined 
in 45 healthy individuals using a real-time quantitative RT-PCR.
Results We detected the highest expression of M DRI mRNA in CD56+ cells, followed by 
C D 8+ > C D 4+ > CD19+ cells. However, genetic polymorphisms of the M DRI gene failed 
to affect (P > 0 05) M D R I mRNA levels in the peripheral blood lymphocytes. Furthermore, 
the transcript levels for the M DRI N-terminal half were almost two-fold lower than that of 
the M DRI С-terminal half in all cell populations investigated (P  < 0 0001).
Conclusions An almost two-fold difference in M DRI C- and N-terminal half expressions 
supports the presence of mini-P-glycoprotein, an alternatively spliced form of the full-length 
molecule, in peripheral blood lymphocytes.
Keywords P-glycoprotein, peripheral blood lymphocytes, M D R I mRNA expression, 
M D R I genetic polymorphism.
E urJC lin  Invest 2003; 33 (3): 261-267
Introduction
P-glycoprotein (Pgp)-related transport of chemotherapeu- 
tics is a well-characterized mechanism of chemoresistance 
in cancer therapy. Overexpression of Pgp has been found 
in different cancers, correlating with lack of response to 
chemotherapy and poor survival in some malignancies 
[1,2]. Within haematopoietic cells, Pgp has been detected
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in peripheral blood C D 4+, C D 8+, CD 19*, and CD56+ 
cells, with the highest level in cells with cytotoxic activity, 
C D 56+ natural killer (NK) and C D 8+ T  cells [3,4]. In 
several studies, N K  and T  cell-mediated cytotoxicity was 
inhibited by Pgp pharmacological inhibitors and anti-Pgp 
monoclonal antibodies [5,6]. In hum anT  lymphocytes, Pgp 
has been reported to participate in the transport of 
cytokines, including IL-2, IL-4 and IFN -y [7,8] . These 
findings indicate that Pgp may play a role in specific immu­
nological functions.
In humans, Pgp is encoded by the M D R I gene, a member 
of the ATP-binding cassette transporter family. Recently, 
several single nucleotide polymorphisms in the M DR I gene 
were identified [9]. C3435T in exon 26 was found to deter­
mine intestinal Pgp expression. Comparison of area-under- 
the-curve (AUC) values for digoxin after oral administration 
revealed that subjects homozygous fo rT T  had significantly 
higher AUC values than those with CC genotype. Fellay 
era/. [10] demonstrated that the C 3435T polymorphism
24
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predicted immune recover after initiation of antiretroviral 
treatm ent in H IV -1-infected individuals, as estimated by 
a greater rise in CD 4+ cell count in T T  than in CC or C T  
patients. However, no association between the C3435T 
mutation and the doses needed to maintain similar cyclos­
porine A trough concentrations was observed in renal 
transplant recipients [11].
The aim of the present study was to evaluate Pgp expres­
sion, by the means o f the mRNA level, in peripheral 
blood C D 4 \ CD8+, C D 19+, and CD 56+ cells from healthy 
individuals with different M D R l genotypes. The influence 
of two partially linked polymorphisms, G 2677T in exon 21 
and C3435T in exon 26 of the M D R l gene, was investi­
gated in 45 healthy individuals. A previous study has 
shown that N K  cells did not express detectable levels of 
full-length 170 kDa Pgp [12]. The presence of a small- 
molecular-weight mini-Pgp in peripheral blood NK cells 
was postulated. Hence, two specific primer pairs, designed 
to distinguish the full-length and the suggested mini-Pgp 
were used in RT-PCR
Materials and methods
Clinical study
The study protocol was approved by the Ethics Committee 
of H um boldt University. After an informed consent, 45 
healthy Caucasians (six female and 39 male, age range 21- 
33 years) were enrolled. The subjects took no medication 
and were ascertained to be healthy by a clinical examination.
Materials
All oligonucleotide prim ers and hybridization probes 
for PCR and RT-PCR were purchased from Tib Molbiol 
(Berlin, Germany). Biocoll lymphocyte separating solution 
(density 1 077) was from Biochrom KG (Berlin, Germany). 
Fluorescein isothiocyanate (M I C)- and phycoerythrin (PE)- 
conjugated antibodies were obtained from Immunotech 
Beckman Coulter (Munich, Germany); allophycocyanin 
(APC)- and periclinin chlorophyll protein cyanine 5 conjugate 
(PerCP-Cy5-5)-conjugated antibodies were obtained 
from Becton Dickinson (San Jose, CA USA). Recombinant 
Rnasin® ribonuclease inhibitor, T7 RNA polymerase and 
RQ1-DNase were purchased from Promega (Madison, WI, 
USA); and M-MLV reverse transcriptase and Taq D NA 
polymerase from Invitrogen (K arlsruhe, Germany).
DNA isolation and genotyping o f  M D R l exon 21 
G2677T and exon 26 C3435T polym orphism s
DNA was isolated from 200 (J.L of whole blood by MagNA 
Pure LC (Roche, M annheim, Germany). Genotyping was 
performed on real-time PC R  assays in a LightCycIer™ 
(Roche), as described previously [13].
Cell sorting assay and isolation o f total RNA
Peripheral blood mononuclear cells (PBMC) were isolated 
from 20 m L of whole blood by gradient centrifugation over 
Biocoll lymphocyte separating solution (density 1 077) 
according to the manufacturer’s protocol. The lymphocyte 
layer was washed twice with PBS/0T%BSA and stained 
with H  I C-anti-CD4, APC-anti-CD8, PerCP-Cy5-5-anti- 
CD19 and PE-anti-CD56 antibody. Appropriate isotype 
controls were used. Cells were sorted using FACSDiva 8- 
color Turbosorter (Becton Dickinson). The samples were 
gated on forward-scatter vs. side-scatter to include lym­
phocytes. A second gate was set around the FITC-, APC-, 
PerCP-Cy5-5- or PE-positive cells. Purity o f sorted cells 
was analyzed with FACSCalibur and was = 98% (n = 10). 
Total RNA from FACS-sorted cells was isolated with the 
RNeasy Mini Kit (QIAGEN, H ilden, Germany). RNA 
concentration was measured spectrophotometrically and 
samples were maintained at -8 0  °C until analysis.
Real-tim e quantitative RT-PCR  
(LightCycIer) analysis
cDNA was synthesized from total RNA in a 25-|iL final 
reaction volume containing 50 ng of sample RNA or dilu­
tions of standard RNA (run in the same plate but separate 
tubes), 1 x First Strand Buffer, 10 mM of dithiothreitol, 
0-4 mM of each dN I P, 8 U  of ribonuclease inhibitor, 120 
U  of M-MLV reverse transcriptase and 0-8 (tM of oligo 
dT(15) primer. The mixture was preincubated for 10 min 
at 26 °C, then incubated at 42 °C for 60 min followed by 
heating at 95 °C for 2 min, and cooled. Quantitative PCR 
was performed with gene-specific primers in the LightCy­
cIer™. The principles of real-time quantitative PCR in a 
LightCycIer has been described elsewhere [14]. To avoid 
amplification of possible contaminating genomic DNA, the 
selected forward or reverse primers and/or hybridization 
probes were designed to span intron/exon junctions. The 
sequences of primers and hybridization probes are shown 
in Tables 1 and 2. Also, control reactions without reverse 
transcriptase were run to verify the absence of contaminat­
ing DNA.
PCR  amplification was carried out in a 16-jtL reaction 
volume containing 5 (iL of cDNA (of 25 |iL  of total cDNA), 
1 -25 U  of Taq DNA polymerase, 1-6 |iL  of 10x PCR buffer, 
and M gCl2, dN I Ps, reverse and forward primer, hybridi­
zation probes, BSA and DMSO optimized for each reaction. 
The PC R  reactions were initiated with denaturation at
94 °C for 60 s, followed by amplification with 45 cycles at
95 °C 0 s, annealing (depending on the primer pair) for 
10 s, and 72 °C for 10 s. Annealing temperatures were 
55 °C for M D R l С -term inal half, 60 °C for M D R l 
N -term inal ha lf and 60 °C for the housekeeping gene 
ß2-microglobulin. The PCR products migrated as a single 
fragm ent with an expected size on an agarose gel. The 
specificity was verified by direct-sequencing with each 
one-side prim er (ABI Prism™  310, Applied Biosystems, 
Foster City, CA).
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Table 1 Oligonucleotide primers used for real-time quantitative RT-PCR
Gene Forward primers* (position) Reverse primers' (position) Product (bp)
MDR1 5'-CCATCATTGCAATAGCAGG-3' 5'-GAGCATACATATGTTCAAACTTC-3' 168
C-half (3018-3036) (3163-3185)
MDR1 5-AAAGTCGGAGTATCTTCTTCCAAG-3' 5'-CCAATTTGAATAGCGAAACATTGA-3' 201
N-half (359-382) (536-559)
ß2-micro 5'-CCAGCAGAGAATGGAAAGTC-3' 5'-CATGTCTCGATCCCACTTAAC-3' 258
globulin (113-132) (350-370)
T7 primer 5'-AGAGCGTAATACGACT CACTATAG-
GGTATCTGCAGA-
RT primer 5'-Tl 1 1 1 l l l l 1 1 1 1 1 1 -
Area amplified refers to sequences with accession numbers as follows: NM_000927 (MDR1), NM_004048 (ß2-microglobulin). 
T7 promoter sequence was incorporated at the 5 -end of the forward primers to obtain templates for in vitro external standard RNA 
synthesis.
dT(l 5) sequence was incorporated at the 5'-end of the reverse primers to obtain templates for in vitro external standard RNA 
synthesis.
Table 2 Sequences of hybridization probes used for real-time quantitative RT-PCR
Gene Sensor (position) Anchor (position)
MDR1
C-half
MDR1
N-half
ß2-micro
globulin
5'-TGGGAAGATCGCTACTGAAGCAAT-3'- 
fiuorescein (3100-3123) 
5'-TTCTTCTTTGCTCCTCCATTGCGG-3'- 
fluorescein (442-465)
5 '-TT CTT С AGTAAGT С AACTT CAATG- 
TCGGA-3'- fluorescein (170-198)
5'-LC Red640 -  AACTTCCGAACCGTTGTTTC- 
TTTGA-3'-phosphate (3128-3152)
5'-LC Red640 -  CCCCTTCAAGATCCATCCC- 
GACC-3'-phosphate (418-440)
5'-LC Red705 -  ATGAAACCCAGACACATAG- 
CAATTCAG-3'-phosphate (140-166)
*Area amplified refers to sequences with accession numbers as follows: NM_000927 (MDR1), NM_004048 (ß2-microglobulin).
Synthesis o f external standards for quantitative 
real-tim e RT-PCR analysis
In order to establish the calibration standard curve, external 
standard RNA was prepared. RT-PCR was carried out in a 
two-step reaction for each gene, as above-described using 
the primers listed in Table l.T h e  subsequent PCR withT7 
primer (T7 promoter sequence was incorporated at the 5'- 
end of the forward primer) and RT primer [dT(15) 
sequence was incorporated at the 5'-end of the respective 
reverse primer] was carried out to obtain a template for in 
vitro transcription. After purification with Ultrafree MC 
30 000 filters, the template was used for in vitro transcnp- 
tion at 37 °C for 90 m in using the DNA-dependent T7 
RNA polymerase. After digestion with RNase-free RQ1- 
DNase, RNA transcripts were purified using RNeasy Mini 
Kit and RNA Cleanup Protocol from QIAGEN. All of the 
RNA standards were quantified spectrophotometrically 
and maintained at -  80 °C. The num ber of standard RNA 
molecules was determ ined as described elsewhere [15]. 
A series of dilutions o f external standard RNA, ranging 
from 1010 to 10ft copies for ß2-m icroglobulin, and from 
10* to 10l copies for M DR1 C- and N-terminal half, were 
performed. T he  specificity o f obtained transcripts was 
verified by sequencing with the ABI P rism IM 310 gene 
analyser.
Q uantification o f  m RNA in the LightCycler™
T he data was evaluated with the LightCycler1 M-run  
software, version 3-5. The C t (threshold cycle) values were 
calculated using the second derivative maximum method. A 
calibration curve was generated from serial dilutions of the 
standard RNA by plotting C t vs. the logarithm of the copies 
of standard RNA, and was used to calculate the number of 
RNA copies in the samples. The housekeeping gene ß2- 
microglobulin was used for normalization of M DR  1 mRNA 
expression. Final results were expressed as MDR1 cDNA 
copies/ng of total RNA and as the normalized ratio of 
M DR1 cDNA copiessamplt. x ß2-microglobulin cDNA 
copiesmi:an/ß2-microglobulin cDNA copies4am[,]c.
Statistical analysis
Data were presented as the mean + SD. MDR1 mRNA levels 
between cell populations and differences in the MDR1 C- 
and N-terminal half expressions were analyzed by the Wil- 
coxon signed ranks test. MDR1 mRNA expression between 
the three genotypes was analyzed by the Kruskal-Wallis test. 
All calculations were performed with SPSSIM for Windows 
(version 10 0, SPSS Inc., Chicago, II.)- A P-value of 0 05 
was considered to be of statistical significance.
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264 K. Oselin et cd.
(b)
0-10
008
li­ Ü-06ttи
ф 0-04
Iflв
О3 0 0 2
LL
0 0 0
Analysis Method: Second 
Derivative Maximum 
Slope: -3  860 
Intercept: 45 08 
Error O '146 
г:-1-00
50  6-0
Log concentration
18 24
Cycle number
Figure 1 Amplification plot for MDRI 
С-terminal half mRNA expression.
(a) Calibration curve was generated by 
plotting the Ct value vs. the log of starting 
copies of standard RNA. Ct values for 
samples were interpolated on the calibration 
curve and used to calculate the number of 
copies in samples, (b) Amplification curves 
of serial dilutions of standard RNA, ranging 
from 1 x 10s to 1 x 103 starting copies, were 
displayed by plotting the fluorescence data 
vs. cycle number. No template controls for 
RT and PCR were also performed.
Results
Quantification o f the M DRI m RNA in CD4+, CD8+, 
CD19+, and CD56+ cells
Calibration curves were generated from serial dilutions 
of the external standard cDNAs. The calibration curves 
were linear as shown by a correlation coefficient (R2 value) 
of > 0-98 (Fig. la ).T he  slopes (> -3-860) were close to the 
theoretical optim um  (-3-322), which indicates a very 
high PC R  efficiency. T he  coefficients o f variation for 
M DR I С -term inal half, M D R I N -term inal half, and ß2- 
microglobulin mRNA levels were 8-9%, 35-9% and 9-7%, 
respectively, as determined with data obtained from six sep­
arate RT-PCR experiments with the same RNA sample 
(n = 5). Figure 1(b) shows a representative amplification 
plot of M D R I С-terminal half; similar standard curves 
were obtained for ß2-microglobulin and M D R I N-terminal 
half.
Using 50 ng of total RNA, M D R I mRNA was detected 
and quantified by RT-PCR in FACS-sorted CD 4+, CD 8+, 
CD19+, and CD 56+ cells. T he M D R I mRNA C-terminal 
half exhibited the highest abundance in the CD56+ cells 
(mean 1-43 x 103 m olecules/ng o f to ta l RNA ± 4-85 x 
102) and a 14-fold variation between individuals (Fig. 2).
8 1-5
0
1
E  1
□  MDR1 С-terminal half 
■  MDR1 N-terminal hall
1
*
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i
Y i J 1
CD4+ CD8+ CD19+ CD56+
Figure 2 Quantitative determination of the MDRI C- and N- 
terminal half mRNA levels in human peripheral blood 
lymphocytes. Each bar represents the mean + SD number of copies 
(xlO3) ng'1 of total RNA, as determined in 45 individuals. 
’Differences between the C- and N-terminal half expression were 
significant (P  < 0 0001) in all cell populations, as determined with 
Wilcoxon’s signed ranks test.
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The lowest expression o f the M D R l mRNA (c-terminal 
half) was found in the C D 19+ cells (mean 2-23 x 102 
molecules/ng o f total RNA ± 98 8) w ith an 8-fold var­
iation between individuals. The differences in M D R l 
mRNA expression between cell populations were statisti­
cally significant (P  < 0 0001), except C D 4+ vs. C D 19+ 
(P > 0 09). All pairwise differences remained statistically 
significant at 5% level after applying Bonferroni’s correction 
for multiple comparison.
Effect o f M D R l genetic polym orphism s on M D R l 
mRNA expression
We compared the mRNA levels of M D R l С-terminal half 
in CD4 , CD 8+, CD 19+, and CD 56+ cells between indi­
viduals with different genotypes in the M D R l gene. Statis­
tical analysis revealed no significant (P  > 0 05) difference in 
the M DR l expression in regard to different genotypes in 
exon 21 G2677T and in exon 26 C 3435T (Fig. 3a-b). 
Although the difference was not significant, both mutations 
were associated with the lowest level o f mRNA in 
homozygous mutant individuals in C D 8+ and CD 56+ cells, 
and heterozygous individuals displayed an intermediate 
phenotype. However, these differences in M D R l expression 
were not found when the transcript levels were normalized 
(Table 3). The mean ß2-microglobulin values used for nor­
malization were 5-8 x 105 copies for CD 4+, 6 0 x 105 copies 
for CD8+, 3-22 x 104 copies for CD19+, and 6-64 x 105 
copies for CD56+ cells, as determined in 45 individuals.
Mini-Pgp expression in CD4+, C D 8+, CD19+, and 
CD56+ cells
Pgp is composed of two homologous halves, C- and N - 
terminal half, each containing six transmembrane domains 
and an ATP-binding domain [ 16] .To elucidate the presence 
of mini- and full-length Pgp in PBM C, primers amplifying 
the C- and N-terminal half of Pgp were designed. Previous 
studies have shown that mini-Pgp contains the C-terminal 
half of die molecule and is not glycosylated [12,17,18]. 
Hence, the primers amplifying the C-terminal half deter­
mined both the mini- and the full-length molecule, but the 
primers amplifying the N-term inal half determ ined only
CD4+ CD8+ CD19+ CD56+
Figure 3 The mRNA levels of the MDRl C-terminal half in 
FACS-sorted peripheral blood lymphocytes from individuals with 
different genotypes in (a) exon 21 G2677T and (b) exon 26 
C3435T of the MDRl gene. One individual was determined to 
carry ТА in exon 21 and was excluded from the analysis of the 
G2677T polymorphism. Data are presented as mean ± SD number 
of copies (xlO3) ng_l of total RNA. P-values according to the 
Kruskal-Wallis test exceeded 0  05.
the full-length Pgp. Using these primer pairs, we detected the 
expression of both the N- and C-terminal half of Pgp in all 
cell types investigated. Indeed, the transcript levels for the 
M D R l N-terminal half were almost two-fold lower than 
that of the M D R l C-terminal half (P <  0 0001) in all cell 
populations (Fig. 2). A comparison of ß2-microglobulin- 
normalized data displayed the same pattern (data not shown). 
As found for the M D R l C -term inal half, the genotype
Table 3 Normalized values of MDRl mRNA (C-terminal half) levels in peripheral blood lymphocytes from individuals with different 
MDRl genotypes
G2677Tin exon 21 C3435T in exon 26
GG (n = 21) GT (n = 16) TT (n = 7) CC (n = 13) CT (n = 15) TT (n = 17)
CD4+ 3-47 ±1-69 3-73 ±2-18 3-69 ±1-43 3-23 ±1-39 4-18 ± 2-33 3-24 ±1-52
CD8+ 8-62 ±3-68 8-67 + 2-27 6-90 ±2-00 8-34 ±3-53 9-02 + 2-61 7-97 ±2-99
CD19* 2-62 + 1-49 2-30 ±0-70 2-60 ±1-45 1-87 ±0-90 2-94 ±1-17 2-59 ± 1 34
CD56* 15 5 + 6-13 15-3 ±4 49 13 0 ± 6-04 12-6 ±3-69 18-2 ±6-07 14-8 ±6-03
Mean ± SD (xlO2) are presented. The data was expressed as a ratio of MDRl cDNA copiessaroplc x ß2-microglobulin cDNAcopiesrac.Jn/ 
ß2-microglobulin cDNA copies,ampk. Numbers in parenthesis indicate the number of individuals. One individual was determined to carry 
ТА in exon 21 and was excluded from analysis of the G2677T polymorphism. P-values according to the Kruskal-Wallis test exceeded 0 05.
I 2003 Blackwell Publishing Ltd. European Journal of Clinical Investigation, 33,261 267
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did not have any apparent effect on the N-terminal half 
expression (data not shown).
Discussion
In the present study, we investigated the M DRI mRNA 
expression in peripheral blood C D 4+, CD 8+, CD19+, and 
CD56+ cells from healthy individuals with different 
G2677T and C3435T genotypes in the M DRI gene. Using 
a real-time quantitative RT-PCR assay, we detected the 
highest expression of M D R I mRNA in the CD56+ cells, 
followed by the C D 8+ > C D 4+ > C D 19+ cells. These 
findings are in accordance with studies published pre­
viously [3,4]. However, we could find no significant impact 
of the M DRI genetic polymorphisms on M DR I mRNA 
levels.
The association betw een the M D R I genetic poly­
morphisms and Pgp expression and /or activity has been 
investigated in several studies. Hitzl et al. [19] dem on­
strated a slower R hl23 efflux in CD56+ cells in individuals 
with T T  genotype at 3435 compared with CC genotype. 
Calado et al. [20] investigated the functional im portance 
of G2677T and C3435T polymorphisms in CD 34+ cells. 
A R hl23  efflux assay revealed no significant differences 
in Pgp function between individuals with different geno­
types. Higher mRNA levels, in duodenal enterocytes in 
subjects homozygous for T l  at 3435 than in C T  or CC 
individuals, were observed by N akam ura et al. [21]. In 
contrast, quantification of M D R I transcripts and Pgp 
expression in PBM C from H IV-infected individuals 
showed significantly lower levels of M D R I mRNA and Pgp 
in 3435 T T  subjects [10]. The conflicting results obtained 
by different authors indicate the complex regulation of the 
M DRI expression. Therefore, it is unlikely that variable 
responsiveness of patients to drugs, which are substrates for 
Pgp, could be attributable solely to single nucleotide poly­
morphisms in M DRI gene. Also, other genetic and non- 
genetic determinants might have an impact on Pgp function.
Several reports have identified the presence of a small- 
molecular-weight Pgp in a drug-resistant variety of cell lines 
from different species [18]. Recently, Trambas et al. [12] 
reported that the mini-Pgp is constitutively expressed in 
human NK cells. The classic 170-kDa Pgp protein was not 
detected by Western blot analysis, instead smaller Pgp prod­
ucts of approximately 70 and 80 kDa were featured. It was 
suggested that both the 70 and 80 kDa proteins contain the 
С-terminal half of full-length Pgp. Moreover, when a cDNA 
containing full-length mRNA of the hamster pgp 1 gene was 
transfected into cells, both the full-length 4-3 kb mRNA and 
a 2-3-kb transcript were produced [17]. Later experiments 
showed that the 2-3-kb transcript encoded a 57-kDa min- 
iprotein. Full-length Pgp contains N-linked glycosylation 
sites. All three sites are located within the first extracellular 
loop at amino acid residues 91, 94 and 99 [22]. Never­
theless, previous studies have shown that mini-Pgp is not 
glycosylated [17,18]. In  the present study, an attem pt to 
elucidate the presence of both mini- and full-length Pgps
in human peripheral blood lymphocytes was performed. 
Two primer pairs, amplifying specifically the С-terminal half 
and the N-terminal half, upstream from N-glycosylation 
sites of the Pgp molecule, were used.
Based on the results obtained, we made the following 
conclusions: (i) on the mRNA level, both the C- and N- 
terminal half of Pgp are expressed in PBMC; (ii) we suggest 
that the full-length molecule is present in PBM C on the 
mRNA level. It is not very probable that only mini-Pgp, 
containing the С-terminal half of the molecule, is expressed 
in N K  cells, as demonstrated by Trambas et al. [12]. It has 
been suggested that alternative splicing of the M D R I gene 
could result in production of mini-Pgp. However, the 
molecule cleavage of full-length Pgp may also occur post- 
transcriptionally, and both C - and N -term inal half could 
be expressed as a form of small molecular weight Pgp. And 
(iii) almost two-fold lower M D R I N -term inal half than 
С-terminal half expression in PBMC could indicate the 
presence of mini-Pgp, an alternatively spliced form of the 
full-length molecule. We also consider that the differences 
observed might result from the different efficacy of RT- 
PCR, especially the lower RT efficacy for long N-terminal 
transcripts compared with short С-terminal products.
In conclusion, using a quantitative real-time RT-PCR 
assay, we determined M DR I mRNA expression in human 
FACS-sorted peripheral blood lymphocytes. The M DRI 
mRNA level was highest for the CD 56+ cells, followed by 
the CD8+ > CD4+ > CD19+ cells. However, the geneuc 
polymorphisms, G 2677T in exon 21 and C3435T in exon 
26 of the M D RI gene, did not have any apparent effect on 
M DR I mRNA expression. Furtherm ore, we demonstrated 
that human PBM C express both the C- and N-terminal half 
of M DRI on a mRNA level. An almost two-fold difference 
in the C- and N -term inal half expression supports the 
presence of a small molecular weight Pgp, an alternatively 
spliced form of M D R I, in hum an peripheral blood lym­
phocytes. Further studies are required to verify the presence 
and role of mini-Pgp in these cells.
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determ ination  o f  the  h u m an  M RP1 and  M R P 2 m R N A  expression 
in FA C S-sorted periphera l b lood C D 4 ',  C D 8 ~ , C D 19 + , and  
C D 56" cells.
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A bstract: Objectives: A T P -b ind ing  cassette (ABC) tran sp o rte rs  ex trude 
a wide variety  o f  endogenous and  exogenous com pounds. In  cancer 
cells, they are  know n to  confer m u ltid rug  resistance. T he aim  o f  the  
present study was to  determ ine the expression o f  the  m u ltid ru g  resist­
ance-associated p ro te in  1 (M R P 1) an d  2 (M R P 2), which are  m em bers o f 
the subfam ily С o f  the  A B C  tran sp o rte rs  fam ily, in h um an  h em ato ­
poietic cells. M ethods: C D 4 ',  C D 8 + , C D 1 9 " , and  C D 5 6 + cells were 
isolated from  w hole b lood by FA C S-sort in 20 healthy  volunteers. 
MRP1 and M R P 2  m R N A  levels were quantified using real-tim e reverse 
transcrip tase-po lym erase  chain  reaction  (R T -P C R ) assays on a L ight­
Cycler * (R oche, M annheim , G erm any). Results: The M RP1 m R N A  
exhibited the highest abundance  in C D 4 cells (7.4 x  103 ±  3. i 9 x  105 
molecules/ng o f to ta l R N A ), followed by C D 8^  > C D 19 > C D 56 
cells. The M R P 2  m R N A  expression was highest in C D 4 * cells 
(6.7 x  102 ±  2.84 x  102), followed by C D 8 T > C D 56*  > C D 1 9 ' 
cells. N o  co rre la tion  betw een the M RP1 and  M R P 2  m R N A  expression 
was observed. Interestingly , ß2-m icroglobulin  m R N A  expression in 
CD19* cells was found  to  be tw ofold lower in com parison  w ith o ther 
cells. Conclusions: O n an  m R N A  level bo th  M R P1 and  M R P 2  were 
expressed in periphera l b lood  cells, w ith m ore th a n  sevenfold higher 
MRP1 expression in all cell popu la tions investigated. The im pact o f  the 
MRP1 and M R P 2 transcrip tion  in these cells rem ains to  study. T he  use 
of ß2-m icroglobulin as a housekeeping  gene could have a  critical im pact 
on the in te rp reta tion  o f  R T -P C R  data .
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A T P -b ind ing  cassette  (A B C ) tra n s p o r te rs  p lay  an 
im portan t ro le  in  th e  t ra n s p o r t  o f  v a rio u s  
endogenous a n d  e x o g en o u s  c o m p o u n d s  across  b io ­
logic m em b ran es  (1). In  c an c e r  cells, they  a re  k n o w n  
to confer m u ltid ru g  re s is ta n c e  th ro u g h  en h an ced  
efflux o f  c h em o th e rap e u tic s . T h e  h u m a n  m u ltid ru g  
resistance-associated  p ro te in  1 (M R P 1 ) a n d  2 
(M R P2) b e lo n g  to  su b fam ily  С  o f  th e  A B C  tra n s ­
porters , a n d  w ere  firs t iden tified  by C o le  el al. (1992) 
(2) in h u m a n  sm all cell lu n g  c an ce r cells, an d  by 
T an iguch i e t al. (1996) (3) in  c isp la tin -re s is tan t
h u m a n  h e ad  a n d  n eck  can ce r cell line, respectively . 
W ith in  h em a to p o ie tic  cells it h as  been  fo u n d  th a t  
C D 3 + cells exh ib ited  the  h ighest an d  C D 1 9 *  cells 
th e  low est M R P 1  m R N A  levels (4). P ro te in  analy sis  
d e te rm in ed  th a t  C D 4 + cells ex h ib ited  h ig h er M R P 1 
ex p re ss io n  th a n  o th e r  cells. In  a n o th e r  s tu d y . A b b a- 
szad eg an  et al. (5) show ed  th a t  regard less  o f  th e  cell 
lineage, n o rm a l p e rip h e ra l b lo o d  a n d  b o n e  m a rro w  
h e m a to p o ie tic  cells express sim ila r b asa l levels o f  the  
M R P 1  m R N A . L aupeze  e t al. (6) investigated  M R P  
ac tiv ity  in  n o rm a l m a tu re  leukocy tes u sing  the
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carboxy-2',7 '-dichlorofluorescein efflux assay. Sim­
ilar cellular export was evidenced in CD3 + , C D 4 + , 
CD8 + , CD  14 \  C D  15 + , CD20 + , and CD 56 1 cells, 
whereas CD 34 1 cells showed higher efflux rate. 
Investigation o f  the m R N A  expression revealed that 
leukocytes were found to m ostly express M R P1, 
whereas M R P2 transcripts were no t present o r only 
at very low levels.
The variable and limited results available in the 
literature, characterizing M RP1 and M R P2 
expression in hum an peripheral blood cells, 
encouraged us to determ ine the M RP1 and M R P2 
m R N A  expression in CD 4 + , CD8 + , CD 19 + , and 
C D 564 cells. MRP1 and M R P2 have similar 
substrate specificity (7). There are no drugs yet that 
specifically inhibit a single M R P  species w ithout 
effect on other transporters. Therefore, we used a 
sensitive technique, reverse transcriptase-polym - 
erase chain reaction (R T -P C R ), instead o f  efflux 
assays, to discrim inate between the MRP1 and 
M RP2.
Materials and methods
Study protocol was approved by the ethics 
com m ittee o f the H um boldt University. A fter an 
informed consent, 20 healthy volunteers (17 males 
and three females, age range 21-33 yr) were 
enrolled in the study.
FITC
Peripheral blood m ononuclear cells (PBM C) were 
isolated from 20 m L whole blood by gradient 
centrifugation over Biocoll lymphocyte separating 
solution (Biochrom K G , Berlin, G erm any). Cells 
were stained with fluorescein isothiocyanate-anti- 
CD4, PE-anti-CD 56 (Im m unotech Beckman 
Coulter, M unich, G erm any), A PC -anti-CD 8, and 
PerCP-Cy5.5-anti-CD 19 antibody (Becton 
Dickinson, San Jose, CA, USA) and sorted using 
FA CSD iva T urbosorter (Becton Dickinson). 
A ppropriate isotype controls were used. Purity  o f 
sorted cells was analyzed with FA C SC alibur and 
was >98% . Total RN A  from  FA CS-sorted cells 
was isolated with the RNeasy M ini K it (Q IA G EN , 
Hilden, G erm any). R N A  concentration  was m eas­
ured spectrophotom etrically  and samples were 
m aintained at -8 0 °C  until analysis.
RT-PCR
cD N A  was synthesized from  50 ng o f sam ple R N A  
and a series o f d ilutions o f external standard  R N A  
using a 120 U M -M LV  reverse transcriptase 
(Invitrogen, K arlsruhe, G erm any) and 0.8 цм oligo 
dT(15) primer. The m ixture was preincubated for
10 min at 26°C, then incubated at 42°C fo r 60 min 
followed by heating at 95°C for 2 min, and cooled. 
Q uantitative PC R  was perform ed on the 
LightC ycIer™  (Roche, M annheim , G erm any) with 
gene specific prim ers and hybridization probes 
listed in Table 1. All oligonucleotide prim ers and 
hybridization probes were purchased from  Tib 
M olbiol (Berlin, G erm any). To avoid amplification 
o f possible contam inating  genomic D N A , the 
selected forw ard or reverse prim ers were designed 
to span intron/exon junctions. Also, control 
reactions w ithout reverse transcriptase were run 
to verify the absence o f contam inating  D N A .
The PC R  am plification was carried out in a 16-nL 
reaction volume containing 5 jxL o f cD N A  (of 25 nL 
o fto ta lc D N A )an d  1.25 U o f  Taq  D N A  polymerase. 
The PC R  reactions were initiated with denaturation  
at 94°C for 60 s, followed by am plification with 45 
cycles at 95°C 0 s, annealing (64°C for M R P1, 63°C 
for M RP2, and 60°C for ß2-microglobulin) for 10 s, 
and 72°C for 10 s. The d ata  was evaluated with the 
LightCycIer™  run softw are, version 3.5. The thresh­
old cycle (Ct) was calculated using the second 
derivative m axim um  m ethod. A calibration curve 
was generated from  serial dilutions o f the standard 
R N A  by plotting C t vs. the log o f  the copies o f 
standard  R N A , and used to calculate the num ber of 
copies in the samples. The housekeeping gene 
ß2-microglobulin was used for norm alization o f the 
MRP1 and M R P2 m R N A  expression. Final results 
were expressed as M RP1 (or M R P2) cD N A  copies 
per ng o f to tal R N A  and as the norm alized ratio  of 
MRP1 (or M R P2) cD N A  copies per 103 copies of 
ß2-m icroglobulin cD N A .
In order to establish the calibration standard 
curve, external standard  RN A  was prepared as 
described previously (8). Briefly, R T -P C R  was 
carried out in a two-step reaction for each gene, as 
described above using the prim ers listed in Table 1. 
To obtain  a tem plate for in vitro transcription, 
subsequent PC R  with T7 prim er (T7 prom oter 
sequence was incorporated at the 5'-end of the 
forw ard prim er) and RT prim er [dT( 15) sequence 
was incorporated at the 5'-end o f the reverse primer] 
was carried out. In vitro transcrip tion  was perform ed 
at 37°C for 90 min using the D N A -aependent T7 
R N A  polymerase. A fter purification, RN A  stand­
ards were quantified spectrophotom etrically. A ser­
ies o f  dilutions o f standard  R N A  was perform ed and 
m aintained at -80°C .
Statistical analysis
D ata  were presented as m ean ±  SD. m RN A  
expression between the different cells was analyzed 
by W ilcoxon signed ranks test. All calculations 
were perform ed with SPSS™  for W indows (version
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Determination of the human M R Pl and MRP2 mRNA expression
Table 1. Oligonucleotide primers and hybridization probes used for real-time quantitative RT-PCR
Gene Sequence' Position (bp|
MRPl
forward primer 5'-TTCCGGAACTACTGCCTGCGCTA-3' 4079-4101
Reverse primer 5'-GGGTCCTGGGGGATGATGGTGA-3' 4305-4326
LightCycler probes 5'-CTCGTTGATCCGAAATAAGCCCAGGGTCA-3'-fluorescein 4231-4203
5 Ч С  Red640-ACGACTTCCCAGCTCCCGTCCGCC-3'-phosphate 4199-4176
MRP2
Forward primer 5 ' GGCTGAGATTGGAGAGAAGGGTATA-3' 2292-2314
Reverse primer 5'-ACTGCAGACAGGGGGTCAT-3' 2409-2391
LightCycler probes 5'-TTTGGTAGGTAGCTCTGGCCAGGCT-3'-fluorescein 2369-2345
5 Ч С  Red640-ATCCGCTGCTTCTGACCCCCAC-3'-phosphate 2343-2322
p2-microglobulin
Forward primer 5'-CCAGCAGAGAATGGAAAGTC-3' 113-132
Reverse primer 5'-CATGTCTCGATCCCACTTAAC-3' 350-370
LightCycler probes 5'-TTCTTCAGTAAGTCAACTTCAATGTCGGA-3'-fluorescein 170-198
5'-LC Red705-ATGAAACCCAGACACATAG CAATTCAG-3'-phosphate 140-166
"Area amplified refers to sequences with accession numbers as follows: NM_004996 (MRP1), NM_000392 (MRP2I, NM_004048 (ß2-microglobulin).
10.0; SPSS, Inc., C hicago, IL , USA). P-values of 
0.05 were considered to be o f  statistical significance.
Results
The coefficients o f variation  for M R P l, M R P2, and 
ß2-microglobulin m R N A  levels were 26.1% , 
21.5%, and 13.6%, respectively. The M R P l 
mRNA exhibited the highest abundance in C D 4 + 
cells (7.4 x 103 ±  3.2 x 103 m olecules/ng o f total 
RNA) with a 6.7-fold difference between individu­
als, followed by C D 8 + (5.7 x 103 ±  2.5 x 103), 
C D 19+ (4 x 103 ±  1.8 x  103), and  C D 5 6 4 
(3.6 x 10? ±  1.3 x  103) cells (Fig. 1A). The 
differences between cell populations were statisti­
cally significant ( P  < 0.01), except C D 1 9 + vs. 
CD 56+ cells. Also the M R P2 m R N A  expression 
was highest in C D 4 + cells (6.7 x  102 ±  2.8 x 102) 
with a 5.2-fold difference between individuals, 
followed by C D 8 + (5.7 x  102 ±  1.9 x 102), 
CD 56+ (4.9 x  102 ±  2.2 x 102), and CD 19 + 
(4.2 x 102 ±  1.6 x 102) cells (Fig. IB). The differ­
ences observed were statistically significant 
(P < 0.05). N o  corre la tion  between the M R P l 
and M RP2 m R N A  expression was observed (data 
not shown).
The M R P l and M R P 2 m R N A  levels norm alized 
to ß2-microglobulin are show n in Table 2. H ow ­
ever, we found th a t the m ean ß2-microglobulin 
expression in C D 1 9 + cells was significantly lower 
(2.6 x 10s ±  7.8 x 104; P  <  0.001) in com parison 
with other cells (5.5 x  105 ±  1.8 x 105 in CD 4 1, 
5 x 105 ±  1.2 x  105 in CD 8 f , and 
5.5 x 10s ±  1.9 x 105 in C D 5 6 4 cells). This indi­
cates that the use o f ß2-m icroglobulin to  norm alize 
mRNA levels m ay have a critical im pact on the 
interpretation o f R T -P C R  data.
C D 4 +  C D 8 +  C D 1 9 +  C D 5 6 +
Fig. 1. Quantitative determination of the M RPl ( A )  and 
M RP2 (B) mRNA levels in human peripheral blood 
lymphocytes. Each bar represents the mean ±  S D  number 
of copies per ng of total RNA, as determined in 20 indi­
viduals. The differences in M RPl expression between cell 
populations were statistically significant (P  < 0.01), except 
CD 19+ vs. CD56+ cells. All differences in MRP2 expres­
sion were statistically significant (P < 0.05).
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Table 2. Normalized MRP1 and MRP2 mRNA expression in human peripheral blood 
lymphocytes (n =  20)
Cell MRP1 MRP2
C04- 12.6 ± 4.6’ 1.3 ± 0.33
CD8- 10.0 + 3.0 1.2 ±0.4J
CD19' 14.4 ± 6.01 1.7 t 0.5, г
CD56‘ 5.9 ± 2.2,za 1.0 ± 0.5й -3
Mean ± SD of MRP1 or MRP2 cDNA copies per 103 copies of ß2-microglobulin are 
presented.
Values are significantly different from 'C D 8 \ 2CD4\ and 3CD19’ cells.
P <  0.05 according to Wilcoxon signed ranks test.
Discussion
The M R P l is highly expressed th roughout the 
body, but poorly in the liver and intestine (7). In 
contrast, M R P2 is predom inantly expressed in the 
liver. In the present study, we found that both 
M R P l and M R P2 were expressed in peripheral 
blood CD4 + , CD 8 + , CD19 + , and C D 5 6 + cells, 
with m ore than  sevenfold higher M R P l expression 
in all cell populations.
Similar to the results published previously (4), 
the highest expression o f the M R P l was observed 
in C D 4 + cells. However, larger interindividual 
variation (20-fold) than  in the present study was 
observed by Legrand et al. (4). In  con trast to 
Laupeze et al. (6) who found that M R P2 m R N A  
was not present in PBM C, in the present study 
M R P2 m R N A  was evidenced in all cell populations 
investigated. The m ain goal o f this study was to 
investigate M R P l and M R P2 expression in differ­
ent subtypes o f PBM C. A sensitive m ethod as 
quantitative real-tim e R T -P C R  was used. H ow ­
ever, it would have a great im pact to confirm  the 
protein expression in cell surface. O ur study group 
consisted o f  young healthy volunteers and any age- 
related differences could no t be determ ined. N o 
significant differences in M R P l and M R P2 m R N A  
expression between males and females (17 vs. three 
subjects, respectively) were observed (data not 
shown). Because o f  the small num ber o f female 
subjects potential sex-related differences could not 
be excluded.
ß2-M icroglobulin is com m only used as a house­
keeping gene for quantitative R T -P C R . W e found 
that ß2-m icroglobulin expression in C D I9  + cells 
was alm ost twofold lower in com parison with o ther 
cells. The expression o f 10 com m only used house­
keeping genes in 13 different hum an tissues was 
found to vary considerably (9). ß2-M icroglobulin 
expression level was 112-fold higher in leukocytes 
com pared with fetal brain, indicating large tissue 
specific variation. A lthough it was concluded that 
ß2-microglobulin was a good m arker for norm al­
ization o f leukocyte m R N A  expression, its expres­
sion in different subtypes o f PBM C was not 
studied. O ur data  indicates that the use o f 
ß2-microglobulin for norm alization o f  the target 
m R N A  expression in different subsets o f  PBM C 
could lead to m isinterpretation o f the data . There is 
no universal control gene for norm alization and the 
validity o f the conclusions is highly dependent on 
the applied control. Therefore, the use o f an 
absolute num ber o f copies o f target gene m R N A  
per total R N A  seems to be appropriate, at least for 
hom ogenous samples as PBM C.
The im pact o f the M R P l and M R P2 transcrip­
tion in PBM C rem ains unknow n. P-glycoprotein, 
a member o f the subfam ily В o f the ABC 
transporters encoded by the M D R l gene, has 
been found to  be highly expressed in C D 8 + and 
C D 5 6 + cytotoxic cells (10). In the present study, 
C D 4 + cells exhibited the highest abundance o f the 
M R P l and M R P2 m R N A . This indicates that the 
expression o f different ABC transporter genes in 
hem atopoietic cells m ay be variously regulated 
during differentiation. M iscellaneous ABC trans­
porters may have different function. F o r instance, 
P-glycoprotein has been reported to be involved in 
the natural killer and T  cell m ediated cytotoxicity 
(11, 12) and in the transport o f cytokines (13). 
M R P l, unlike P-glycoprotein, facilitates the secre­
tion o f leukotrienes, the m ajor m ediators of 
inflamm ation (14).
Several HIV protease inhibitors and reverse 
transcriptase inhibitors are substrates for M R P l 
and M R P2 (15, 16). W e found that both M R P l and 
M R P2 were expressed in PBM C with the highest 
level in C D 4 + cells, at m ajor site o f virus replica­
tion. M R Ps may have an im portant role in limiting 
drug exposure within these cells and therefore the 
efficacy of HIV therapy. Jones et al. (17) dem on­
strated that the accum ulation o f ritonavir, indina­
vir, saquinavir, and nelfinavir in M R P l expressing 
cells was significantly reduced in com parison with 
control cells. M R P l inhib itor MK571 partially 
reversed these effects. M eaden et al. showed an 
inverse relationship between the M R P l expression 
and intracellular accum ulation o f ritonavir and 
saquinavir in PBM C from HIV-infected individuals 
(18). Both M R P l and M R P2 expression in PBM C 
indicates that not only M R P l, but also M R P2 and 
probably o ther M R P s account for the resistance to 
anti-HIV-drugs.
Clinical relevance o f the expression o f the M R P l 
and M RP2 in PBM C is not limited to HIV therapy. 
These ABC transporters also extrude a num ber of 
anticancer drugs (7). Lower expression o f M R P l 
and M R P2 in C D 1 9 H and C D 5 6 + cells could 
predispose these cells to cytotoxicity during che­
m otherapy. Also, individual differences in the 
expression of M R P l and M R P2 could determ ine
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individual sensitivity tow ard  hem atologic side 
effects o f  various drugs.
In conclusion, on an m R N A  level, both MRP1 
and M R P2 were expressed in hum an peripheral 
blood C D 4 \  CD 8 + , CD 19 + , and C D 56+ cells. 
F urther studies are required to specify the physio­
logic function and clinical im portance o f the MRP1 
and M R P2 transporters in these cells.
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Abstract Objective: The aim  o f the present study was to 
determine the frequency o f the G816A, T825C, T1684C, 
and G4002A genetic polym orphism s of the hum an 
MRP!  gene in 230 healthy Caucasians. The functional 
assessment o f these m utations was performed in fluo- 
rescence-activated cell sorting (FA CS)-sorted peripheral 
blood C D 4+ cells in a further 61 healthy volunteers by 
determining M R Pl m R N A  expression.
Methods: Genotyping of the M R P l  was carried out 
using real-time polymerase chain reaction (PCR) assays. 
Quantitative determ ination o f the M R Pl m RN A  
expression was performed with real-time reverse-tran- 
scription-PCR.
Results'. A novel silent m utation G816A in exon 8 was 
found in this study. Allele frequencies o f the 816A, 
825C, 1684C, and 4002A were 4.1, 30.0, 80.0, and 
28.3%, respectively. The frequency of the T825C poly­
morphism was com parable with that found in a previous 
Japanese study. In contrast, the frequency of the 
T1684C (OR 0.06, 95% C l 0.03 0.11, /><0.0001, vs 
Japanese) and the G4002A (OR 0.47, 95% Cl 0.24 0.86, 
/’ =0.01, vs Japanese) was significantly rarer. The mean 
MRPl m RN A  expression in peripheral blood CD4 + 
cells was 1,03xl04 ±  3.8x10’' molecules/ng of total RNA 
with an eightfold variation am ong individuals. However, 
MRPl m RNA expression in C D 4 + cells was not found 
to correlate with genetic polymorphisms investigated in 
this study.
Conclusions: The genotypic results observed show an 
ethnic difference in the frequencies o f the M R P l  genetic 
polymorphisms between Japanese and Caucasians.
Further studies are required to better understand the 
clinical consequences o f the M R P l  genetic variants.
Keywords M R P l • Genetic polymorphisms • mRNA 
expression
Introduction
The ATP-binding cassette (ABC) transporters play an 
im portant role in the transport o f drugs as well as 
endogenous substances across biological membranes [1]. 
The hum an m ulti-drug resistance-associated protein 1 
(M R P l) belongs to subfamily С of the ABC transporters 
(ABCC1), and was first identified in 1992 by Cole et al. 
[2] in doxorubicin-selected hum an small cell lung cancer 
cells. Recently, identification o f several single nucleotide 
polymorphisms (SNPs) in the hum an M R P l  has been 
reported [3, 4, 5, 6].
In the present study, the prevalence o f the genetic 
polymorphisms G816A, T825C, T1684C, and G4002A 
in the M R P l  was investigated in 230 healthy C auca­
sians. All these m utations were silent m utations, which 
do not alter the am ino acid sequence. However, wobble 
m utations might afTect RNA folding and stability [7]. 
Therefore, to assess the functional im portance o f 
these polymorphisms, peripheral blood CD4 cells were 
analyzed for M R Pl m RN A  levels using a quantitative 
real-time reverse-transcription polymerase chain 
reaction (RT-PCR ) assay.
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Materials and methods
Study population
We studied DNA samples from 230 healthy Caucasians of German 
origin (194 males and 36 females, age range 20-59 years, mean 
30 years). MRPl mRNA levels in fluorescence-activated cell 
sorting (FACS)-sorted peripheral blood CD4’ cells were deter­
348
mined in a further 61 healthy volunteers (47 males and 14 females, 
age range 21-32 years, mean 26 years). The study protocol was 
approved by the ethics committee of the Humboldt University, 
Berlin. Germany.
Genotyping of the MRPI using LightCycler assays
The reaction mixture (20 |il) for PCR amplification consisted of 
lxPCR buffer, 0.1 mM each dNTP, 30 mg/1 bovine serum albumin 
(BSA). and 1 U BioTherm DNA polymerase. The concentration of 
MgCb, dimethyl sulfoxide, primers and hybridization probes (Ta­
ble 1) was optimized for each reaction. After an initial denatur- 
ation at 95°C for 30 s, the amplification was performed by means 
of 45 cycles of denaturation at 95°C for 0 s, annealing (Table 1) for
15 s, and extension at 72°C for 15 s. Melting curves were recorded 
subsequently to an amplification run from 35°C to 95°C at 0.2°C/s, 
35°C to 85°C at 0.15°C/s, 40°C to 85°C at О.ГС/s, and 40°C to 
95°C at 0.2°C/s for the detection of the G816A, T825C, TI684C, 
and G4002A SNPs. respectively. Confirmation of the LightCycler 
analysis was performed by sequencing and PCR-restriction frag­
ment length polymorphism (RFLP) analysis.
Quantitative determination of the MRPI mRNA expression
The principles of the methods, used for cell sorting, total RNA 
isolation and real-time quantitative RT-PCR on the LightCycler, 
have been described previously [8]. The human MRPI mRNA 
(NM_004996) was amplified with gene specific primers 5'-TTC 
CGG AAC TAC TGC CTG CGC TA-3' (forward, 0.3 цМ) and 
5'-GGG TCC TGG GGG ATG ATG GTG A-3' (reverse,
0.3 |iM. annealing temperature 64°C). The reaction mixture also 
included hybridization probes 5'-CTC GTT GAT CCG AAA 
ТА A GCC CAG GGT CA-3'-flourescein (0.13 цМ) and 5'-LC- 
Red640-ACG ACT TCC CAG CTC CCG TCC GCC-3'-phos- 
phate (0.13 цМ). PCR amplification for the housekeeping gene 
/52-microglobulin (NM_004048) was carried out, as described 
previously [8].
Statistical analysis
Odds ratios (OR) with their 95% confidence interval (Cl) were 
calculated using Fisher's exact test (STATA, version 7.0, Stata 
Corporation, College Station, TX, USA). MRPI mRNA levels 
were presented as the mean±SD. Differences in MRPI mRNA 
expression between the genotypes were analyzed by Kruskal-Wallis 
test. Calculations were performed with SPSS for Windows (version 
10.0, SPSS Inc., Chicago, IL, USA). P values of 0.05 were con­
sidered to be of statistical significance.
Results
G eno typ ing  o f  h um an  M R P I
A  novel G 816A  su bstitu tion  in exon 8 o f  the  M R P I  was 
identified heterozygously  in 19 o f  230 subjects. F irst, the 
long sensor p ro b e  (position  a t  813-834 bp) used for 
T825C  genotyping , de term ined  fo u r ind iv iduals  w ith 
atypical m elting  curves. S ubsequen t sequencing  showed 
th a t all these indiv iduals, b u t n o t subjects w ith typical 
m elting curves fo r T825C , were heterozygous G A  at 
position  816. T he G 816A  su b stitu tio n  destabilized  the 
binding  o f  the long T825C  sensor. T herefore  a new, 
sh o rte r sensor p ro b e  (position  a t 817 834 bp , see 
M ethods) for T825C  detection , an d  an o th e r  p a ir o f 
hybrid iza tion  p robes (position  a t 779-800 bp  anchor, 
a n d  803-821 bp  sensor) fo r G 816A  de tection  was 
designed.
T he results o f  M R P I  g eno typ ing  in 230 healthy  
C aucasians are  given in Table 2. A linkage dysequilibri- 
um  betw een the G 816A  and  T825C  po lym orph ism s was 
observed, since the [816GA, 825TT] w as n o t observed
Table 1 Oligonucleotide primers and hybridization probes used for polymerase chain reaction (PCR)
SNP Sequence* Position (bp) Annealing (°C)
G816A
Forward
Reverse
Sensor
Anchor
5'-TGTGGTAGGGGGCTGCA-3'
5'-TTCGCATCCACCTTGGAACT-3'
5'-LC-Red705-GTTCCAGGCAGCCAGTGAA-3'-phosphate
5'-CCCACAACGGCTTCACCTCCTT-3-fluorescein
(13-29)
(125-144)
(66-84)
(42-63)
60
T825C
Forward
Reverse
Sensor
Anchor
5'-TGTGGTAGGGGGCTGCA-3'
5'-TTCGCATCCACCTTGGAACT-3'
5'-GTGAAGGTCGTGTACTCC-3'-fluorescein
5'-LC-Red640-CCAAGGATCCTGCCCAGCCGAA-3'-phosphate
(13-29)
(125-144)
(80-97)
(99-120)
60
T1684C
Forward
Reverse
Sensor
Anchor
5'-ACTCGGGGCACAGCAGT-3'
5'-TTGAACAAGGCCAAAGACA-3'
5'-ACGGCAAATGTGCACAAGGCC-3'-fluorescein
5'-LC-Red640-CCTGCAAGCAAGAACGCCCAGTG-3'-phosphate
(33-49)
(149-167)
(78-98)
(54-76)
56
G4002A
Forward
Reverse
Sensor
Anchor
5'-GCCAGCATTCCCACCACACCT-3' 
5'-GCTTGCCAGCTCTGGCTCACC-3'* * 
5'-GGTCAGGGACGACTTCCC-3'-fluorescein 
5'-LC-Red640-CTCCCGTCCGCCCCACG-3'-phosphate
(28-48)
(251-271)
(95-112)
(76-92)
71
*Area amplified refers to sequences with accession numbers as **PCR primer as reported by Ito et al. [4]
follows: AF022830 (G816A, T825C), AF022835 (T1684C), The position of the variable base in sensor is underlined
AF022850 (G4002A)
ассогШ п^о^р 'на 1^ ?,11^ 016!  of M R ?.} ßenetic variants in 230 healthy Caucasians. Expected genotype frequencies were calculated 
__________________dy~Weinberg equilibrium from the allele frequencies
Position Allele Frequency % Genotype Number of subjects Frequency
% Observed 95% Cl % Expected
816 G 95.9 GG 211 91.7 87.40-94.95 91.9A 4.1 GA 19 8.3 5.05-12.60 7.9
825
AA 0 0.0 0 .0- 0.02 0.0
T 70.0 TT 115 50.0 43.36-56.64 49.0
С 30.0 TC 92 40.0 33.62-46.64 42.0
CC 23 10.0 6.45-14.63 9.0
1684 T 20.0 TT 15 6.5 3.70-10.53 4.0
с 80.0 TC 62 27.0 21.34-33.18 32.0
CC 153 66.5 60.02-72.59 64.0
4002 G 71.7 GG 118 51.3 44.65-57.93 51.4
A 28.3 GA 94 40.9 34.45-47.52 40.6
AA 18 7.8 4.70-12.09 8.0
(4% expected vs 0%  observed; / ’<0.01) and the [816GA, 
825CC] was more frequently observed than expected 
(0.007% expected vs 0.04% observed; P <  0.001).
o f /f2-microglobulin-normalized data displayed the same 
pattern (data not shown).
M RPl m RN A  expression in peripheral blood CD4 + 
cells from individuals with different M R P l  genotypes
The mean M R Pl m R N A  expression in peripheral blood 
CD 4+ cells was 1.03xl04±  3.8xl03 molecules/ng of total 
RNA with an eightfold variation am ong individuals. 
However, statistical analysis revealed no significant 
(P>0.05) difference in M R P l expression with regard to 
different genotypes in the M R P l  (Fig. 1). A comparison
Discussion
In the present study, genotype frequencies o f the four 
genetic polymoprhisms in the hum an M R P l  were 
determined in 230 healthy Caucasians. T825C, T1684C, 
and G4002A polymorphisms have been described pre­
viously [4, 5, 6]. A novel m utation G816A was identified 
in this study. N o functional importance of these m uta­
tions was observed, as determined by M R Pl m R N A  
expression in peripheral blood CD 4* cells.
Fig. 1 Quantitative 
determination of the MRPl 
mRNA expression in peripheral 
blood CD4+ cells from 
individuals with different 
M R P l genotypes. Data are 
presented as number of copies 
of MRPl mRNA/ng of total 
RNA. Bars represent the mean 
values for each genotype. No 
difference in MRPl mRNA 
expression was observed 
between subjects with the 
different M R P l  genotypes 
(P>0.05)
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M R P l  is polym orphic and more than 80 SNPs have 
been identified in the gene [3, 4, 5, 6]. M ost o f the SNPs 
are located in intronic sequences. Three o f the 
SNPs—T825C, T1684C, and G4002A, located in exons 
8, 13, and 28, respectively— were selected for the present 
study. O ther SNPs identified previously in exonic re­
gions occurred with a low frequency (1%), and were 
observed only by a single investigator, but not confirmed 
by the others.
A novel silent m utation in exon 8, a G to A trans­
version at position 816 (Pro to Pro a t codon 272) was 
identified in this study with an allele frequency of 4.1% . 
The allele frequency of the T  allele a t position 825 was 
found to be 70.0% in Caucasians, as determined in the 
present study, and 62.5% in Japanese (л = 48), as re­
ported by Ito et al. [4] (OR 1.4, 95% Cl 0.86-2.26, 
/> = 0.18). The frequency of the G  allele a t position 4002 
was 71.7% in Caucasians and 84.4% in Japanese (OR 
0.47, 95% Cl 0.24-0.86, /> =  0.01). The results obtained 
indicate an ethnic difference in the frequency of M R P l  
genetic polymorphisms. W hen genotype results o f the 
T 1684C polymorphism were com pared between Cauca­
sians and Japanese, it was found that the frequency of T 
allele was 20.0% in Caucasians, and 80.2% in Japanese 
(OR 0.06, 95% Cl 0.03-0.11, /><0.0001). In the first 
published M R P l  sequence (AF022835), derived from a 
lung cancer cell line, a T nucleotide at position 1684 was 
reported and defined as a wild-type allele. We found that 
a С allele at position 1684 was the most common variant 
for Caucasians.
As shown by Conrad et al. [5], sense m utations 
T825C and C1704T seemed to correlate with a lower 
M R Pl m RNA expression in peripheral blood lym pho­
cytes, but the numbers o f samples for each genotype 
were too low for statistical analysis. In  the present study, 
M R Pl m RN A  levels were measured in FACS-sorted 
peripheral blood C D 4+ cells. N o correlation between 
the M R Pl m RN A  levels o f the 61 samples and G816A, 
T825C, T1684C, and G4002A genetic polymorphisms in 
the M R P l  gene was found.
The effects of various genetic variants in the ABC 
transporter genes on the pharm acokinetics o f drugs as 
well as on the etiology of several genetic disorders have 
been reported. In the present study, a marked difference
in the frequencies o f the M R P l  genetic polymorphisms 
was observed between Caucasians and Japanese. F ur­
ther studies are required to determine the prevalence of 
the M R P l  genetic variants in different ethnic groups and 
their functional im portance in vivo.
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